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Zusammenfassung
Durch die Fortschritte in der Hochdurchsatz-Massenspektrometrie hat sich ge-
zeigt, dass posttranslationale N-(ε)-Lysin-Acetylierung bei Tausenden von Pro-
teinen vorkommt. So modifizierte Proteine finden sich beim Menschen und an-
deren Organismen in allen Zellkompartimenten und sind in vielen Fa¨llen an es-
sentiellen zellula¨ren Prozessen beteiligt. Viele Aspekte posttranslationaler Lysin-
Acetylierung sind jedoch nur unvollsta¨ndig verstanden, einschließlich ihrer Regulie-
rung durch Lysin-Acetyltransferasen und Lysin-Deacetylasen (KDACs). In dieser
Arbeit wurde untersucht, welchen Einfluss diese Modifikation auf die Funktion des
kleinen GTP-bindenden Proteins Ran hat, dem in der Zelle unter anderem eine
zentrale Rolle bei der Regulation des Kerntransports zukommt. Hierzu wurde mit
Hilfe eines erweiterten genetischen Codes stellenspezifisch acetyliertes Ran in E.
coli hergestellt.
Untersucht wurden zuna¨chst fu¨nf zuvor identifizierte Ran-Acetylierungsstellen hin-
sichtlich ihrer Auswirkungen auf die intrinsische GTP-Hydrolyse Rate von Ran, die
Bildung von Exportkomplexen (anhand des Exportrezeptors CRM1 und des Ex-
portsubstrats Spn1) und die Interaktion von Ran mit RanBP1 und dem GTPase-
aktivierenden Protein RanGAP. Insgesamt waren sowohl bei der intrinsischen als
auch der RanGAP-stimulierten GTP-Hydrolyse nur schwache Effekte zu messen.
Dahingegen sorgte die Acetylierung von Ran am Lysin 159 (K159) fu¨r eine deut-
lich gesenkte Affinita¨t von Ran zu RanBP1, wenn Ran im aktiven Zustand vor-
lag. Daru¨berhinaus war eine sta¨rkere Bindung von Spn1 an einen Komplex aus
CRM1·Ran zu beobachten, wenn Ran an den Stellen K37, K99 oder K159 acety-
liert war. Anhand dieser Ergebnisse la¨sst sich schließen, dass wesentliche Funktio-
nen des Proteins Ran durch Acetylierung beeinflusst werden.
Ein in vitro Screen wurde durchgefu¨hrt, um potenzielle KDACs fu¨r Ran zu identi-
fizieren. NAD+-abha¨ngige KDACs der Sirtuin-Klasse zeigten Aktivita¨t gegenu¨ber
zwei Acetylierungsstellen von Ran, K37 und K71. Die Spezifita¨t der SIRTs wur-
de daraufhin anhand einer weiteren acetylierten Variante von Ran (RanAcK38)
analysiert. Da bei RanAcK38 im Vergleich zu RanAcK37 eine deutlich langsamere
Deacetylierungsrate zu beobachten war, wurde als na¨chstes di-acetyliertes Ran-
AcK37/38 getestet. Die Deacetylierungsrate von di-acetylierten Ran war erstaun-
licherweise vergleichbar mit derjenigen von RanAcK37. Deacetylierungsexperimen-
te unter single turnover -Bedingungen ergaben, dass die Deacetylierung im Ran-
AcK37/38-Hintergrund als erstes an der Stelle K38 erfolgen muss. Die Fa¨higkeit
von Sirtuinen zwei benachbarte AcKs zu deacetylieren wurde schließlich anhand
zweier weiterer Proteine untersucht, von denen bekannt war, dass sie unter an-
derem di-acetyliert vorkommen. Dabei handelte es sich um das Tumorsuppressor-
Protein p53 und Phosphoenolpyruvatcarboxykinase 1 (PEPCK1). Es stellte sich
heraus, dass p53 an zwei Di-Acetylierungsstellen (K372/372 und K381/382) durch
Sirtuin 1 und 2 deacetyliert wird. Entgegen der Erwartungen war bei PEPCK1
keine Deacetylierung durch Sirtuine festzustellen. Diese Ergebnisse lassen einige
bedeutende Schlussfolgerungen fu¨r die Substratspezifita¨t von Sirtuinen zu.
“Now my own suspicion is that the Universe is not only queerer than we suppose,
but queerer than we can suppose.”
John Burdon Sanderson Haldane, Biologist

Abstract
Through recent advances in high-throughput mass spectrometry it has become
evident that post-translational N-(e)-lysine-acetylation is a modification found on
thousands of proteins of all cellular compartments and all essential physiological
processes. Many aspects in the biology of lysine-acetylation are poorly under-
stood, including its regulation by lysine-acetyltransferases and lysine-deacetylases
(KDACs). Here, the role of this modification was investigated for the small GTP-
binding protein Ran, which, inter alia, is essential for the regulation of nucleocy-
toplasmic transport. To this end, site-specifically acetylated Ran was produced in
E. coli by genetic code expansion.
For five previously identified sites, Ran acetylation was tested regarding its impact
on the intrinsic GTP hydrolysis rate, the assembly of export complexes (modeled
in vitro with the export receptor CRM1 and the export substrate Spn1) and the
interaction of Ran with its GTPase activation protein RanGAP and RanBP1.
Overall, mild e↵ects of Ran acetylation were observed for intrinsic and RanGAP-
stimulated GTP hydrolysis rates. The interaction of active Ran with RanBP1 was
negatively influenced by Ran acetylation at K159. Moreover, CRM1 bound to
Ran acetylated at K37, K99 or K159 interacted more strongly with Spn1. Thus,
lysine-acetylation interferes with essential aspects of Ran function.
An in vitro screen was performed to identify potential Ran KDACs. The NAD+-
dependent KDACs of the Sirtuin class showed activity towards two acetylation
sites of Ran, K37 and K71. The specificity of Sirtuins was further analyzed based
on an additional Ran acetylation site, K38. Since deacetylation of RanAcK38
was much slower compared to RanAcK37, di-acetylated RanAcK37/38 was tested
next. The deacetylation rate of di-acetylated Ran was comparable to that of
RanAcK37. Deacetylation experiments under single turnover conditions revealed
that deacetylation occurs first at the K38 site in the di-acetylated RanAcK37/38
background. The ability of Sirtuins to deacetylate two adjacent AcKs was further
investigated based on two proteins, which had previously been found to be di-
acetylated and targeted by Sirtuins, namely the tumor suppressor protein p53 and
phosphoenolpyruvate carboxykinase 1 (PEPCK1). p53 was readily deacetylated
at two di-acetylation sites (K372/372 and K381/382), whereas PEPCK1 was not
deacetylated in vitro. Taken together, these results have important implications
for the substrate specificity of Sirtuins.
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1 Introduction
The acquisition of a bacterial endosymbiont by an archeon about two billion years
ago marks the beginning of eukaryotic evolution (reviewed in Koonin, 2015; Spang
et al., 2015). The energetic gain associated with this symbiosis is thought to have
allowed for the seemingly unconstrained genome size and morphological complexity
seen in eukaryota (Lane and Martin, 2010). To account for the diverse novel tasks
in the evolving eukaryotic cell, many protein families have undergone massive
functional diversification, one of which is the Ras superfamily, which is essential
for the regulation of cell proliferation, cellular adhesion, the cytoskeleton, vesicular
transport and membrane tra cking (Jkely, 2003). Ran (Ras-related nuclear) has
taken a central role in establishing the nuclear envelope and the regulation of
nuclear transport and mitosis, all three being hallmarks of the eukaryotic domain of
life. In this introduction, an overview is presented of the mechanisms of these Ran-
directed processes. Furthermore, lysine-acetylation as a conserved and reversible
post-translational modification is introduced, which will lead to the question how
it might regulate Ran function, a question that will be of central relevance in this
thesis.
1.1 The small GTP-binding protein Ran
Ran is a member of the Ras superfamily, the founding member of which is Ras
(Rat sarcoma). Ras was initially discovered as the factor conferring oncogenicity
to two murine viruses, the Kirsten and the Harvey murine sarcoma virus, hence
the names K-Ras and H-Ras, respectively (Harvey, 1964; Kirsten et al., 1970). It
later turned out that specific point mutations in the Ras sequences lead to this
oncogenicity and that their wildtype counterparts are present in rat and human
genomes (Capon et al., 1983; Chang et al., 1982; Ellis et al., 1981; Tsuchida et al.,
1
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1982). Ras has since been regarded as a proto-oncogene, having important cellular
functions in the non-mutated form but also becoming an oncogenic factor upon
mutation of certain amino acid residues.
As stated above, the Ras superfamily has expanded in the early eukaryotic evolu-
tion and members of the five major branches (Ras, Rho, Rab, Ran and Arf) can
thus be found in all eukaryotes unless they have been lost secondarily (Colicelli,
2004). About 167 members of the Ras superfamily are present in humans. Inter-
estingly and in contrast to the many paralogs of other Ras superfamily members,
only one Ran gene is found in mammals and a few often almost identical ones in
plants (Rojas et al., 2012). In addition, Ran is one of the most conserved proteins
of nucleated cells (Ach and Gruissem, 1994; Bush and Cardelli, 1993; Chen et al.,
1994).
All Ras superfamily members have in common that they are relatively small pro-
teins (20-30 kDa), able to bind guanosine di- or triphosphates (GDP and GTP,
respectively) with high a nity and to adopt two three-dimensional conformations,
depending on which nucleotide is bound. This behavior is referred two as a binary
‘molecular switch’ and makes this protein family particularly well-suited to act in
cellular signaling pathways (Vetter and Wittinghofer, 2001). This is reflected by
the diverse cellular processes that are regulated by these small guanine nucleotide
binding proteins (GNBPs). In addition to the mere binding of GDP or GTP, Ras
superfamily members are intrinsically able to hydrolyze bound GTP, although this
activity is generally very low and di↵ers substantially between di↵erent groups. In
particular, the GTPase activity of the Arf members Sar1, SRb and Arf are hardly
detectable (Bi et al., 2002; Legate and Andrews, 2003; Randazzo and Kahn, 1994).
The shared features of small GNBPs and other GTP binding proteins can be
directly attributed to their shared central domain, the G-domain, a fold consist-
ing of a twisted beta sheet with six parallel and anti-parallel beta strands, four
alpha helices packed on both sides of the beta sheet and nine connecting loops
(de Vos et al., 1988; Pai et al., 1989). This approximately 20-kDa domain pos-
sesses characteristic consensus elements, so called G boxes, which on the one hand
are required for nucleotide binding (and hydrolysis) and on the other hand me-
diate the switch-like behavior: G1, GxxxxGK(S/T); G2, x(P/A)T(I//V/L); G3,
DxxGQ; G4, (T/N)KxD; and G5, (C/S)A(K/L)(S/T) (Bourne et al., 1991; Dever
et al., 1987). While the G4-5 confer specificity for the guanine base over adenine,
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the G1 or P-loop makes contacts with the b- and g-phosphates of GTP and coor-
dinates the Mg2+-ion, which is needed for high a nity nucleotide binding (Saraste
et al., 1990). Interestingly, the G2 and G3, besides also being involved in binding
of the Mg2+-ion, contact the g-phosphate, which is only present in GTP. Thus,
upon GTP hydrolysis these interactions are released, which results in a change in
conformation and is the explanation for the switch-like behavior of small GNBPs.
Due to this behavior, G2 and G3 are called switch I and switch II, respectively and
their GTP-bound conformation has been compared to a loaded spring (Milburn
et al., 1990; Vetter and Wittinghofer, 2001). As shown in Fig. 1.1, the switch I
and II regions adopt a flexible conformation in the GDP-bound state compared to
the rigid conformation seen in the GTP-bound state.
Figure 1.1: Structural comparison of GDP- and GTP-bound GNBPs.
Selected Ras-related proteins in GTP- or GDP-form are shown as superimposed
ribbon representations. The switch I and II regions are shown in green and
turquoise, respectively. Characteristic elements of Rho, Arf and Ran are in-
dicated (red: C-terminus of Ran, magenta: Rho insert, blue: Arf N-terminal
helix) (taken from Vetter and Wittinghofer, 2001).
1.1.1 Localization of Ras proteins
Another feature of many Ras superfamily members is their post-translational mod-
ification by lipids, which anchor them to cellular membranes. In many cases this
reflects their roles in membrane-associated processes. For instance, members of
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the Rab and Arf families are important for vesicle formation and transport and the
Rho family for the regulation of cell shape changes. However, the type of modifi-
cation di↵ers between the subfamilies. Ras and Rho family members are modified
at a cysteine residue in their C-termini by farnesyltransferase or geranylgeranyl-
transferase type 1 (GGTase 1), which recognize a C-terminal CAAX motif (C:
Cys, A: aliphatic, X: any amino acid) (Anderegg et al., 1988; Casey et al., 1989;
Clarke et al., 1988; Katayama et al., 1991; Maltese et al., 1990). In addition to the
farnesyl- or geranylgeranyl-modifications, a nearby palmitoylation or polybasic
patch can further strengthen their membrane attachment and direct their sub-
cellular localization through interactions with distinct membrane compartments
of di↵erent lipid compositions (Apolloni et al., 2000; Choy et al., 1999; Hancock
et al., 1990; Rocks et al., 2005; Roy et al., 2005). Similarly, Rab family proteins are
geranylgeranylated at their cysteine-containing C-termini by the action of RabG-
GTase (Jiang et al., 1993; Khosravi-Far et al., 1991). However, in most cases, two
prenyl-groups are attached to Rab proteins. This is not specified by a CAAX motif
but by an interaction between a conserved surface feature of Rab proteins with the
Rab escort protein-1 (REP-1), which in turn interacts with RabGGTase (Andres
et al., 1993; Pylypenko et al., 2003). REP-1 can accommodate both hydrophobic
prenyl-groups (one in its interior and the other more solvent exposed) and remains
bound to Rab proteins after prenylation until delivery to their target membrane
(Pylypenko et al., 2006). Besides REP-1, there are also other proteins that can
bind prenylated Rho or Rab proteins and regulate their delivery to or retrieval
from membranes. These are subsumed under the term GDP-dissociation inhibitor
(GDI) and, as the name suggests, preferentially bind to GDP-bound small GNBPs
and prevent their activation (Gosser et al., 1997; Longenecker et al., 1999; Sasaki
et al., 1990). Another factor that solubilizes a variety of farnesylated proteins,
inter alia Ras subfamily members, is phosphodiesterase 6 d subunit (PDE-d). In
this case however, the binding occurs regardless of the GNBP’s nucleotide state
(Chandra et al., 2012; Nancy et al., 2002). Members of the Arf family are often an-
chored to the membrane by a myristoyl-group, which is linked to their N-terminus.
In addition to the myristoyl-anchor, an amphipathic N-terminal helix, which is re-
leased from an intramolecular sequestration upon GTP-loading, can insert itself
into the membrane (Antonny et al., 1997). In fact, some Arf family members,
like for instance Sar1, localize to membranes solely based on the action of this
helix (Bielli et al., 2005). Ran is one of only a few Ras superfamily members that
does not localize to membranes but is instead predominantly found in the nucleus
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during interphase (Bischo↵ and Ponstingl, 1991b). It is furthermore not lipidated
(i.e. prenylated or modified by fatty acid esterification) and has no poly-basic
patch.
1.1.2 Nucleotide exchange and hydrolysis
Through their dynamic switch regions, GNBPs have the ability to bind to di↵erent
interaction partners, depending on which nucleotide is bound. Most interaction
partners bind with high a nity to the more rigid conformation of the switch re-
gions of GTP-bound GNBPs and are activated upon binding. These so-called
e↵ectors can subsequently exert their down-stream signaling functions or directly
mediate e↵ects such as actin nucleation. Nevertheless, there are also many pro-
teins known to interact with the GDP-bound state of GNBPs, which likewise play
important roles. The fact that GNBPs usually show slow rates of intrinsic nu-
cleotide exchange and GTP hydrolysis (Bischo↵ et al., 1990; Klebe et al., 1995),
make GNBPs appear not well-suited for dynamic signaling processes. However,
both the nucleotide exchange and the GTPase rates can be accelerated over several
orders of magnitude by guanine nucleotide exchange factors (GEFs) and GTPase
activating proteins (GAPs), which are usually specific for individual GNBPs (re-
viewed in Bos et al., 2007) (Fig. 1.2).
Figure 1.2: The nucleotide exchange cycle. Overview of the nucleotide
exchange cycle of GNBPs (G: small GNBP, GAP: GTPase activating protein,
GEF: guanine nucleotide exchange factor, GDI: GDP dissociation inhibitor)
(taken from Bos et al., 2007).
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The a nity of GNBPs for nucleotides typically lies in the picomolar range and,
as a consequence, the dissociation rate of the nucleotide is very slow (John et al.,
1990; Klebe et al., 1995). The binding of a GEF to its cognate GNBP promotes the
dissociation of the bound nucleotide and thus allows for a new nucleotide molecule
to bind. For the latter step to take place, the incoming nucleotide has to displace
the GEF, which remains bound to the GNBP after nucleotide release. Since the
GEF-GNBP complex is highly stable (as is the nucleotide-GNBP complex), the
new nucleotide has to modify the a nity of the GEF for the GNBP, ultimately
leading to the release of the GEF. Thus, the exchange reaction relies on the recip-
rocal negative influence on the a nity of either GEF or nucleotide for the GNBP
and occurs in successive reversible steps (Vetter and Wittinghofer, 2001).
The modulation of the nucleotide a nity by GEFs is achieved by a similar mech-
anism even though GEFs are structurally unrelated for di↵erent Ras superfamily
branches (Boriack-Sjodin et al., 1998; Renault et al., 2001; Worthylake et al.,
2000). The high a nity for the nucleotide is to a large extent a result of the inter-
actions of the phosphates with the Mg2+-ion and the P-loop. GEFs use a so-called
‘push-and-pull’ mechanism to interfere with these interactions: The GEF pushes
out the Mg2+-ion by relocating residues of the P-loop and the switch II of the
GNBP or, instead for the latter, by introducing own elements into the nucleotide
binding pocket. In addition, the switch I is pulled out of its normal position,
which further reduces nucleotide a nity (Vetter and Wittinghofer, 2001). In gen-
eral, GEFs promote nucleotide exchange of GNBPs irrespective of the nucleotide
state of the GNBP (GTP or GDP) (Haney and Broach, 1994; Lenzen et al., 1998).
However, because the concentration of GTP in the cell is about 10-fold higher
than that of GDP, the accelerated nucleotide exchange by GEFs e↵ectively lead
to GTP-loading of the respective GNBP. Nevertheless, depending on the physi-
ological state of the cell the GTP:GDP ratio can change substantially and lead
to a shift in favor of GDP- or GTP-loading, which, at least in yeast, can have a
profound influence on intracellular signaling processes (Rudoni et al., 2001; Sagot
et al., 2005). The specific GEF for Ran is RCC1 (regulator of chromatin conden-
sation), which enhances the nucleotide exchange rate of Ran by about 105-fold
(Bischo↵ and Ponstingl, 1991a,b; Klebe et al., 1995).
As mentioned above, the GTPase activity of Ras superfamily proteins is generally
very low although intrinsically the catalytic machinery is present. The mechanism
by which GAPs stimulate the hydrolysis activity involves the stabilization of the
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intrinsically mobile catalytic center of GNBPs and, in most cases, the introduction
of catalytic residues. However, like GEFs, GAPs are structurally unrelated for dis-
tinct GNBPs and thus di↵erences in the molecular details of GTPase activation are
found. In principle, GTP-hydrolysis by GNBPs most likely occurs through a sub-
strate assisted catalysis mechanism. This means that GTP itself serves as a base
to abstract a proton from a water molecule. The resulting OH  then performs a
nucleophilic attack on the g-phosphate leading to an inversion at the g-phosphorus
atom (Schweins et al., 1995). The reaction probably happens in a single step, a
so-called in-line transfer (Feuerstein et al., 1989). For Ras, it was shown that the
reaction is catalyzed by stabilization of the transition state by the critical residue
glutamine-61, the mutation of which renders Ras unable to hydrolyze GTP (Priv
et al., 1992). This glutamine is also critical for the action of RasGAP, which sta-
bilizes it and makes it able to orient the water molecule for nucleophilic attack of
the g-phosphate. Moreover, it inserts an arginine into the phosphate-binding site,
which neutralizes negative charges of the b and g-phosphate and thereby stabilizes
the transition state (Sche↵zek et al., 1997). A similar mechanism is also observed
for Rho and Cdc42 and, with some variations, also for Rab and Sar1 (Bi et al.,
2002; Nassar et al., 1998; Pan et al., 2006; Rittinger et al., 1997). The mechanism
of Ran GTPase activation through RanGAP is di↵erent in that RanGAP does not
introduce any catalytic residue into the GTP binding pocket. Instead, RanGAP
uses an Asp to correct the, in this case, improperly positioned catalytic glutamine
(Gln69). The role of the arginine provided in trans by other GAPs is taken over
by a tyrosine 39 of Ran that forms hydrogen bonds to the g-phosphate as well as
the Gln69 side chain (Seewald et al., 2002) (see Fig. 1.3).
The location of RCC1 and RanGAP in the cell provides clues for the distribution
of RanGDP and RanGTP in the cell. RCC1 associates with chromatin through-
out the cell cycle and is thus found in the nucleus during interphase (Ohtsubo
et al., 1989). Binding of Ran to RCC1 allosterically promotes the interaction of
RCC1 with chromatin, which in turn stimulates nucleotide exchange (Chen et al.,
2007; Li et al., 2003a). Thus, RanGTP is generated close to chromatin. By con-
trast, RanGAP is located in the cytoplasm during interphase, which leads to the
conversion of RanGTP into RanGDP in the cytoplasm (Hopper et al., 1990).
This di↵erential distribution of RanGTP and GDP is key for nucleocytoplasmic
transport since the stability of import and export complexes is directly regulated
by RanGTP. Moreover, it is important for the role of Ran in mitotic spindle
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Ran/RanGAPRho/RhoGAPRas/RasGAP
Figure 1.3: Mechanisms of GTPase activation by GAPs. (a) Depic-
tion of two di↵erent mechanism of GTPase activation for Ran and Ras/Rho.
RanGAP induces GTP hydrolysis without introducing an arginine finger. (b)
Ribbon representation of di↵erent Ras-like proteins (blue) with their cognate
GAPs (red). The GNBPs are shown in the same orientation (taken from Bos
et al., 2007).
assembly and nuclear envelope formation. These three processes will be briefly
introduced in the subsequent sections.
1.1.3 Nucleocytoplasmic transport
The nuclear compartment is the most distinctive feature of eukaryotes. It pro-
vides a compartmentalization between the cytosol and the nucleoplasm, which
is essential for a number of cellular processes and perhaps most importantly to
spatially separate transcription and translation, preventing the translation of un-
spliced mRNAs (Cavalier-Smith, 1991; Martin and Koonin, 2006). The nuclear
envelope consists of two parallel membranes and forms a continuous lumen with
the endoplasmic reticulum (ER). The two membranes are pierced with nuclear pore
complexes (NPCs) that allow the unaided passage of molecules with a diameter of
⇠5 nm, which corresponds to a molecular weight of ⇠30 kDa (Mohr et al., 2009).
Larger macromolecules are not able to pass NPCs by passive di↵usion or are at
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least significantly delayed and their transport thus relies on nuclear transport re-
ceptors. Depending on the transport direction they facilitate, these are subdivided
in importins and exportins. NPCs are large (125 MDa) protein complexes that, in
vertebrates, comprise about 30 di↵erent protein species, each multiply represented
to form a hollow cylinder with a central pore. The permeability barrier consists
of disordered FG-repeat domains (FG: phenylalanine-glycine) that extent into the
central pore and form a dense network of filaments. Transport receptors are able
to traverse the barrier formed by NPCs by interacting with the FG-repeats while
other proteins are rejected (reviewed in Gruenwald et al., 2011) (see Fig. 1.4).
Figure 1.4: The nuclear pore complex (NPC). (Left) Schematic model
of the NPC. NTF: nuclear transport factor, ONM/INM: outer/inner nuclear
membrane, Nup: nuclear pore protein (taken from Strambio-De-Castillia et al.,
2010). (Right) Electron microscopic pictures of the NPC with top picture show-
ing the cytoplasmic side and bottom picture showing the nucleoplasmic side
(taken from Allen et al., 2000).
Importins, such as the prototypical importin-b, bind nuclear import signals (NLS)
of import cargo (via the adapter protein importin-a) in the cytoplasm where
the level of RanGTP is low (Goerlich et al., 1995, 1994). Once the import
receptor·cargo complex enters the nucleoplasm, it encounters the high concen-
tration of RanGTP. Upon binding of RanGTP, the complex disassembles, leading
to the release of the cargo (Moroianu et al., 1996). The importin remains bound
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to RanGTP until it exits the nucleus where RanGAP can stimulate GTP hydrol-
ysis of Ran. Similarly, exportins, such as CRM1 (chromosomal maintenance 1),
that reside predominantly in the nucleus bind to RanGTP. However, in contrast
to importins, the interaction of exportins with RanGTP allows the simultaneous
binding to cargo molecules that carry nuclear export signals (NES) (Fukuda et al.,
1997; Ossareh-Nazari et al., 1997; Stade et al., 1997). Upon binding to its export
receptor, the cargo molecule can translocate into the cytoplasm where the ex-
port receptor·cargo complex is disassembled and RanGTP converts into RanGDP
through the action of RanGAP. Thus, the di↵erential distribution of RanGDP and
RanGTP is instrumental for the facilitated transport of macromolecules through
the nuclear pore. The fact that each transport event ultimately involves the hy-
drolysis of a GTP-molecule also satisfies the energetic prerequisites posed by the
second law of thermodynamics (Nachury and Weis, 1999). Ran itself is concen-
trated in the nucleus during interphase. However, for stoichiometric reasons, the
import of Ran cannot be mediated by bona fide importins (Ribbeck et al., 1998).
Instead, Ran is imported specifically by NTF2 (nuclear transport factor 2), which
binds Ran only in its GDP-form and drastically accelerates its transport through
the NPCs (Ribbeck et al., 1998; Smith et al., 1998). The complex of RanGDP
and NTF2 is then disassembled in the nucleus by a yet unknown process (Yamada
et al., 2004).
Importins and exportins require an additional factor for the dissociation from Ran,
which in mammals is either RanBP1 or RanBP2 (Ran binding protein 1 and 2,
respectively). This is due to the fact that Ran is inaccessible to RanGAP when
bound to importins/exportins and thus GTP hydrolysis cannot be stimulated.
Through the binding of RanBP1 or -2 to exportin/importin-RanGTP complexes
RanGAP can e ciently induce GTP hydrolysis and the complex can be disassem-
bled (Lounsbury and Macara, 1997; Maurer et al., 2001; Yaseen and Blobel, 1999).
RanBP1 is a ⇠23 kDa protein with a single Ran binding domain (RanBD) that is
essential for its high a nity for RanGTP (Bischo↵ et al., 1995; Vetter et al., 1999).
RanBP2 is a much larger multidomain protein (358 kDa) anchored to NPCs, which
not only possesses four RanBDs but also catalyzes the transfer of SUMO1 (small
ubiquitin like modifier) and interacts with SUMO-modified proteins. Interest-
ingly, a major target of the SUMOylation activity of RanBP2 is RanGAP, which
remains bound to RanBP2 after SUMO-transfer (Mahajan et al., 1997; Matunis
et al., 1996; Pichler et al., 2002; Zhu et al., 2006). Thus, the RanBP2·RanGAP
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complex combines transport receptor disassembly and GAP activity, both pro-
cesses occurring immediately at the cytoplasmic side of NPCs (for an overview of
nucleocytoplasmic transport see Fig. 1.5).
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Figure 1.5: Ran-dependent nuclear import and export. Ran gradient:
RanGDP is imported by its cognate transport factor NTF2. RCC1 is chro-
matin associated and catalyzes the conversion of RanGDP to RanGTP, leading
to high RanGTP concentrations in the nucleus. Import: Importin-a and -b
form a complex in the cytoplasm, which then recognizes a substrate carrying
a nuclear localization signal (NLS). The import complex is disassembled after
passage through the nuclear pore upon binding of RanGTP. The RanGTP-
importin-b complex is disassembled by the action of RanBP2/SUMO-RanGAP
at the cytoplasmic periphery of the nuclear pore or, alternatively, by soluble
RanGAP and RanBP1 (not shown), both leading to the conversion of RanGTP
to RanGDP. Export: Export substrates, carrying a nuclear export signal (NES),
and RanGTP cooperatively bind to CRM1 to form an export complex. As for
importin-b, this complex is then disassembled by RanBP2/SUMO-RanGAP or
by soluble RanGAP and RanBP1. For clarity reasons, the re-import of CRM1
is not shown (NPC model adapted from Katta et al., 2014).
Introduction 12
1.1.4 Mitotic spindle assembly
In addition to its role in nucleocytoplasmic transport, Ran plays a central role
in the assembly of the bipolar mitotic spindle during cell division. The mitotic
spindle is a highly organized microtubule structure responsible for the equal dis-
tribution of chromatids to each daughter cell and starts to form after nuclear
envelope breakdown. Interestingly, many factors involved in nucleocytoplasmic
transport are also important during mitotic spindle assembly. RCC1 remains
bound to chromatin during mitosis and, thus, catalyzes the localized nucleotide
exchange of GDP to GTP on Ran (Carazo-Salas et al., 1999). The activity of
soluble RCC1 is controlled by RanBP1 during mitosis through the formation of
an inhibitory complex comprising RanBP1, Ran and RCC1 (Zhang et al., 2014a).
The localized source of RanGTP is crucial for the spatially controlled release of
inhibitory complexes between importin-a/-b and NLS-containing spindle assem-
bly factors (SAFs) in the vicinity of the chromatin (Kalab et al., 1999; Nachury
et al., 2001; Zhang et al., 1999). One important SAF is TPX2 (Targeting protein
for Xklp2), which, after it is released from importin-a /-b inhibition, interacts
with Aurora A kinase and keeps it in an active state (Gruss et al., 2001). Au-
rora A kinase then phosphorylates microtubule nucleation and stabilization factors
around the chromatin (Bayliss et al., 2003; Eyers et al., 2003; Scrofani et al., 2015;
Tsai et al., 2003). Thus, the RanGTP gradient is e↵ectively translated into a
phosphorylation gradient. The microtubule nucleation-promoting environment in
proximity to the chromosomes is further refined by the CPC (chromosomal passen-
ger complex): It is located to the centromeric regions of each chromosome where
its kinase subunit Aurora B promotes spindle assembly through phosphorylation
of microtubule destabilizing factors (Sampath et al., 2004). Recent studies suggest
that the newly formed microtubules then serve as a starting point for microtubule
amplification by Augmin, a process that is also stimulated by RanGTP (Petry
et al., 2013). Eventually, microtubules are captured by kinetochore proteins and
polymerization pushes their (-)-ends towards the spindle poles. The protection of
these (-)-ends is mediated by MCRS1 (microspherule protein 1), which, again, is
positively regulated by RanGTP (Meunier and Vernos, 2011).
Interestingly, other components of nucleocytoplasmic transport are involved in
the formation of the kinetochores. The nucleoporin complex Nup-107-160 (Orjalo
et al., 2006) and a complex of RanGAP, RanBP2 and CRM1 are both found at
kinetochores and are important for attachment, polymerization and stability of
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kinetochore fibers to kinetochores (Arnaoutov et al., 2005; Arnaoutov and Dasso,
2005). Moreover, CRM1 appears to play a role in the proper centromeric localiza-
tion of the CPC (Knauer et al., 2006) and to antagonize the negative regulation
of the kinetochore localization of RanGAP by importin-b (Roscioli et al., 2012)
(Fig. 1.6).
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Figure 1.6: Roles of Ran during mitotic spindle assembly. (a) RanGTP
mediates the release of spindle assembly factors like TPX2 from inhibitory
complexes with importin-a/b. TPX2 can then bind and activate Aurora A
kinase, which in turn promotes the microtuble nucleation activity of the g-
Tubulin ring complex (g-TuRC). RanGTP is also required for the localization
of CRM1·RanGAP·RanGTP to kinetochores. (b) Together with other pro-
tein complexes, CRM1·RanGAP·RanGTP regulate the stability and formation
of kinetochore fibers. These are amplified by the action of Augmin, which is
positively regulated by RanGTP (adapted from Scrofani et al., 2015).
1.1.5 Nuclear envelope formation
In contrast to fungi and many unicellular (‘lower’) eukaryotes, in which the nuclear
envelope (NE) remains intact during mitosis, in plants and metazoans it is usually
completely disassembled during mitosis, a situation referred to as ‘open mitosis’
(reviewed in Boettcher and Barral, 2013). Reassembly of the NE is temporally
controlled by the dephosphorylation of integral inner nuclear membrane proteins
(for instance Lamin B receptor), which can then reassociate with chromatin (Fois-
ner and Gerace, 1993; Pfaller et al., 1991; Tseng and Chen, 2011). In addition,
the RanGTP gradient is again used by cells to guide the coating of post-mitotic
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chromatin by ER sheets (Anderson and Hetzer, 2007; Lu et al., 2011; Zhang and
Clarke, 2000). Generation of RanGTP is also required for the reassembly of NPCs
after mitosis (Askjaer et al., 2002; Rotem et al., 2009; Zhang et al., 2002). The
fact that NE and NPC structures are formed around RanGTP-coated beads con-
vincingly demonstrated the involvement of Ran in both NE and NPC formation
(Zhang and Clarke, 2000). These functions of Ran appear to be mediated by the
release of NPC components and membrane vesicles on the surface of chromatin,
which were previously bound to Importin-b (Anderson and Hetzer, 2007; Askjaer
et al., 2002; Rotem et al., 2009; Zhang et al., 2002). However, the precise roles of
Ran during NE and NPC formation are not fully understood and it is not clear
how they are integrated with other pathways involved.
1.2 Lysine-acetylation
Acetylation is a very common protein modification in eukaryotes. However, two
forms of acetylation exist, one that occurs at the N-(a)- and the other at the N-
(e)-amino group. Approximately 85% of eukaryotic proteins are co-translationally
acetylated at their N-(a)-termini (Van Damme et al., 2011), which is catalyzed by
N-terminal acetyltransferases (NATs). Despite the fact that many di↵erent roles
for N-terminal acetylation have been found, it remains largely enigmatic why it
is so widespread (Hollebeke et al., 2012). It has been shown to influence the fate
of a protein in di↵erent and, in some cases, contradictory ways. These include
protein stability (Hershko et al., 1984; Hwang et al., 2010), localization (Forte
et al., 2011) and protein synthesis (Kamita et al., 2011). The role of acetylation
at the e-amino group of lysines has been studied only for relatively few cases
while for a majority of proteins its role is poorly understood, both functionally
and on the level of regulation. Importantly and in contrast to N-(a)-terminal
acetylation, N-(e)-acetylation is highly reversible and is thus potentially involved
in many dynamic signaling processes in the cell.
In theory but also from the known examples, it is clear that lysine-acetylation
can impact the fate of a protein in several di↵erent ways, many of them being a
direct consequence of the di↵erent chemical properties of acetyl-lysine compared
to lysine (for details on immediate molecular e↵ects of lysine-acetylation see Fig.
1.7). For instance, lysine-acetylation of a particular protein can (positively or
negatively) influence its a nity to another macromolecule, co-factor or substrate.
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More indirect e↵ects of lysine-acetylation include the crosstalk with other post-
translational modifications such as ubiquitination or the alteration of subcellular
localization of a protein by changing the properties of a specific localization signal
(Li et al., 2012). As will be discussed in the following second part of the intro-
duction, post-translational lysine-acetylation has captured the attention of many
researchers in recent years. This is mainly due to the identification of many novel
acetylation sites throughout the proteome, which was possible through the huge
technological advances in high-throughput mass spectrometry (MS). Given that
the functional consequences of most of these newly discovered acetylation events
is not known, many questions in the acetylation research field remain unanswered
and are di cult to address in a high-throughput manner. The next sections will
cover the most important proteins subjected to this modification and will give an
overview about its regulation.
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1.2.1 The writers: Lysine-acetyltransferases (KATs)
Lysine-acetyltransferases (KATs) catalyze the transfer of the acetyl-group from
acetyl-Coenzyme A (acetyl-CoA) to an N-(e)-amino group of a lysine side chain.
KAT activity was first demonstrated in an enzyme from Tetrahymena thermophila
that e ciently acetylates lysines in histones and was thus termed histone acetyl-
transferase type A (HATA) (Brownell and Allis, 1995; Brownell et al., 1996).
HATA turned out to be a close ortholog of Gcn5 (general control nonrepressed
5), which had previously been identified as a transcriptional regulator and thus
the discovery of Gcn5-KAT activity immediately provided a link between histone
acetylation and transcriptional regulation. To date, 21 proteins with KAT activity
are known to be present in humans (EC 2.3.1.48), the substrates of which are not
limited to histones (hence the term KAT instead of HAT) (Glozak et al., 2005; Lee
et al., 2007). Based on structure and sequence characteristics, the di↵erent KATs
have been assigned to one of five subfamilies: HAT1, Gcn5/pCAF, MYST (MOZ,
Ybf2, Sas2, and Tip60), p300/CBP, or Rtt109. All KATs discovered until now,
share a conserved fold comprising a three-stranded b-sheet and an a-helix, which
is crucial for binding of acetyl-Coenzyme A and substrate coordination. How-
ever, despite this similarity, the sequence homology between the KAT subfamilies
is remarkably low and di↵erent catalytic mechanisms can be observed between
KAT subfamilies (Friedmann and Marmorstein, 2013). Importantly, the N- and
C-terminal extensions around the core region and also other protein domains (such
as bromodomains; see below) are required for their substrate specificity and activ-
ity (Polesskaya and Harel-Bellan, 2001). Moreover, KAT activity may be modu-
lated by their intracellular localization, embedding into multi-protein-complexes or
post-translational modifications, including auto-acetylation (Creaven et al., 1999;
Lee et al., 2007; Poveda et al., 2004; Santos-Rosa et al., 2003). Despite significant
advances in the identification of KAT targets it remains largely an open question
how KAT specificity is achieved. It seems however that due to the low sequence
conservation many more KAT genes remain to be discovered in the human genome
(Yuan and Marmorstein, 2013). This view was recently substantiated in a study by
Montgomery et al. (2014), in which several proteins with previously unrecognized
KAT activity were identified.
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1.2.2 The erasers: Lysine-deacetylases (KDACs)
Enzymes that catalyze the removal of an acetyl-group from a lysine residue have
initially been discovered for histones and hence been termed histone deacetylases
(HDACs). To account for their emerging role in deacetylation of non-histone pro-
teins, they are now more generally referred to as lysine-deacetylases (KDACs). To
date, two groups of KDACs have been identified, which use remarkably di↵erent
reaction mechanisms and co-factors. One group comprises the so-called classical
KDACs, which catalyze the removal of the acetyl-moiety via a Zn+2-dependent
hydrolysis reaction. Based on their sequence similarity to yeast homologs and
their domain organization, these enzymes have initially been subdivided into dif-
ferent classes (class I: KDAC1, -2, -3 and -8; class IIa: KDAC4, -5, -7 and -9;
class IIb: KDAC6 and -10; class IV: KDAC11) (Dokmanovic et al., 2007; Marks
et al., 2001). The class I KDACs KDAC1 and KDAC2 are almost identical and
can partially compensate for each other (Lagger et al., 2002). Mild phenotypes
are observed for most lineage specific knockouts of either KDAC1 or KDAC2 but
deletion of both has dramatic e↵ects, leading to blockade of G1-to-S-phase tran-
sition (Yamaguchi et al., 2010). Nevertheless, full-body knockout of either one
results in perinatal lethality in mice as does the full-body knockout of KDAC3
and -8 (Bhaskara et al., 2008; Haberland et al., 2009a; Montgomery et al., 2007).
The e↵ects class I KDAC ablation can in most cases be attributed to their role in
regulating transcription. However, they are also involved in splicing, DNA repair,
replication, mitosis and meiosis. They are part of large multi-protein complexes
such as CoREST and are themselves able to homo- or heterodimerize (Moser
et al., 2014, reviewed in). Class IIa KDACs are di↵erent from the other classical
KDACs in that they posses an N-terminal domain that is an important site for
post-translational phosphorylation and is required to establish interactions with
transcription factors. Phosphorylation leads to nuclear export and thus prevents
repression of their target genes (McKinsey et al., 2000). The expression of class IIa
KDACs are often tissue-specific, which is reflected in their tissue-specific functions
(Chang et al., 2006; Dequiedt et al., 2003; McKinsey et al., 2000). Relatively little
is known about the function of class IIb member KDAC10 and class IV member
KDAC11, although the latter has recently gained attraction for its role in sup-
pression of an anti-tumor immune response (Sahakian et al., 2015). In contrast,
the second class IIb member, KDAC6, is well described for its role in a-tubulin
deacetylation (see section 1.2.4). In general, KDAC6 appears to have the most
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non-histone targets among the classical KDACs (Bertos et al., 2004; Verdel et al.,
2000; Zhang et al., 2003). Interestingly, KDAC6 possesses a zinc-finger domain in
its C-terminus through which it can bind to ubiquitin and thus establishes a link
between ubiquitination and acetylation (Boyault et al., 2006; Hook et al., 2002).
Class III KDACs are unrelated to the classical KDACs and are referred to as
Sirtuins based on their homology to the founding member, the yeast Silent infor-
mation regulator 2 (Sir2). Sir2 is critical for the silencing of mating type loci in
yeast, which is mediated by deacetylation of critical lysines of histones H3 and H4
(Imai et al., 2000). For deacetylation, Sirtuins require nicotinamide adenine dinu-
cleotide (NAD+) as a co-factor, which is broken down to the to reaction products
nicotinamide (NAM) and 2’- or 3-’O-acetyl-ADP-ribose (OAADPr) (Tanny and
Moazed, 2001) (Fig. 1.8a). Interestingly, NAM, is an inhibitor of Sirtuins and,
thus, NAM turnover by PNC1 (pyrazinamidase/nicotinamidase 1) modulates Sir-
tuin activity in the cell (Avalos et al., 2005; Gallo et al., 2004). In addition, the
second reaction product, OAADPr is an important signaling molecule and sub-
strate for downstream enzymatic processes (Liou et al., 2005; Tong and Denu,
2010). Given their NAD+-dependence, the activity of Sirtuins is intimately linked
to the NADH/NAD+ ratio and thus the metabolic state of the cell. In fact, it is
becoming increasingly clear that age-dependent decline of NAD+-levels, which is
caused by increased activity of PARPs (poly-ADP-ribose-proteins) in response to
DNA damage (PARP1 also uses NAD+ as a substrate), leads to a concomitant
decline of Sirtuin activity (Bai et al., 2011; Mohamed et al., 2014; Pillai et al.,
2005).
Seven Sirtuins are present in human, of which SIRT3, -4 and -5 are predominantly
found in mitochondria, SIRT6 and -7 are mostly nuclear and SIRT1 and -2 shuttle
between the cytoplasm and the nucleus (Michishita et al., 2005). They all share
a conserved domain structure consisting of a small domain that binds a Zn2+
ion and a second domain in a Rossmann-fold, which is characteristic for NAD+-
binding proteins. The two domains are connected by several loops, which form
an extended cleft between both domains. Acetyl-lysine and NAD+ enter this cleft
from opposing sides and meet in a tunnel where they contact the catalytic residues
of the enzyme (Sanders et al., 2010) (Fig. 1.8b).
Sirtuins are in fact not restricted to acetyl-lysine as a substrate but can catalyze
the removal of other lysine-acylations such as crotonylation (SIRT1, -2, -3; Brooks
and Gu, 2011), malonylation and succinylation (SIRT5; Du et al., 2011; Peng et al.,
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Figure 1.8: Chemistry and structure of Sirtuin deacetylases. (a)
Educts and products of the deacetylation reaction catalyzed by Sirtuins
(adapted from Feldman et al., 2012). (b) Structure of SIRT3 in complex with a
substrate peptide (ACS2, acetyl-CoA synthetase 2) and a non-reactive NAD+-
analog (carba-NAD+) (PDB: 4FVT). On the left a cartoon representation is
shown with the loops connecting the small domain and the Rossmann-fold do-
main are colored in grey. On the right, the same is shown but as a surface
representation of SIRT3.
2011), or long-chain fatty acid acylations (SIRT6, Feldman et al., 2013). Moreover,
the deacetylase activity of SIRT6 can be stimulated by free fatty acid, which induce
a conformation that promotes acetyl-lysine binding, again emphasizing the role of
Sirtuins in metabolic processes (Feldman et al., 2013). Sirtuins are on the one
hand involved directly in gene regulation via the deacetylation of histones and
nuclear transcription factors and co-factors. On the other hand, most Sirtuins,
especially those located in the mitochondria, deacylate metabolic enzymes.
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SIRT1 is the best-studied Sirtuin and well-known for its role in counteracting
p53 activation, making SIRT1 a potential pro-oncogene (see section 1.2.4). How-
ever, this view is challenged by the fact that other pro-oncogenic and/or pro-
inflammatory factors such NF-kB, c-Myc and b-catenin are negatively regulated
by SIRT1 (Firestein et al., 2008; Yeung et al., 2004; Yuan et al., 2009). Moreover,
SIRT1 is crucial for the lifespan extension e↵ect observed under caloric restriction
(Cohen et al., 2004). Such pleiotropic e↵ects are also observed for SIRT2, which
can most likely also be attributed to its diverse targets in the nucleus and cytosol
(as for example a-tubulin; see section 1.2.4). For instance, SIRT2 positively regu-
lates myelination by Par-3 (partitioning-defective 3) deacetylation but inhibition
of SIRT2 is also neuroprotective by ameliorating the toxic e↵ects of a-synuclein.
Therfore, it is regarded as a potential therapy for Parkinson’s disease (Beirowski
et al., 2011; Outeiro et al., 2007). The mitochondrial Sirtuins, SIRT3, -4, -5 are
particularly important for energy homeostasis. While their precise roles still re-
main to be identified, it is evident that lack of the mitochondrial Sirtuins lead
to metabolic syndrome, obesity and defects in fatty acid oxidation and insulin
signaling (Haigis et al., 2006; Hallows et al., 2011; Hirschey et al., 2011; Rardin
et al., 2013). SIRT6 has become one of the most interesting Sirtuins for the field
of aging research, given its clear progeroid phenotype upon knockout. Overexpres-
sion of SIRT6 in turn increases lifespan by 15%. These phenotypes are most likely
a result of its function in cellular DNA damage response where on the one hand
it mono-ADP-ribosylates the DNA-repair factor PARP1 and on the other hand
deacetylates histone H3 to prevent further DNA damage. Moreover, SIRT6 is also
able to negatively regulate glycolysis and inflammation. SIRT7 localizes to the
nucleolus and controls the production of rRNA by RNA polymerase I (Tsai et al.,
2012). Furthermore, it is important for mitochondrial function in that it positively
regulates the transcription of nuclear-encoded mitochondrial genes. Loss of SIRT7
thus leads to several age- and metabolism-related phenotypes and a decrease in
lifespan (Ryu et al., 2014).
An open question is what exactly determines the specificity of deacylation/deacety-
lation by Sirtuins. While some studies suggest that SIRT1-3 deacetylate residues
that lie in unstructured regions, mostly irrespective of the amino acid sequence
(Avalos et al., 2002; Blander et al., 2005; Khan and Lewis, 2005), others reported
that substrate recognition is primarily dictated by the residues in direct vicinity of
the acetyl-lysine moiety. However, no clear consensus motif was found but instead
that substrate recognition is highly contextual. This means that one amino acid
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at a certain position might be preferred in combination with another one (also in
a certain position) but not so in di↵erent combinations (Garske and Denu, 2006;
Gurard-Levin et al., 2010; Smith et al., 2011).
1.2.3 The readers: Bromodomain containing proteins
In addition to the direct e↵ect on chromatin assembly, the di↵erent histone mod-
ifications serve as a docking site for a number of DNA/chromatin binding pro-
teins. These proteins are referred to as ‘readers’ since they interpret the his-
tone code and mediate the transcriptional control or play important roles for
DNA repair and DNA replication. Monoubiquitinated histones are recognized by
the chromatin remodeling complex SWI/SNF (SWItch/Sucrose Non-Fermentable)
(Shema-Yaacoby et al., 2013) while several factors such as INO80 and NuA4 can
sense phosphorylation of histones (Downs et al., 2004; Morrison et al., 2004). Mem-
bers of the so-called ‘Royal Family’ or Tudor domain family are readers of protein
methylation. This family includes the domains Tudor, plant Agenet, Chromo,
PWWP and MBT (Maurer-Stroh et al., 2003), each with a di↵erent degree of
specificity for the type of methylation: three forms of lysine methylation (mono-,
di- and tri-) and three forms of arginine methylation (mono- and symmetric or
asymmetric di-) (Aletta et al., 1998; Bannister et al., 2001; Eissenberg, 2012; Kim
et al., 2006a; Liu et al., 2010).
To date, the only readers of lysine-acetylation that have been identified are bro-
modomains (BRDs) (Dhalluin et al., 1999). Interestingly, BRD binding is not
limited to histone proteins. The conserved fold of BRDs, comprising a bundle
of four a-helices linked by loop regions that determine the binding specificity for
di↵erent sequence contexts, provides a deep hydrophobic pocket for the binding
of acetyl-lysine (Filippakopoulos et al., 2012; Owen et al., 2000) (Fig. 1.9a). Sin-
gle or multiple BRDs are present in a number of proteins of di↵erent functions
such as transcriptional regulation (TRIM/TIF1, TAFs), chromatin remodeling
(BAZ1B), methyltransferases (MLL, ASH1L) and helicases (SMARCA) (Muller
et al., 2011) (Fig. 1.9b). Interestingly, bromodomains are also found in KATs
such as CBP, pCAF and Gcn5, immediately implying regulatory feedback between
di↵erent acetylation events. For instance, CBP not only lysine-acetylates p53 at
its C-terminus but the binding of CBP to the acetylated K382 residue of p53 is
also required for the recruitment of transcriptional co-activators, which results in
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p21-mediated cell cycle arrest (Ito et al., 2001; Mujtaba et al., 2004). Likewise,
KATs can in many cases directly bind to histones via their BRDs and stimulate
transcription by acetylation of nucleosomal histones and transcription factors in
their surrounding or by serving as binding platforms for the basal transcription
machinery (Leo and Chen, 2000; Malik and Roeder, 2000; Manning et al., 2001;
Schiltz et al., 1999).
b
a
Figure 1.9: Bromodomains are readers of acetylated lysine residues.
(a) Crystal structure (PDB: 2WP1) of the BD2 bromodomain of Brdt, a testis-
specific member of the BET protein family, bound to an acetylated H3 peptide
(taken from Morinire et al., 2009). (b) A diverse set of proteins contain bro-
modomains (taken from Filippakopoulos et al., 2012).
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1.2.4 The canonical roles of lysine-acetylation
Now more than fifty years ago, it became apparent that histones are heavily mod-
ified by lysine-acetylation and that it plays an important role in the regulation
of gene expression (Allfrey et al., 1964; Phillips, 1963). However, compared to
phosphorylation, the regulatory role of acetylation and the responsible enzymes
controlling this modification remained largely elusive until the mid-1990s. It is
now known that histones are post-translationally modified at their highly con-
served N-terminal tails by acetylation, methylation, phosphorylation and ubiqui-
tination. These can, in a combinatorial fashion, both positively and negatively
influence gene expression, a fact that has led to the proposition of the histone
code (Strahl and Allis, 2000). Post-translational modification of histones a↵ects
internucleosomal and histone-DNA interactions and can therefore make DNA more
or less accessible for transcription factors and other DNA-binding proteins (Arya
and Schlick, 2006; Dorigo et al., 2003; Shogren-Knaak et al., 2006). Acetylation
has been described as having mostly an activating e↵ect on gene expression by
disrupting higher-order nucleosomal structures and hence enhancing transcription
(Shahbazian and Grunstein, 2007). This e↵ect of acetylation in histone tails is
only partially a result of charge neutralization. In fact, acetylation-induced charge
reduction of only 10% has already a substantial inhibitory e↵ect on chromatin
packing (Tse et al., 1998).
Another protein that has been identified relatively early as being highly acetylated
is the cytoskeletal protein a-tubulin (L’Hernault and Rosenbaum, 1983). The site
of this acetylation was later mapped to a single lysine residue (K40) (LeDizet and
Piperno, 1987), which, interestingly, lies at the luminal surface of microtubules
(Nogales et al., 1999). Its major KAT seems to be a-TAT, formerly MEC-17,
which exclusively acetylates a-tubulin at K40 (Akella et al., 2010). a-tubulin
deacetylation is mediated by the KDAC6 and SIRT2 (Hubbert et al., 2002; North
et al., 2003). Both SIRT2 and KDAC6 are able to deacetylate a-tubulin in the
polymerized and the soluble dimer state (North et al., 2003). As for a-TAT, it
is not clear how these enzymes act on the luminal site of microtubules. Initially
thought to be important for microtubule stabilization, it turned out that a-tubulin
acetylation can be an indicator of stable microtubules but is probably not causative
(Schulze et al., 1987; Webster and Borisy, 1989). In fact, albeit being studied ex-
tensively, the role of a-tubulin acetylation remains poorly understood. It has been
suggested that acetylated microtubules can more e ciently recruit the molecular
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motors dynein and kinesin-1 and thus promote axonal transport (Dompierre et al.,
2007; Reed et al., 2006). Moreover, the recruitment of the chaperone Hsp90 to
microtubules is positively a↵ected by acetylation as well as the sliding dynamics of
ER cisternae along microtubules (Friedman et al., 2010; Giustiniani et al., 2009).
Although mice lacking a-TAT show loss of a-tubulin acetylation across multiple
tissues, they do not show any overt phenotype, again leaving the question about
the precise role of this acetylation unanswered (Kalebic et al., 2013; Kim et al.,
2013).
One of the best studied proteins that is subject of extensive post-translational
lysine-acetylation is the tumor suppressor p53 protein (Gu and Roeder, 1997).
Since the discovery that p53 is acetylated in its regulatory C-terminus, many ad-
ditional acetylation sites have been described, also in other domains (Fig. 1.10).
p53 acetylation prevents its degradation via Mdm2 (mouse double minute 2 ho-
molog) and promotes its association with transcriptional co-activators and target
gene promoters, and is essential for the p53-mediated response to DNA damage
and the presence of activated oncogenes (Ito et al., 2001; Pearson et al., 2000; Tang
et al., 2008). Interestingly, the di↵erent acetylation sites of p53 can compensate
for each other extensively. In fact, the residues K120, 164, 370, 372, 373, 381, 382
and 386 had to be mutated to arginine (termed 8KR) to render p53 incapable of
mediating its anti-tumorigenic e↵ects. This mutant is however still able to acti-
vate transcription of its negative regulator, the E3 ubiquitin ligase Mdm2 (Tang
et al., 2008). What adds to this complexity is that six di↵erent KATs seem to
be involved in p53 lysine-acetylation, which can be attributed to the two groups
p300/CBP/pCAF and Tip60/MOF/MOZ (Gu and Roeder, 1997; Liu et al., 1999;
Rokudai et al., 2013; Sykes et al., 2006; Tang et al., 2006). These are in turn
regulated by a diverse set of proteins such as ubiquitin ligases, kinases and viral
factors (Jin et al., 2002; Patel et al., 1999; Shiseki et al., 2003).
SIRT1 and KDAC1 are the major deacetylases of p53 and counteract its anti-
tumorigenic potential (Luo et al., 2001, 2000; Vaziri et al., 2001). Some evidence
also points to deacetylation of p53 mediated by SIRT2 and KDAC6 (Ding et al.,
2013; Ho↵mann et al., 2014; Jin et al., 2008; Peck et al., 2010). Given that p53 is
acetylated at 13 di↵erent lysines, it seems unlikely that any one of these deacety-
lases has the same specificity for all sites. In fact, KDAC1 deacetylates p53 at
K320, K373 and K382 (Ito et al., 2002), whereas K382 appears to be the major
substrate for SIRT1 (Vaziri et al., 2001). More indirect evidence indicates that
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Figure 1.10: Domain structure and acetylation sites of p53. The known
sites of lysine-acetylation of p53 are shown with their respective location in the
protein. Acetylation sites that are essential for p53 activation are shown in red.
p53 is acetylated by six di↵erent KATs (adapted from Brooks and Gu, 2011).
the residues K120 and K164 (Zhang et al., 2014b) as well as K373 might also be
deacetylated by SIRT1(Frazzi et al., 2013; Knights et al., 2006). How KDAC1
and SIRT1 control the function of p53 is however not well understood. This is
especially true for SIRT1 since in many cases it negatively regulates p53 activa-
tion, suggesting a pro-oncogenic role, but mice lacking SIRT1 display increased
tumorigenesis and defects in DNA damage response (Cheng et al., 2003; Wang
et al., 2008).
In addition to p53 and a-tubulin, there is an increasing number of non-histone pro-
teins, often transcription factors, for which lysine-acetylation has been described
to have functional consequences, ranging from alterations in protein-protein-inter-
actions to increased or decreased stability and transcriptional activation (Farria
et al., 2015; Glozak et al., 2005).
1.2.5 The acetylome: Novel roles for lysine-acetylation?
In the last ten years, advances in high-throughput MS have led to the discovery of
thousands of acetylation sites in proteins of all cellular compartments and diverse
cellular processes (Choudhary et al., 2009; Kim et al., 2006b; Zhao et al., 2010).
Interestingly, the notion that acetylation might be of similar importance as phos-
phorylation was already proposed by Kouzarides (2000) years before these large
datasets became available. The number of acetylated proteins and acetylation
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sites is in stark contrast to the relatively few proteins for which acetylation had
been shown before.
The patterns of acetylation sites are often tissue-specific (Lundby et al., 2012)
and change, for instance, in response to metabolic (Yang et al., 2011) or genetic
perturbations (Chen et al., 2012). Moreover, lysine-acetylation is found not only
in eukaryotes but also in bacteria, where it is strongly influenced by the levels of
acetyl-phosphate, a metabolic intermediate between acetate and acetyl-CoA. Inter-
estingly, in bacteria, acetylation appears to happen globally and non-enzymatically
at many sites when the cellular acetyl-phosphate concentration rises (Weinert
et al., 2013). Similarly, the chemical environment in mitochondria (pH7.9-8.0,
acetyl-CoA concentration of 0.1-1.5mM) would allow for non-enzymatic acetyla-
tion (and other acylations) to occur (Wagner and Payne, 2013). Strikingly, ba-
sic patches of proteins were foun to be most prone to non-enzymatic acetylation
(Baeza et al., 2015), which coincides with the substrate specificity of SIRT3 in
vivo and in vitro, indicating that SIRT3 evolved specifically to deacetylate sites
of non-enzymatic acetylation (Hebert et al., 2013; Smith et al., 2011). In fact,
acetylation is found in up to 65% of mitochondrial proteins, many of which are
key players of mitochondrial metabolism (Hebert et al., 2013; Hirschey et al.,
2011), and typically acetylation inhibits the activity of these enzymes (Lin et al.,
2012). Taken together, these observations have led to the picture that SIRT3
constitutively suppresses the low-stoichiometry non-enzymatic acetylation in mi-
tochondria to reverse its mostly adverse e↵ects on mitochondrial function (Wagner
and Hirschey, 2014; Weinert et al., 2015).
Non-enzymatic acetylation is however less likely to occur in the cytoplasm and
nucleus due to the lower pH and acetyl-CoA levels. It has indeed been shown in
S. cerevisiae that the majority of acetylation sites have a very low stoichiometry
in both the nucleocytoplasmic compartment and in mitochondria but that, consis-
tent with their di↵erent chemical environments, this basal level is generally higher
in the latter. Only the stoichiometry of acetylation sites of histones, transcription
factors and proteins embedded in KAT- and KDAC-complexes were exceptionally
high (Weinert et al., 2014). However, the fact that many sites are evolutionary
conserved and often found in regulatory hot spots of proteins argues for a signif-
icant physiological role of acetylation beyond the above protein groups (Beltrao
et al., 2012; Weinert et al., 2011). Moreover, there are situations were even a
low stoichiometry acetylation can have a strong impact on cellular metabolism
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or signaling. For example, acetylation might activate the signaling function of a
protein or a new binding partner thereof (such as a kinase or KAT), which would
in turn amplify the initially low signaling strength imposed by low stoichiometry
acetylation, an e↵ect that could be regarded as a gain-of-function. As another
example, the activity of an enzyme might be dependent on its multimerization.
Upon acetylation of a small fraction of these enzymes an e cient assembly of mul-
timers could be prevented and thus likewise lead to a strong e↵ect on enzymatic
activity, a constellation that would resemble a dominant negative e↵ect.
1.2.6 Lysine-acetylation of Ran
Information about the role of post-translational modifications in the regulation
of Ran is so far very limited. This does however not apply to other proteins of
the Ran interaction network. For instance, as described above, a large fraction
of RanGAP is SUMO1-modified throughout the cell cycle (Mahajan et al., 1997).
Phosphorylation of RanBP1 is important for the release of RCC1 from the in-
hibitory Ran·RCC1·RanBP1 complex at the end of mitosis (Zhang et al., 2014a).
Acetylation of importin-a has been described as a mechanism to promote nuclear
import of mRNA-destabilizing factors in response to metabolic stress (Bannister
et al., 2000; Wang et al., 2004). For Ran, recent data shows that it is targeted for
SUMOylation by RanBP2-SUMO-E3 complex (Sakin et al., 2015). SUMOylation
of Ran had been previously identified for residue K152 (Tammsalu et al., 2014)
but in vitro it occurred preferentially at K130. Since NTF2 is able to interact with
SUMOylated Ran, it has been hypothesized that some cargo proteins might rec-
ognize SUMOylated Ran and then piggyback into the nucleus (Sakin et al., 2015).
To date, twelve acetylation sites were identified in Ran, all by high-throughput MS
(K23, K28, K37, K38, K60, K71, K99, K123 K134, K141/142, K152 and K159).
Of these sites, K37, K60, K71, K99 and K159 were initially found by Choudary et
al. (2009) in human cell lines treated with deacetylase inhibitors and have since
been repeatedly confirmed in other screens, not only in human but also in mouse
and rat samples. These five sites were thus selected for investigation in this study.
Another site that was also found in human is K38 (albeit with lower confidence
in the Choudary screen), which will be of importance in the second experimental
part of this work.
Introduction 28
1.2.7 The genetic code expansion concept (GCEC)
In the last decade, advances in the field of synthetic biology have resulted in the
ability to incorporate non-natural amino acids into proteins. These systems have
in common that they involve the introduction of an orthogonal translation system
into the host. The genetic code is degenerate, with all possible 64 triplet codons
assigned to specific amino acids and/or translation termination signals. However,
the frequency with which individual codons are being used varies significantly from
species to species. One striking example is the amber stop codon (UAG), which, in
E. coli, is used with a frequency of below 10% (with respect to the other two stop
codons) (VanBogelen et al., 1990). In many cases, genetic code expansion relies
on the assignment of this low-frequency codon to a non-natural amino acid, which
is then incorporated into the nascent polypeptide chain. Other concepts involve
the use of quadruplet codons in combination with specifically modified ribosomes
(Neumann et al., 2010). A prerequisite for both methods is the availability of
a tRNA- and tRNA-synthetase-pair, which does not adversely interfere with the
endogenous translational machinery and, vice versa, the specificity of which is
not compromised by host cell factors (especially tRNA-synthetases and tRNAs).
If these conditions are fulfilled a system is referred to as bioorthogonal. One
such system is the pyrrolysyl-tRNA synthetase/tRNACUA pair that mediates the
incorporation of pyrrolysine in the methanogenic archeon Methanosarcina barkeri
through amber stop codon suppression (Srinivasan et al., 2002). Neumann et
al. (2008) used directed evolution to develop this naturally pyrrolysine-specific
tRNA-synthetase into an N-(e)-acetyl-lysyl-tRNA-synthetase, based on the fact
that significant similarities exist between the chemical structure of pyrrolysine and
N-(e)-acetyl-lysine (see Fig. 1.11a). Thus, if the respective evolved gene PylRS and
the corresponding tRNA-gene pylT are introduced into E. coli and, in addition,
the cells are supplied with exogenous acetyl-lysine, recombinant proteins can be
produced, which carry an acetyl-lysine at a position specified by an amber stop
codon in the gene of interest (Fig. 1.11b).
The material that can be obtained with the GCEC, is natively folded and quanti-
tatively and site-specifically acetylated. Thus, the this system represents a unique
tool for the study of post-translational lysine-acetylation in a site-specific man-
ner and has been successfully scaled up to yield protein of su cient purity and
quality to perform biophysical analysis including X-ray crystallography (Lammers
et al., 2010). By contrast, previous methods relied either on chemical acetylation
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Figure 1.11: The genetic code expansion concept (GCEC). (a) Chem-
ical structures of L-lysine, N-(e)-acetyl-L-lysine and L-pyrrolysine. (b) Scheme
of the genetic code expansion concept used to co-translationally incorporate
N-(e)-acetyl-lysine into recombinant proteins in E. coli.
using, for instance, acetic anhydrate or enzymatic acetylation with purified KAT
complexes. Both methods have several disadvantages, such as non-homogeneous
and/or unspecific acetylation of the desired proteins. The often challenging pu-
rification of KAT complexes is an additional complicating factor. In the present
work, the GCEC was of critical importance since it enabled the biophysical and
biochemical study of Ran acetylation in a site-specific manner.
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1.3 Aim of the thesis
The available proteomics data show that Ran is a target of post-translational
lysine-acetylation. However, the role of Ran-acetylation was not known at the
beginning of this study. Two questions were addressed in the present work:
1. What is the impact of Ran-acetylation on nuclear export and GAP-mediated
GTP-hydrolysis?
The acetylation sites K37, K60, K71, K99 and K159 were the first that were dis-
covered in human Ran (Choudhary et al., 2009). Based on the available structural
data, it seemed likely that acetylation at some lysine residues could have an im-
pact on GTP hydrolysis and export complex formation. To test this specifically,
acetylated Ran and the binding partners involved in GTPase activation and export
complex formation (RanGAP, RanBP1 and CRM1) were purified. The methods
of choice for the subsequent experiments were, on the one hand, isothermal titra-
tion calorimetry (ITC) for the measurement of binding constants, thermodynamic
parameters and stoichiometries of binding and, on the other hand, high pressure
liquid chromatography (HPLC) for the determination of GDP/GTP ratios.
2. How is Ran-acetylation regulated by KATs and KDACs?
To gain insight into possible physiological role of Ran acetylation, I first sought
to identify its KATs by their overexpression in cell culture and subsequent identi-
fication by immunoblotting and/or MS. With the site-specifically acetylated Ran
variants at hand, it was also possible to analyze the specificity of their deacetyla-
tion. To this end, an initial in vitro screen was performed with purchased recom-
binant deacetylases. The results of this screen suggested an unexpected degree of
specificity of Sirtuin deacetylases in a full-length protein context, which was then
further characterized on the basis of other known Sirtuin substrates.
2 Material and Methods
2.1 Materials
2.1.1 Chemicals, kits and enzymes
Unless otherwise stated, chemicals were purchased from AppliChem, Carl Roth
and VWR in highest available purity. Guanine nucleotides were obtained from
Analytik Jena. Suberoylanilide hydroxamic acid (SAHA) was purchased from
Cayman Chemical and Sirtinol from Calbiochem/Merck. N-(e)-acetyl-L-lysine was
purchased from Chem-Impex International. Custom peptides were synthesized by
the AG Neundorf, Institute for Biochemistry, University of Cologne. All enzymes
were obtained from New England Biolabs. QIAGEN reagent kits were used for
DNA isolation and purifications. Malate dehydrogenase (Ultra pure grade) was
purchased from Amresco.
2.1.2 Primers
Primers were purchased from Eurofins Genomics in ’Salt free’ grade. Primers ex-
ceeding 35 nucleotides were ordered in ’HPSF’ grade. The primers used for cloning
and site-directed mutagenesis are listed in Table 2.1 and Table 2.2, respectively.
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Table 2.1: Cloning primers
Name Sequence (5’ ! 3’) Enzyme
RSFohGSTfo ctttaataaggagatataccatgtcccctatactaggttattgg CPEC
RSFohGSTre gctagttattgctcagcggtcagtcacgatgcggccgctcg CPEC
GSTohRSFfo cgagcggccgcatcgtgactgaccgctgagcaataactagc CPEC
GSTohRSFre ccaataacctagtataggggacatggtatatctccttattaaag CPEC
pGEX-MmCRM1-fo gaaaacctttattttcagggcggaatgccagcaattatgacaatgttagc CPEC
pGEX-MmCRM1-re ccgggagctgcatgtgtcagaggttaatcacacatttcttctgg CPEC
MmCRM1-pGEX-re gctaacattgtcataattgctggcattccgccctgaaaataaaggttttc CPEC
MmCRM1-pGEX-fo ccagaagaaatgtgtgattaacctctgacacatgcagctcccgg CPEC
DuSirt1-225Ba-fo gcggatccgattaatatcctttcagaaccacc BamHI
DuSirt1-664Xho-r ccgctcgagcggttagtcatcttcagagtctgaatatacc XhoI
Sirt2-50DuBfo gcggatccgagcctgggcagccag BamHI
Sirt2-356DuXfo ccgctcgagcggttacgactgggcatctatgc XhoI
Sirt2-43-foB cgggatccaacttattctcccagacgctcagc BamHI
Sirt2-370-revE cggaattccgttacttgggggaagctgaagtgctgg EcoRI
Sir2Ba34fopG cgcggatccggagaagcagacatg BamHI
Sir2No356repG ttttccttttgcggccgcttttttccttttacgactgggcatctatgc NotI
Sirt3for118Bam cgcggatccgacaaggggaagctttccctgcag BamHI
Sirt3re399Xho gaaactgggaagcttgatggaccagacaaataaccgctcgagcgg XhoI
pGEXp53-Ba-fo cgggatccatggaggagccgcagtc BamHI
pGEXp53-Eco-rev cggaattccgtcagtctgagtcaggcccttc EcoRI
PEPCK1-DuBafo cgcggatcccggaatgcctcctcagctgcaaaacg BamHI
PEPCK1-DuKpnre ggggtaccccttacatctggcttattctttgcttcaaggc KpnI
RanBP11foB cgggatccatggcggccgccaaggacac BamHI
RanBP1201revE cggaattccgttattgcttctcctcagc EcoRI
RanGAPSp1foB cgcggatccgcgatgtcgcgtttttc BamHI
RanGAPSp386reE ccggaattctcaaatatgagcttttg EcoRI
Ranf.l.foB cgggatccatggctgcgcagggag BamHI
Ranf.l.revE cggaattccgttacaggtcatcatcctc EcoRI
RSFRan1foB cgcggatcccggaatggctgcgcagggagagc BamHI
DuRanf.l.revX ccgctcgagcggttacaggtcatcatcctc XhoI
HsSpn1-foB cgggatccatggaagagttgagtcaggcc BamHI
HsSpn1-revE cggaattccgttaattctccatgaggcatcc EcoRI
Tip60BamTriEXfo cgggatccgatggcggaggtgggggagataatcgag BamHI
Tip60XhoTriEXrev ccgctcgagcggttaccacttccccctcttgctccagtc XhoI
pcDNA-noKTag-fw gtaccaggatccagtgtggtgg
pcDNA-noKTag-rev atcgtcatcgtcgtacagatccc
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Table 2.2: Primers for site-directed mutagenesis
Name Sequence (5’ ! 3’)
p53-K120a gcattctgggacagcctagtctgtgacttgcacg
p53-K120a-re cgtgcaagtcacagactaggctgtcccagaatgc
p53-K164a gccatggccatctactagcagtcacagcacatg
p53-K164a-re catgtgctgtgactgctagtagatggccatggc
p53-K381a gtctacctcccgccattagaaactcatgttcaag
p53-K381a-re cttgaacatgagtttctaatggcgggaggtagac
p53-K382a ctacctcccgccataaatagctcatgttcaagacag
p53-K382a-re ctgtcttgaacatgagctatttatggcgggaggtag
p53-K381/382a gtctacctcccgccattagtagctcatgttcaagac
p53-K381/382a-re gtcttgaacatgagctactaatggcgggaggtagac
p53-K372a cagccacctgaagtcctagaagggtcagtctacc
p53-K372a-re ggtagactgacccttctaggacttcaggtggctg
p53-K373a cacctgaagtccaaatagggtcagtctacctcc
p53-K373a-re ggaggtagactgaccctatttggacttcaggtg
p53-K372/373a cagccacctgaagtcctagtagggtcagtctacc
p53-K372/373a-re ggtagactgaccctactaggacttcaggtggctg
QC-PEPCK1-K71a catcctcaggcggctgtagaagtatgacaactgc
QC-PEPCK1-K71a-re gcagttgtcatacttctacagccgcctgaggatg
QC-PEPCK1-K71-72a ctcaggcggctgtagtagtatgacaactgctgg
QC-PEPCK1-K71-72a-re ccagcagttgtcatactactacagccgcctgag
QC-PEPCK1-K72a catcctcaggcggctgaagtagtatgacaactgc
QC-PEPCK1-K72a-re gcagttgtcatactacttcagccgcctgaggatg
QC-PEPCK1-K594a ggtggaagacatcgagtagtatctggtggatcaag
QC-PEPCK1-K594a-re cttgatccaccagatactactcgatgtcttccacc
QCPEPCK1-EFE-fw ggaagagggcatcctcgagtttgagtagtagtatgacaac
QCPEPCK1-EFE-rev gttgtcatactactactcaaactcgaggatgccctcttcc
QCPEPCK1-VAT-fw cggctgtagtagtatgtagccacctggttggctctcactg
QCPEPCK1-VAT-rev cagtgagagccaaccaggtggctacatactactacagccg
QCRan37amber ggtgaatttgagtagaagtatgtagccaccttggg
QCRan38amberfo ggtgaatttgagaagtagtatgtagccaccttggg
QCRanK60amber caacagaggacctatttagttcaatgtatgggac
QCRanK71amber cacagccggccaggagtagttcggtggactgagag
QCRanK99amber gagagttacttactagaatgtgcctaactgg
QCRanK159amber gtaactacaactttgaatagcccttcctctggcttgc
QCRan-K37R-K38amb-fw ctggtgaatttgagaggtagtatgtagccac
QCRan-K37R-K38amb-fev gtggctacatactacctctcaaattcaccag
QCRan-K37A-K38amb-fw ctggtgaatttgaggcgtagtatgtagccac
QCRan-K37A-K38amb-fev gtggctacatactacgcctcaaattcaccag
QCRan-K37Q-K38amb-fw ctggtgaatttgagcagtagtatgtagccac
QCRan-K37Q-K38amb-fev gtggctacatactactgctcaaattcaccag
2.1.3 Vectors and constructs
For the expression of Glutathione-S-transferase (GST)-tagged proteins, a modified
pGEX-4T1 (GE healthcare) was used, in which a Tobacco Etch Virus (TEV)-
protease cleavage site was inserted between the Thrombin cleavage site and the
multiple cloning site (MCS). This vector was named pGEX-4T5. Hexahistidine
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(His6)-tagged proteins were expressed from a modfied pRSF-Duet-1 (Novagen)
coding for a Gly2Pro substitution, which prevents a-N-6-phosphogluconoylation
at the N-terminus (Geoghegan et al., 1999).
To allow for the post-translational incorporation of N-(e)-acetyl-L-lysine, the pRSF-
Duet-1 was further modified by insertion of the synthetically evolved M. barkeri
pylS (termed AcKRS-3 ) under control of an glnS promoter/terminator using an
SphI restriction site and pylT under control of an lpp promoter/rrnC terminator
using an XbaI restriction site (Neumann et al., 2008). This gave rise to pRSFDuet-
1-pylT-AcKRS-3.
p53 was expressed from pRSFGST-pylT-AcKRS-3. It was generated by replacing
both MCS of pRSFDuet-1-pylT-AcKRS-3 with the GST-ORF-MCS from pGEX-
4T5 using circular polymerase extension cloning (CPEC) (see 2.2.4).
For expression of Ran in HEK293T (human embryonic kidney 293T) cells, a mod-
ified pcDNA3.1C vector was used. Specifically, a lysine codon in the N-terminal
tag was deleted to prevent the occurence of acetylation at this site. All lysine-
acetyltransferases (HAT) were expressed from pCMV-C-Myc, except for TIP60,
which was expressed from pTriEx-2.
Maps of the vectors for recombinant protein expression can be found in Appendix
A.1. The constructs used in this work are listed in Table 2.3.
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Table 2.3: Constructs for recombinant protein expression
Vector / Amino acids Species Accession
Protein (UniProt)
pGEX-4T5:
CRM1 full-length M. musculus Q6P5F9
RanBP1 full-length M. musculus P34022
RanGAP full-length S. pombe P41391
RanWT full-length H. sapiens P62826
SIRT2 34-356 H. sapiens Q8IXJ6
SIRT2 43-370 H. sapiens Q8IXJ6
SIRT2 50-356 H. sapiens Q8IXJ6
SIRT3 118-399 H. sapiens Q9NTG7
Spn1 full-length H. sapiens O95149
pRSFDuet-1:
His6-RanWT full-length H. sapiens P62826
His6-SIRT2 50-356 H. sapiens Q8IXJ6
SIRT1 225-664 H. sapiens Q96EB6
pRSFGST-pylT-AcKRS-3:
p53 full-length H. sapiens P04637
pRSFDuet-1-pylT-AcKRS-3:
His6-Ran-AcK full-length H. sapiens P62826
PEPCK1 full-length H. sapiens P35558
2.1.4 Crystallization screens
Table 2.4 lists the crystallization screens used in this work. Screens were aliquoted
(50 µl) into 96-well sitting drop iQ plates (TPPlabtech), sealed with HDclear tape
(Duck, Henkel) and stored at 4 C until use.
Table 2.4: Crystallization screens
Name Manufacturer
JCSG Molecular Dimensions
PACT premier Molecular Dimensions
MORPHEUS Molecular Dimensions
Clear Strategy Screen I HT-96 Molecular Dimensions
Clear Strategy Screen II HT-96 Molecular Dimensions
PGA-LM HT-96 Crystallization Screen Molecular Dimensions
Index Screen Hampton Research
PEG/Ion Screen Hampton Research
PEG/Ion 2 Screen Hampton Research
PEG/Ion 2 Screen Hampton Research
Structure Screen 1 Hampton Research
Structure Screen 2 Hampton Research
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2.1.5 Bu↵ers
PBS(T): 140mM NaCl
2.7mM KCl
10.1mM Na2HPO4
1.8mM KH2PO4
pH 7.4-7.6
(0.1% (v/v) Tween-20)
Standard bu↵er: 50mM Tris/HCl, pH 7.4
100mM NaCl
5mM MgCl2
2mM  -ME
GST-Wash bu↵er: 50mM Tris/HCl, pH 7.4
500mM NaCl
5mM MgCl2
2mM  -ME
Ni-Wash bu↵er: 50mM Tris/HCl, pH 7.4
1M NaCl
5mM MgCl2
10mM Imidazole
2mM  -ME
Ni-Elution-I bu↵er: 50mM Tris/HCl, pH 7.4
100M NaCl
5mM MgCl2
10mM Imidazole
2mM  -ME
Ni-Elution-II bu↵er: 50mM Tris/HCl, pH 7.4
100M NaCl
5mM MgCl2
500mM Imidazole
2mM  -ME
Laemmli bu↵er: 50mM Tris/HCl, pH 6.8
50% (v/v) Glycerol
500mM DTE
10% /w/v) SDS
0.5% (w/v) Bromphenol blue
SDS-PAGE Running bu↵er: 25mM Tris/HCl, pH 8.3
192mM Glycine
2% (w/v) SDS
Transfer bu↵er: 25mM Tris, base
150mM Glycine
10% (v/v) Methanol
Staining solution: 40% (v/v) Methanol
10% (v/v) Acetic acid
0.4% (w/v) Coomassie brilliant blue R-250
0.4% (w/v) Coomassie brilliant blue G-250
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Destaining solution: 10% (v/v) Ethanol
10% (v/v) Acetic acid
HPLC bu↵er: 100mM KPi, pH 6.4
10mM Tetra-n-
butylammonium bromide (TBAB)
2% (v/v) Acetonitrile
KDAC-assay bu↵er: 25mM Tris/HCl, pH 8.0
137mM NaCl
2.7mM KCl
1mM MgCl2
0.1mg/ml BSA
0.5mM NAD+
PEPCK1-assay bu↵er: 50mM Tris/HCl, pH 7.4
20mM NaHCO3
0.5mM Phosphoenolpyruvate
1mM MnCl2
0.2mM GDP
0.1mM NADH
2U/ml Malate Dehydrogenase
(Amresco, Ultra Pure)
Developer solution: 5 µg/ml Trypsin (diss. in 10mM acetic acid)
100mM Nicotinamide
2⇥BBS: 50mM (N,N-bis(Hydroxyethyl)-
2-Aminoethansulfonat, pH 6.96
1.5mM Na2HPO4
270mM NaCl
Pull-down lysis bu↵er: 10mM Tris/HCl, pH 8.0
100mM NaH2PO4
100mM NaCl
2mM  -Mercaptoethanol
8M Urea
10mM Imidazole
0.05% (v/v) Tween 20
Pull-down wash bu↵er: 10mM Tris/HCl, pH 8.0
100mM NaH2PO4
300mM NaCl
2mM  -Mercaptoethanol
8M Urea
20mM Imidazole
0.05% (v/v) Tween 20
Pull-down elution bu↵er: 10mM Tris/HCl, pH 8.0
100mM NaH2PO4
300mM NaCl
2mM  -Mercaptoethanol
8M Urea
250mM Imidazole
0.05% (v/v) Tween 20
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2.1.6 Media, Antibiotics and inhibitors
Lysogeny broth (LB)-medium (1 l): 10 g NaCl
10 g Tryptone
5 g Yeast extract
Stock Working concentration
Ampicillin 100mg/ml 0.1mg/ml
Kanamycin 25mg/ml 0.025mg/ml
Trichostatin A (TSA) 5mM 1µM
SAHA 10mM 2µM
Sirtinol 10mM 10µM
Na-Butyrate 1M 1mM
Nicotinamide 2M 10mM
2.2 Molecular biology techniques
2.2.1 Purification of DNA
Isolation of plasmid DNA from E. coli was performed with the QIAprep Spin
Miniprep Kit or QIAprep Spin Midiprep Kit. Digested plasmid DNA or PCR
products were purified using the QIAquick PCR Purification Kit or, alternatively,
the QIAquick Gel Extraction Kit if fragments were isolated after agarose gel elec-
trophoresis.
2.2.2 Polymerase chain reaction (PCR)
The Phusion polymerase kit (NEB) was used for preparative PCR reactions ac-
cording to the manufacturers protocol. PCR reactions were performed in a VWR
Collection Thermal Cycler DOPPIO. Primer melting temperatures (Tm) were
calculated with the NEB Tm Calculator (tmcalculator.neb.com). The desired re-
striction enzyme sites were included at the 5’-termini of the primers with 5-10
additional bases for optimal digestion e ciency. Reactions were typically car-
ried out in a 50 µl volume according to the following pipetting scheme and PCR
program:
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10 µl 5x HF Bu↵er
1.5 µl DMSO
1 µl dNTPs (10mM each)
1 µl Forward primer (10µM)
1 µl Reverse primer (10 µM)
1 µl Template DNA (2-10 ng/ µl)
0.5 µl Phusion polymerase (2 units/µl)
35 µl ddH2O
98 C 2min
98 C 10 s
55-72 C 10 s 25-35 cycles
72 C 15 s/kb
72 C 2min
For colony-PCR, the MasterMix (5 PRIME) was used according to the manufac-
turers instructions. Since this kit includes the Taq-polymerase, the extension time
was adjusted to 1min/kb.
2.2.3 Restriction enzyme-based cloning
All restriction enzymes were used according to the manufacturers instructions. For
the insertion of DNA fragments into the desired vector, purified PCR products and
vector DNA (3 µg) were digested with 20 units (U) of each respective restriction
enzyme for 2 h at 37 C and subsequently purified by PCR purification or agarose
gel extraction (see 2.2.1). The DNA concentration of each fragment was then
determined on a BioPhotometer Plus (Eppendorf) at 260 nm (A260). For ligation,
50 ng of digested vector DNA was mixed with the insert DNA at a 1:3 to 1:5 molar
ratio and 1U T4 DNA Ligase in the manufacturers reaction bu↵er in a final volume
of 20 µl. The ligation mixture was incubated at 23 C for 20min and subsequently
used for transformation of E. coli DH5 a (see 2.2.6).
2.2.4 Circular polymerase extension cloning (CPEC)
CPEC is a polymerase based cloning method, allowing for seamless assembly of
multiple DNA fragments (Quan and Tian, 2009). Primers were designed with
⇠25 nt complementarity to the fragment to be amplified and a ⇠25 nt 5’-overhang
matching the sequence of the adjacent fragment. Tms were adjusted to not di↵er
more than ±3 C between all overhangs. After a PCR for each fragment, the
resulting amplicons were purified by agarose gel extraction. 100 ng of amplified
vector DNA and an equimolar amount of insert fragments were used in a 25 µl
reaction (as described in 2.2.2). The reaction was run with the respective annealing
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temperature, elongation time and for 5-10 cycles. The whole reaction was used
for transformation of E. coli DH5 a (see 2.2.6).
2.2.5 Site-directed mutagenesis
For the directed introduction of point mutations into DNA sequences, the Quik-
changeTM method (Stratagene, La Jolla, USA) was used. Forward and reverse
primers were designed to contain the desired mutation flanked by 15 bp comple-
mentary sequences. The reaction was carried out as detailed in 2.2.2 but with
100 ng template and subsequently digested with DpnI for 2 h at 37 C. The entire
reaction was used for transformation of E. coli DH5 a (see 2.2.6).
2.2.6 Transformation of E. coli
Chemically competent E. coli DH5 a and BL21(DE3) were generated by the CaCl2-
method (Mandel and Higa, 1970). In brief, 400ml LB medium were inoculated
with a fresh 5ml pre-culture and grown until an OD600 of 0.3. The culture was
then centrifuged at 500⇥ g for 10min in eight pre-chilled 50ml centrifuge tubes.
Each pellet was resuspended in 25ml sterile ice-cold 0.1M CaCl2, incubated on ice
for 20min and again centrifuged as before. Each pellet was then resuspended in
2ml ice-cold 0.1M CaCl2/15% glycerol and incubated on ice for 1-4 hours. 200 µl
aliquots were snap-frozen in liquid N2 and stored at  80 C. For transformation,
cells were thawed on ice, incubated with plasmid DNA for 30min, heat-shocked
at 42 C for 1min, chilled on ice for 2min and subsequently recovered with 1ml of
LB for 1 h at 37 C. The cells were pelleted for 1min at 8.000⇥ g and plated on
LB agar containing the appropriate antibiotic.
2.3 Biochemical methods
2.3.1 Expression of recombinant proteins
For expression of recombinant proteins, 200ml LB-medium with the appropriate
antibiotic were inoculated with several colonies from a plate of E. coli BL1(DE3)
transformed with the desired construct. The culture was grown at 37 C for 3-4 h
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or over night and then used for inoculation of 10 l of LB-medium at a ratio of
1:50. This culture was grown at 160 rpm and 37 C until an OD600 of 0.8 and then
induced with 250 µM Isopropyl-b-D-thiogalactopyranosid (IPTG). Expression of
SIRT2 was induced at a higher OD600 of 1.5. For the expression of acetylated
proteins, the culture was supplemented with 10mM of N-(e)-acetyl-L-lysine and
20mM nicotinamide at an OD600 of 0.5.
After induction, the temperature was lowered to 18 C and the culture was grown
for another 16-18 h. The culture was subsequently centrifuged at 4000⇥ g and
4 C for 10min. The supernatant was discarded and the bacterial pellets were
resuspended in 100ml Standard bu↵er supplemented with 100 µM phenylmethane-
sulfonylfluoride (PMSF). The resuspended cells were either stored at  80 C or
directly subjected to lysis.
2.3.2 Lysis of cells
Lysis of cells was performed by sonication with a Branson Sonifier 250 for 3min
at 60% duty cycle and micro-tip limit 8. The lysate was cleared by centrifugation
at 4 C and 48,254⇥ g for 45min.
2.3.3 Purification of GST-tagged proteins
Proteins tagged with GST from Schistosoma japonicum were purified by a nity-
chromatography using PureCube Glutathione Agarose (Cube Biotech). The cleared
lysate was applied to a GST-Wash-bu↵er equilibrated column packed with 40-60ml
a nity resin at a flow-rate of 1-1.5ml/ml using an A¨KTApurifier (GE healthcare)
or a peristaltic pump (Carl Roth). The unbound proteins were washed o↵ with
5-10 column volumes (CV) GST-Wash bu↵er followed by a 2 CV wash with Stan-
dard bu↵er to reduce the NaCl-concentration. To cleave the GST-fusion protein,
0.5-1mg TEV-protease was applied to the column and circulated overnight at a
flow-rate of 1ml/min. The protein was eluted with 50ml Standard bu↵er and
concentrated to 1-2ml for a final size exclusion chromatography (SEC) using a
centricon with an appropriate molecular weight cut-o↵ (AmiconUltra, Millipore).
Depending on the molecular weight and multimerization tendency, a HiLoad Su-
perdex 75 pg or S200 pg column was used (GE healthcare). After SEC with Stan-
dard bu↵er, the fractions containing the desired protein were again concentrated
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to 5-20mg/ml, aliquoted and snap-frozen in liquid N2. Proteins were then stored
at  80 C until use.
The column-bound GST-p53 fusion protein was ine ciently cleaved by TEV-
protease and was thus eluted with 50ml GSH-Elution bu↵er. TEV-cleavage was
performed in solution overnight with slow agitation. The solution containing GST,
p53 and uncleaved GST-p53 was concentrated and subjected to SEC with a S200
column. p53 eluted shortly after the size exclusion peak.
2.3.4 Purification of His6-tagged proteins
Proteins tagged with His6 were purified by a nity-chromatography using Ni-
Sepharose 6 Fast Flow resin (GE healthcare). The binding and washing steps
were carried out as described for GST-tagged proteins (2.3.3) but with Ni-Wash
bu↵er. The His6-tagged protein was eluted by a 300ml imidazole-gradient using
Ni-Elution-I and Ni-Elution-II bu↵ers. 5ml fractions were collected. The frac-
tions containing the desired protein were pooled and further processed as described
above (2.3.3).
2.3.5 Determination of protein concentration
Protein concentrations were determined by measuring absorbance at 280 nm (A280)
using UV Cuvettes micro (Brand) in BioPhotometer Plus (Eppendorf). The in-
strument was blanked with the respective bu↵er before measurement. The con-
centration can be determined based on the Lambert-Beer law according to the
following formula:
Ax = ✏x · c · l (2.1)
Ax: Absorbance at wavelength   = x nm
✏x: Molar extinction coe cient (M 1cm 1) at wavelength   = x nm
c: Protein concentration (M)
l: Path length (cm)
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ExPASy ProtParam (Gasteiger et al., 2005) was used to obtain extinction coef-
ficients and molecular weights of proteins. For the extinction coe cient of Ran,
the absorbance of guanine nucleotides at 280 nm (7765 cm-1M-1) was taken into
account (Smith and Rittinger, 2002). Alternatively, the concentration of Ran was
determined with BradfordUltra (Expedeon) according to the manufacturers pro-
tocol but with a 5min room temperature incubation step before readout at 595 nm
(Bradford, 1976). A standard curve was generated using a dilution series of bovine
serum albumin (BSA).
2.3.6 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples were seperated by denaturing, discontinuous SDS-polyacrylamide
gel electrophoresis (Laemmli, 1970). To this end, samples were supplemented with
5xLaemmli bu↵er and denatured at 95 C for 5min. Gels were prepared as follows:
Seperation gel Stacking gel
(5%) (12%)
2M Tris-Cl, pH 8.8 (ml) 7.4 -
1M Tris-Cl, pH 6.8 (ml) - 2.4
30% Acrylamide (ml) 16 3.3
10% SDS (µl) 400 200
TEMED (µl) 24 16
ddH2O(ml) 16 13.9
10% APS (µl) 240 160
Gels were run at 200V for 45 - 60min with SDS-PAGE Running bu↵er. Gels were
either stained with Staining solution or used for Western blotting. Destaining of
gels was carried out with Destaining solution.
2.3.7 Western blotting and immunodetection
Proteins seperated by SDS-PAGE were blotted on PVDF membrane (GE health-
care) by semi-dry transfer in Transfer bu↵er at 150mA for 45min. Prior to blot-
ting, PVDF membranes were activated in methanol for 1min. Successful pro-
tein transfer was monitored by Ponceau S staining (Sigma) for 1min and a brief
subsequent wash with ddH2O. Membranes were blocked in 5% (w/v) skim milk
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powder/PBST for 1 h at room temperature and subsequently incubated with pri-
mary antibody (AB) overnight at 4 C. After three 10min washes with PBST, the
membranes were incubated with HRP-coupled secondary AB for 1 h at room tem-
perature. After another three washes for 10min with PBST, the membranes were
ready for detection using Roti-Lumin (Carl Roth) as HRP-substrate. Depending
on signal strength, detection was carried out either with SuperRX Fujifilms (Fuji)
or with a CCD camera-based Vilber Fusion Express detection system. For long-
term storage, membranes were stripped with 0.2M NaOH for 20min, rinsed with
ddH2O and then dried. For re-activiation, membranes were incubated in methanol
and again blocked as described. Table 2.7 details the ABs and working dilutions
used in this work. The Gel Analyzer tool of the ImageJ software was used for
quantitative densitometric analysis of gel band intensities.
Table 2.7: Antibodies
Antigen Catalog # Species Dilution
Ran ab4781 rabbit 1:2500
acetyl-lysine ab21623 rabbit 1:1500
RanAcK37 - rabbit 1:75
His6-tag ab18184 mouse 1:2000
Sirt2 ab75436 rabbit 1:500
Sirt3 sc-49744 (Santa Cruz) 1:500
GST 71097 (Novagen) mouse 1:1000
Myc ab24740 rabbit 1:1000
rabbit-IgG (HRP) ab6721 goat 1:10000
mouse-IgG (HRP) ab6728 rabbit 1:10000
2.3.8 Generation of the RanAcK37-specific antibody
The RanAcK37-specific AB was generated by Thermo Fisher custom antibody
services. Two rabbits were immunized with an acetyl-TGEFE(AcK)KYVAT-[C]-
peptide and the immune response was monitored at 0, 28, 56 and 72 days. To this
end, crude sera were used at a dilution of 1:1000 for immunodetection of whole
cell lysate, RanWT and RanAcK37. The 72-day-bleed was chosen for further
purification by negative adsorption with the non-acetylated peptide. The flow-
through was further purified by positive adsorption using the acetylated peptide.
The resulting RanAcK37 AB had a concentration of 0.11mg/ml and was used at
a dilution of 1:75.
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2.3.9 Exchange of Ran-bound nucleotides
Ran purified from E. coli is predominantly GDP-bound. To exchange GDP against
GTP, 5-10mg of Ran were incubated in Standard bu↵er with 10mM EDTA
(pH8.4) and a 100-fold molar excess of GTP for 1 h at room temperature in a
total volume of 500 µl. Afterwards, 15mM MgCl2 were added to the exchange
reaction.
For the exchange against the non-hydrolyzable GTP-analog Guanosine-5’-[( b,g)-
imido]triphosphate (GppNHp), 5-10mg of Ran were incubated in Standard bu↵er
with a five-fold molar excess of GppNHp, 10 U of calf intestinal phosphatase
(CIP) and 0.3 µM of GST-RCC1 for 2 h at room temperature in a total vol-
ume of 500µl. GST-RCC1 was removed by adding 20µl equilibrated PureCube
Glutathione Agarose and incubation for 15min at 4 C. The solution was then
separated from the beads by it through a micro-spin filter (CIRO).
In both cases, the reactions were centrifuged at 17,000⇥ g for 5min and subjected
to analytical SEC using a S75 Superdex 75 10/300 GL column (GE healthcare)
with Standard bu↵er as mobile phase to remove excess nucleotides. The fractions
containing Ran were subsequently pooled and concentrated with a 10 kDa cut-o↵
centricon (AmiconUltra, Millipore), snap-frozen in liquid N2 and stored at  80 C
until use.
2.3.10 High pressure liquid chromatography (HPLC)
To determine the ratios of Ran-bound nucleotides, isocratic reversed-phase high
pressure liquid chromatography (RP-HPLC) was used with a Chromolith Perfor-
mance RP-18 endcapped (100-4.6mm) column (Merck) as the stationary phase
and HPLC bu↵er at 2ml/min as the mobile phase. A Merck-Hitachi L-4000
UV detector and a L-6000-A pump were used. The ion-pairing reagent TBAB
contained in the HPLC bu↵er binds to negatively charged phosphate groups of
nucleotides. The more phosphate groups are present, the more TBAB molecules
bind. The binding of TBAB increases the hydrophobicity and thus the retention
time and allows for the separation of di↵erent nucleotides based on charge. For the
measurement, 30 µl of a 150µM protein solution was heated to 95 C for 5min and
subsequently centrifuged at 17,000⇥ g for 5min. 25 µl of the supernatant were
injected and the UV absorbance at 254 nm was recorded over 10min. The peaks
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were assigned based on retention times obtained from standard solutions contain-
ing 150µM of the respective nucleotide. To calculate the ratios of nucleotides, the
area of each nucleotide was divided by the sum of the areas of the assigned peaks.
Peak analysis was carried out using Clarity Lite software (DataApex).
2.3.11 Activity assay for deacetylases
Activity assays for purified deacetylases were performed in KDAC-assay bu↵er us-
ing fluorogenic substrates (as specified in Table 2.8) at 5 µM. Reactions were set up
in triplicates in black 96-well plates with a reaction volume of 50 µl (1000 pmol/reac-
tion). The enzyme concentration was adjusted to theoretically allow for a complete
deacetylation of substrate within 1 h at 37 C based on the activities stated by the
manufacturer. After incubation at 37 C for 30min, 5 µl Developer solution were
added to the reaction, which was subsequently incubated for another 30min at
room temperature. Fluorescence readout was carried out on a Beckman Paradigm
(Wavelength: excitation 350 nm, emission 450 nm).
2.3.12 KDAC-screen
The activities of the purchased classical KDACs and Sirtuins that were determined
experimentally di↵ered substantially from the manufacturers specifications. Thus,
a correction factor was calculated for each enzyme by choosing a 40-fold increase
of signal intensity over background in the activity assay as the reference point.
Given that 100 pmol of recombinant Ran were to be used per reaction in the
screen, instead of 1000 pmol of substrate as in the activity assay, the enzyme
amount was calculated as follows: correction factor⇥(enzyme amount in activity
assay/10). The KDAC-screen was carried out in KDAC-assay bu↵er as triplicate
reactions with 20 µl volume in a 96-well PCR plate. Ran incubated without enzyme
served as a negative control. After incubation for 2 h at 30  C, the 2 µl of each
reaction were spotted on a nitrocellulose membrane, which was then subjected
to co-immunodetection with ABs against acetyl-lysine (AcK) and His6 (2.3.7).
Fluorescent anti-rabbit-Alexa Fluor 680- and anti-mouse-Alexa Fluor 778-coupled
secondary ABs (1:40,000) were used for the simultaneous detection of anti-AcK-
and anti-His6-immunoreactivity, respectively. Acquisition was carried out on a
Odyssey CLx scanner (LI-COR). The spot intensities were quantified using the
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ImageJ Gel Analyzer tool. The signal intensities obtained from detection with the
anti-AcK AB were corrected based on the anti-His6 loading control.
Table 2.8: Recombinant KDACs used for the screen
Supplier/ Construct Catalog # Fluorogenic Amount in screen
Enzyme KDAC substrate (ng/per reaction)
Biomol:
KDAC1 full-length 50051 HDAC Substrate 31 4.28
KDAC2 full-length 50002 HDAC Substrate 3 0.69
KDAC3 full-length 50003 HDAC Substrate 3 0.74
KDAC4 627-1084 50004 HDAC Substrate Class2a2 5.24
KDAC5 657-1123 50005 HDAC Substrate Class2a 1.13
KDAC6 full-length 50006 HDAC Substrate 3 6.61
KDAC7 518-end 50007 HDAC Substrate Class2a 0.32
KDAC8 full-length 50008 HDAC Substrate Class2a 2.02
KDAC9 604-1066 50009 HDAC Substrate Class2a 2.35
KDAC10 1-481 50010 HDAC Substrate 3 0.44
KDAC11 full-length 50011 HDAC Substrate Class2a 1226
Sirt3 102-399 50014 SIRT Substrate 13 3100
Sigma:
Sirt1 full-length S8446 SIRT Substrate 1 3100
Sirt6 full-length SRP5273 SIRT Substrate 1 4000
Sirt7 full-length SRP5274 SIRT Substrate 1 4000
Self-made:
His6-Sirt2 50-356 - SIRT Substrate 1 1000
1 Fluorogenic HDAC Substrate 3, Biomol, Catalog # 50037
2 Fluorogenic HDAC Class2a, Biomol, Catalog # 50040
3 SIRT Substrate 1, fluorogenic, Sigma, Catalog # SRP0308
2.3.13 Deacetylase assays
Deacetylase assays were carried out Standard bu↵er supplemented with 1mM
NAD+ at 23 C unless stated otherwise. Acetylated proteins were incubated with
deacetylase at concentrations as stated in the figure legends. 20µl samples were
taken at indicated time points and then heated for 5min at 95 C to stop the
reaction. The first time point (t=0) did not contain enzyme.
2.3.14 PEPCK1 activity assay
To measure the activity of PEPCK1, a coupled enzyme assay as outlined in Fig. 2.1
was used. The assay was carried with a LS55 Fluorescence spectrometer (Perkin
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Elmer) and Quartz SUPRASIL cuvettes (10mm light path, Hellma Analytics).
The four cuvettes were first calibrated with 150µl of PEPCK1-assay bu↵er (exci-
tation wavelength of 345 nm and a readout wavelength of 470 nm). Then, PEPCK1
was added at a final concentration of 0.2 µM and the fluorescence drop was followed
over 60min.
Phosphoenolpyruvate Oxalacetate Malate
PEPCK1
GDP GTPCO2
NADH
Excitation: 
345 nm
Readout:
470 nm
NAD+
Malate
Dehydrogenase
Figure 2.1: Scheme of PEPCK1 activity assay.
2.4 Cell culture
2.4.1 Cultivation of cell lines
HEK293T cells were cultured in Dulbeccos modified Eagles medium (DMEM) sup-
plemented with 1% (v/v) non-essential amino acids, 1% (v/v) Penicillin/Strep-
tomycin (Gibco) and 5% heat-inactivated fetal calf serum (PAN-Biotech). For
passaging, cells were washed with PBS (PAN-Biotech) and then incubated with
0.25% trypsin-EDTA-solution (Sigma) for 5min at 37 C. The cells were diluted
with fresh pre-warmed growth medium and distributed to new culture plates (TC
Dish 100 or 150 Standard, Sarstedt) to yield the desired cell density. Stocks of
cells were prepared by resuspending trypsinized cells in ice-cold DMEM/10% (v/v)
DMSO and slow cooling to  80 C in a Mr. Frosty Freezing Container (Thermo).
For long-term storage, stocks were then kept at  150 C.
2.4.2 Transfection
HEK293T cells were transfected by calcium phosphate precipitation (Graham and
van der Eb, 1973). In brief, cells were seeded 24 h before transfection to yield
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approximately 50% confluency by the next day and fresh medium was given 1-4 h
before transfection. For a 150mm dish, the transfection solution was prepared as
follows:
20 µg DNA
ad 900 µl ddH2O
100 µl CaCl2 (2.5 M)
After mixing:
1000 µl 2⇥BBS
The mixture was vortexed for 15 s, incubated for 15min at room temperature and
then carefully applied to the cells.
2.4.3 Ni2+-NTA pull-down
For pull-down of His6-tagged proteins, HEK293T cells in 15 cm dishes were trans-
fected as described in 2.4.2. Cells were washed with 10ml ice-cold PBS 16 h after
transfection and harvested with a cell-scraper in 5ml ice-cold PBS. Cells were then
centrifuged for 3min at 500⇥ g and 4 C. The cell pellet was resuspended in 1.8ml
Pull-down lysis bu↵er and sonicated twice for 30 sec with a Branson Sonifier 250
using a microtip (25% duty cycle and micro-tip limit 2). The lysates were subse-
quently transferred into 2ml tubes and cleared by centrifugation for 10 min at
17,500⇥ g . The supernatant was then transferred to fresh 2ml tubes and a 50µl
input sample was taken. The lysates were incubated with 50 µl Ni2+-NTA mag-
netic beads (5 Prime) for 2 h or over night at 4  C with agitation. After washing
thrice with 1ml Pull-down wash bu↵er, His6-tagged proteins were eluted by the
addition of 50 µl Pull-down elution bu↵er. For western blotting, the samples were
not heated to 95 C since heating in Urea led to strong unspecific signals when
detection was performed with the anti-AcK AB.
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2.5 Biophysical methods
2.5.1 Isothermal titration calorimetry (ITC)
Isothermal titration calorimetry (ITC) was carried out on a MicroCal ITC200 or an
Auto-ITC200 instrument (GE healthcare) (Wiseman et al., 1989). Unless stated
otherwise, measurements were performed in Standard bu↵er at 20 C, a stirring
speed of 1000 rpm, 2 µl injections (0.5 µl/sec), an injection-spacing of 120 s and
a target di↵erential power (DP) value of 6 µcal/sec. Protein concentrations are
indicated in the figure or table legends.
ITC allows for the thermodynamic characterization of interactions between mole-
cules. Depending on the binding mechanism heat is either released (negative  H,
exothermic) or absorbed (positive  H, endothermic) when interaction between
molecules takes place. If used in the so-called power compensation mode, one
binding partner at a high concentration is titrated in a step-wise manner into a
solution containing the other lower concentrated binding partner. The instrument
tries to keep the temperature in the measurement cell constant and records the
heating power over time that is required to do so with respect to a reference cell.
For each injection, a peak can be observed in the isotherm until saturation of the
lower concentrated binding partner in the cell is reached. The area of each peak
is then plotted and fitted to a one-site-binding model, which allows for the direct
determination of the reaction enthalpy  H, the equilibrium association constant
KA and the stoichiometry. The reaction entropy  S and the Gibbs energy  G
can be calculated using the following formula:
 G =  H   T S =  RTlnKa (2.2)
2.5.2 Mass spectrometry (MS)
For generation of tryptic or Glu-C peptides, filter-aided sample preparation (FASP)
was used as described (Wisniewski et al., 2009). Separation of peptides was per-
formed by ultra-HPLC with a binary bu↵er system A (0.1% (v/v) formic acid in
H20) and B (0.1% (v/v) formic acid in acetonitrile) and an Easy nano-flow LC
1000 system (Thermo Fisher Scientific). The linear gradient was set up as follows:
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4 to 30%B in 40min, 95%B for 10min, and followed by re-equilibration to 5%
B in 5min. The gradient was run on a 50 cm column (75µm internal diameter)
packed with C18 (resin diameter 1.8µm) at a flow rate of 250 nL/min. The col-
umn temperature was kept constant at 45 C over the course of the separation.
Ultra-HPLC-separated was coupled to a quadrupole based QExactive Plus mass
spectrometer via a nano-electrospray ionization source (both Thermo Fisher Sci-
entific). For acquisition of MS spectra, the automatic gain control target was set
to 3·e6 at a resolution of 70,000 (200m/z) in a mass range of 350-1650m/z. For
ion accumulation, the maximum injection time was set to 60ms. MS/MS spectra
were generated accoding to the Top10 method in the high mass accuracy Orbitrap
after HCD (Higher energy C-Trap Dissociation) fragmentation at 25 eV collision
energy in a 100-1650m/z mass range. The settings were as follows: a resolution
35,000 at 200m/z, an injection time of 120ms and an AGC target of 5·e5.
Raw files were analyzed with MaxQuant (version 1.5.2.) with the embedded An-
dromeda search engine (Cox and Mann, 2008; Cox et al., 2011). Uniprot pro-
teome databases for H. sapiens were used for the assignment of electron spray
ionization-(ESI)-MS/MS fragmentation spectra. The database was complemented
with the expected amino acid sequence of the according Ran construct (i.e. from
pRSFDuet-1-pylT-AcKRS-3 or pcDNA3.1C). Search parameters were set to de-
fault except that the trypsin cleavage was allowed anywhere and the minimum
score for modified peptides was set to zero. For in vivo His6-Ran pulldown, the
total intensities of unmodified Ran peptides after label-free quantification were
used for normalization (to an arbitrary value of 1·1011) of the intensities of the
modified peptides in each condition. For experiments with recombinant acetylated
Ran, the raw intensities of unmodified Ran peptides were used for normalization.
Hendrik Nolte created the heat map and perfomred the hierarchical clustering us-
ing the R heatmap.2 function. It represents the average intensity values of two
independent experiments. The Euclidian method was used to calculate distances.
Complete mode was used for the calculation of linkage.
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2.6 Crystallographic methods
2.6.1 Crystallization
Three di↵erent SIRT2 constructs expressed from pGEX-4T5 were tested for their
propensity to crystallize with the Ran-derived 13-mer peptides (see 2.3). Su -
ciently high purity and amounts were obtained with the described purification
protocol (2.3.3). For the initial screen, each construct was adjusted to a concen-
tration of 10 mg/ml in Standard Bu↵er and supplemented with a 1.2-fold molar
excess of the respective peptide. To remove aggregated protein, the mixture was
centrifuged for 10min at 17,000⇥ g and 4 C and the supernatant was transferred
to a fresh tube. 150 nl drops of protein solution were pipetted into the three wells
of 96-well sitting drop plates, in which screening conditions had been aliquoted
(see 2.1.4). Then 150 nl of the reservoir solution was then pipetted onto the pro-
tein drop. Both steps were carried out with a mosquito Crystal pipetting robot
(TTPlabtech) under humidified atmosphere. The plates were immediately sealed
with HDclear tape (Duck, Henkel) and kept at 20 C. This so-called Sparse-Matrix
Sampling screening method allows for the evaluation of a range of di↵erent bu↵ers,
pH, additives and precipitants for their e↵ect on crystal formation. The di↵erent
conditions have been empirically derived from known crystallization conditions of
various proteins (Cudney et al., 1994; Jancarik and Kim, 1991).
2.6.2 Preparation of crystals for data collection
Crystals were shock-frozen in liquid N2 to protect them from disintegration and
radiation damage during data collection. To this end, crystals were captured
under a stereo microscope with an appropriately sized nylon cryoloop attached
to a mounting pin with a magnetic base (CrystalCap HT, Hampton Research).
The crystals were washed twice in mother liquor, which was supplemented with
15% and 30% D-glucose/10% glycerol as cryoprotectant, respectively. The crystals
were then stored in liquid N2 until data collection.
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2.6.3 Data collection and processing
Crystal di↵raction data were collected at the Swiss Light Source (SLS) of the Paul
Scherrer Institute (PSI) in Villigen, Switzerland using the X06DA/PX3 beamline.
The dataset was recorded at a wavelength of 1.0 A˚ and 100K using a Dectris PILA-
TUS 2M detector in a distance of 165mm. The oscillation range was 0.1 and 1200
frames were recorded. Indexing and integration was performed with MOSFLM
(Leslie and Powell, 2007). The program AIMLESS was used for scaling (Evans
and Murshudov, 2013). The data was assessed for redundancy, completeness of
reflexes, signal to noise ratio of I/ I and resolution. An additional measure of
data quality were Rsym and Rmeas, which are calculated as follows:
Rsym =
P
hkl
NP
i=1
|Ii,hkl   hIhkli|P
hkl
NP
i=1
Ihkl
(2.3)
and
Rmeas =
P
hkl
q
Nhkl
Nhkl 1
NP
i=1
|Ii,hkl   hIhkli|P
hkl
NP
i=1
hIhkli
(2.4)
with miller indices hkl and reflex intensities I (Diederichs and Karplus, 1997).
The collected data contains information about the electron density in the unit cell
but this is limited to the Intensity I and does not include pase information ↵hkl.
However, the phase information is required to determine the electron density as
a function of position x, y, z via Fourier transformation (referred to as the phase
information):
⇢(x, y, z) =
1
V
X
hkl
|Fhkl| e 2⇡i(hx+ky+lz)+i↵hkl (2.5)
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⇢(xyz): Electron density at coordinates x, y, z
|Fhkl|: Amplitude of the reflex structure factor (h, k, l)
↵hkl Phase angle of the reflex (h, k, l)
One way of deriving the phase information is so-called molecular replacement,
which can be used if structures of homologous proteins are already available. For
the structure of SIRT2(50-356)·RanTFAcK37-13-mer-peptide, the initial phases
were determined with the program Phaser (as part of the suite Phenix-dec-1893;
Adams et al., 2010) and by using the SIRT2(43-370)·S2iL5 structure as search
model (PDB: 4L3O; Yamagata et al., 2014). With the program Coot 0.7.1, the
model was build into the 2Fo   Fc (countered at 1.0 s) and Fo   Fc (countered at
3.0 s) electron density maps in iterative rounds of refinement, which were carried
out with Phenix.refine (Afonine et al., 2012; Emsley et al., 2010). The quality
of the structure model was assessed with Molprobity (Davis et al., 2007). The
quality factor Rwork is calculated according to the following formula:
Rwork =
P  |Fobs|  |Fcalc|  
|PFobs| (2.6)
with Fo and Fc as the observed and calculated structure factor amplitudes, respec-
tively.
To account for possible overfitting, typically 5 10% of the reflection data is ex-
cluded from each refinement, which is referred to as the ‘test set’ (as opposed the
other 90 95% of the data termed the ‘work set’). The test set is used to determine
the free R factor Rfree with the above formula. In the final model, the di↵erence
of Rfree to Rfree should not exceed 5% (Bruenger, 1992). Structure figures were
prepared with MacPyMOL (Schrdinger).
3 Results
3.1 Ran acetylation: E↵ects and regulation
The use of the GCEC allows for the in-depth analysis of the impact of lysine-
acetylation on protein function. The high-throughput mass spectrometry data
obtained by Choudary et al. (2009) was the motivation to investigate the e↵ects
and the regulation of Ran acetylation. In the PhD thesis of S. de Boor (2015) a
number of important results are shown regarding the influence of Ran acetylation
on RCC1-mediated nucleotide exchange, nuclear import of Ran by NTF2 and the
binding to importin-b. The present work aims to complete this emerging picture
by the analysis of further interaction partners mainly involved in the control of
nuclear export as well as intrinsic and RanGAP-stimulated nucleotide hydrolysis.
Furthermore, results are presented that give insights into the regulation of Ran
acetylation and deacetylation.
3.1.1 Purification of acetylated Ran
Acetylated Ran was expressed in E. coli by using the described GCEC and pu-
rified with a two-step protocol involving a Ni-NTA a nity chromatography and
a subsequent size-exclusion chromatography (SEC). As an example, purification
of RanAcK71 is shown in Fig. 3.1. Depending on the position of the modified ly-
sine residue in Ran, the purification yields varied between approximately 1.5 and
6.0mg/l of culture volume. Ran wildtype (RanWT) was expressed as a GST-fusion
protein and purified by GSH-a nity chromatography. The yields of RanWT pu-
rifications were usually 3-4mg/l of culture volume. After removal of the GST-tag
by on-column TEV-protease cleavage, the RanWT protein was subjected to SEC.
Both wild type and acetylated variants of recombinant Ran eluted as a single
55
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peak suggesting that the purified proteins were properly folded and that acetyla-
tion does not result in multimerization or aggregation of Ran. Recombinant Ran
could be concentrated to more than 20 mg/ml and was stable for several hours at
room temperature.
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Figure 3.1: Exemplary purification of acetylated Ran (RanAcK71).
(a) SDS-PAGE of samples of the cell lysis as well as the imidazol-gradient. The
chromatogram of the imidazol-gradient shows the absorbance at 280 nm and the
concentration of the elution bu↵er (%B). (b) SDS-PAGE of samples of the S75
(16/60) size exclusion chromatography with the according chromatogram. The
gels were stained with Coomassie brilliant blue (CMB).
To judge the purity of the resulting protein, 5µg were analysed by SDS-PAGE.
In addition, 250 ng of protein were subjected to Western blotting and detected
with an anti-Ran and a pan-anti-acetyl-lysine (AcK) antibody (AB). As depicted
in Fig. 3.2a, all Ran variants were obtained with more than 90% purity, each
one showing a single major band corresponding to the molecular weight (MW)
of RanWT or His6-tagged acetylated Ran (24.6 kDa and 26.1 kDa, respectively).
Ran tends to show a second higher MW band, which most likely corresponds to
a dimer, as described for other proteins subjected to SDS-PAGE at high concen-
trations (Egerman et al., 2015). As opposed to detection with the anti-Ran-AB,
which results in similar signals for all Ran variants, only the supposedly acety-
lated Ran variants are immunoreactive to the pan-anti-AcK-AB indicating the
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incorporation of AcK. Interestingly, the signals obtained vary depending on which
site is acetylated, which likely reflects a preference of the anti-AcK-AB for certain
sequence contexts surrounding each site (and possibly also for structural elements
to some extent).
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Figure 3.2: Purification of acetylated Ran and Ran interaction part-
ners. (a) SDS-PAGE of 5 µg of indicated Ran variants stained with Coomassie
brilliant blue (CMB) and Western blot of 250 ng of Ran variants detected with
indicated antibodies. (b) Representative ESI-MS spectrum of RanAcK37 with
the measured molecular weight as indicated. Theoretical mass: 26043.6 Da. (c)
CMB stained gel after SDS-PAGE of 5 µg of indicated Ran interaction partners.
(Parts of this figure are published in the PhD thesis of S. de Boor, 2015. The
remaining ESI-MS spectra can be found in the appendix thereof.)
.
The RanAcKs were subjected to electrospray-ionization mass spectrometry (ESI-
MS), which allows for the determination of their MWs and thus to infer if an
acetyl-moiety is present. Moreover, based on SDS-PAGE alone it could not be
ruled out that the proteins obtained were not a mixture of acetylated and non-
acetylated species, which however is detectable by ESI-MS as additional peak(s)
in the obtained spectra. Each RanAcK gave rise to a single peak corresponding to
a MW of ⇠26044 Da, consistent with the quantitative incorporation of an acetyl-
moiety at an N-(e)-amino group of a lysine residue and distinct from the MW of
non-acetylated protein (expected MW for His6-RanWT and His6-RanAcK lacking
the first methione residue: 26001.6Da and 26043.6Da, respectively) (see Fig. 3.2b
and the appendix of the PhD thesis of S. de Boor, 2015).
Given their high purity and stability, the purified Ran constructs appeared suit-
able for biochemical and biophysical assays to analyze the e↵ects of acetylation on
Ran function. To this end, interaction partners were also purified by GSH-a nity
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chromatography followed and subsequent SEC, similar to the purification pro-
cess shown for RanWT in Fig. 3.1b. As shown in Fig. 3.2c, RanGAP (S. pombe),
RanBP1 (H. sapiens), CRM1 (M.musculus) and Spn1 (H. sapiens) were obtained
in estimated purities of 85-95%. The quantities varied depending on the protein
but were in each case in the range of 1-5 mg/l of culture volume and thus su -
cient for the purpose of this study. Given the successful purification of both, non-
acetylated/acetylated Ran and these interaction partners, it was feasible to study
the molecular e↵ects of Ran acetylation on protein export and GTP-hydrolysis.
3.1.2 E↵ect of Ran acetylation on intrinsic GTP hydrolysis
The intrinsic GTP hydrolysis is very slow with reported rates of 5.4⇥ 10 5 s 1 at
37 C (Klebe et al., 1995) and thus of limited physiological relevance. Given the
positioning of lysines in the switch regions, it was possible that acetylation at these
sites might interfere with the intrinsic GTP hydrolysis rate of Ran. In particular,
K71 is in close proximity to the catalytic Q69 known to be important for GTP
hydrolysis and could thus potentially influence its orientation upon acetylation
(Fig. 3.3a).
For the determination of GTP hydrolysis rates, Ran was loaded with GTP given
that is predominantly GDP-bound after purification from E. coli (as a result of its
intrinsic ability to hydrolyze GTP). In brief, the nucleotide exchange is achieved
by incubation with EDTA to chelate Mg2+ (crucial for nucleotide binding) and
the addition of a 100-fold molar excess of GTP. After this incubation step, MgCl2
is added to allow for the binding of nucleotide and the protein is separated from
excess nucleotide and salts by SEC. This procedure reliably resulted in Ran that
was at least 75% GTP-loaded (hereafter referred to as RanGTP).
The intrinsic hydrolysis rates were determined by incubation of RanGTP (150µM)
at 30 C in Standard bu↵er. As mentioned above, the intrinsic hydrolysis rate of
Ran has previously been determined at 37 C. However, RanAcK159 was slightly
unstable at these elevated temperatures, so that measurements were instead car-
ried out at 30 C. Samples were taken at indicated time points and subjected to
RP-HPLC to separate the di↵erent nucleotide species (see 2.3.10). As shown in
the exemplary RP-HPLC trace in Fig. 3.3b, GDP has a shorter retention time than
GTP due to its lower charge (resulting in fewer TBAB molecules bound). The area
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of each peak was determined and the peak area ratio of GTP was calculated. Im-
portantly, this ratio is largely una↵ected by the total amount of nucleotide loaded
onto the column allowing for relatively accurate determination of hydrolysis rates.
In fact, for RanWT a rate of 5.88⇥ 10 5 s 1 was obtained at 37 C, which is consis-
tent with the reported value mentioned above (not shown). As expected, at 30 C
this rate was slightly decreased (2.61⇥ 10 5 s 1). Measurement of the acetylated
Ran variants revealed that Ran acetylation at K71 has the strongest e↵ect on the
intrinsic GTP hydrolysis rate, leading to an increase by approximately 1.5-fold
(Fig. 3.3c).
3.1.3 GAP-catalyzed nucleotide hydrolysis and binding to
RanGAP is not a↵ected by Ran acetylation
The slow intrinsic GTP hydrolysis of Ran is greatly accelerated by binding of Ran-
GAP. Analysis of the crystal structure of Ran in complex with RanBP1 and Ran-
GAP suggested that acetylation at K71Ran might also a↵ect RanGAP-mediated
activation of GTP hydrolysis, given the presence of a salt bridge to D103RanGAP
(Fig. 3.4a). Since RanGAP shifts the catalytic Q69Ran closer to the catalytic cen-
ter, interruption of the saltbridge between K71Ran and D103RanGAP could influence
the extent of GTPase activation. Moreover, K99Ran faces an acidic patch in Ran-
GAP (E336-E345RanGAP). It was thus possible that acetylation of K99Ran would
electrostatically and sterically interfere with this interaction.
The RanGAP-mediated GTP hydrolysis was determined using the same method as
described for measurement of the intrinsic hydrolysis rates. In this case however,
the temperature was decreased to 25 C and catalytic amounts (5 nM) of the puri-
fied RanGAP were added to the reaction. This drastically accelerated the hydrol-
ysis rate as expected, showing that RanGAP was active. Surprisingly, RanGAP-
stimulated GTP hydrolysis appears to be largely una↵ected by Ran acetylation
(Fig. 3.4b).
Next, it was tested whether Ran acetylation would have an influence on the bind-
ing a nity to RanGAP. RanGAP binds to Ran with a much higher a nity if Ran
is GTP-bound compared to its GDP-bound form (Seewald et al., 2003). Since
GTP would be rapidly hydrolyzed as a consequence of this interaction, making
the determination of the binding a nity impossible, it was necessary to instead
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Figure 3.3: E↵ect of Ran acetylation on intrinsic GTP hydrolysis.
(a) Ribbon-presentation of RanGppNHp (grey) with important residues for nu-
cleotide binding and hydrolysis (green) and potentially acetylated lysines shown
as sticks (red) (from the Ran-importin-b structure, PDB: 1IBR). The polar in-
teractions towards the GDP molecule are also shown in red. (b) Representative
RP-HPLC traces of RanWT intrinsic GTP hydrolysis. Traces of three time
points are shown (0 h, 3 h, 7 h). 25 µl of 150 µM RanGTP were loaded. The
peaks are assigned based retention times of pure nucleotide standards. (c) In-
trinsic hydrolysis at 30 C with RanWT and acetylated variants. Samples were
taken at indicated time points and the data were fitted using a linear regression
model in Graphpad/Prism.
load Ran with the non-hydrolyzable analog GppNHp. This was achieved by a dif-
ferent method than described for GTP-loading. In this case only a 5-fold excess of
nucleotide (GppNHp) was used and catalytic amounts of the GST-tagged RCC1
were added to accelerate nucleotide exchange. The addition of calf intestinal phos-
phatase leads to the dephosphorylation of GDP to GMP, which is thus withdrawn
from the reaction equilibrium. GST-RCC1 was then removed from the reaction
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Figure 3.4: E↵ect of Ran acetylation on RanGAP-stimulated hydrol-
ysis. (a) Ribbon plot of the ternary RanGAP·RanGppNHp·RanBP1 complex
with potentially acetylated lysines shown as red sticks. The inset shows details
of the salt-bridge involving K71Ran in Ran-RanGAP interface. (b) RanGAP-
mediated hydrolysis of RanWT and acetylated variants at 25 C measured by
RP-HPLC. Samples were taken at indicated time points and the data were fitted
using a linear regression model in Graphpad/Prism.
by incubation with GSH-sepharose beads and Ran was subsequently purified by
analytical SEC. With this protocol GppNHp loading of at least 75% were achieved.
ITC was used to determine the binding a nity of Ran to RanGAP. To this end,
20 µM of RanGAP was titrated with 200 µM RanGppNHp. However, no heat
signals were detected, even when di↵erent NaCl concentrations (0mM, 100mM)
and temperatures were used (10, 20, 30 C) (not shown). Possibly, higher pro-
tein concentrations would be required to allow for this interaction to be mea-
sured by ITC. As an alternative, it was tested whether interaction with RanGAP
could be measured if it is titrated with a preformed complex of RanGppNHp and
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RanBP1. In fact, this situation reflects more accurately the sequence of binding
events occurring during nuclear export since the interaction between RanBP1 and
RanGTP is very tight and thus the RanGTP·RanBP1 complex most likely rep-
resents the physiological RanGAP substrate. As shown in Fig. 3.5a, the binding
reaction of RanGAP and RanGppNHp·RanBP1 (at 200 and 40/40 µM, respec-
tively) is endothermic and solely entropically driven. Surprisingly, the observed
stoichiometry of the reaction was 0.5 if RanGAP was the titrant and 1.5 or higher
if the RanGppNHp·RanBP1 complex was titrated against RanGAP (Fig. 3.5a).
This suggests that, at the concentrations used, either one binding site of the
RanGppNHp·RanBP1 complex is inaccessible for RanGAP or that RanGAP can
bind two complexes. The a nity of the interaction measured by ITC was 540 nM,
which is comparable to the reported a nity of 2µM determined by stopped-flow
(Seewald et al., 2003). Moreover, none of the bu↵er controls showed a signal
comparable to measurement of the complex with RanGAP. It was thus assumed
that the observed isotherms represent the specific interaction of RanGAP with the
RanGppNHp·RanBP1 complex.
For all RanAcKs binding to RanGAP was observed with a similar entropically
driven mechanism (Fig. 3.5c). However, di↵erences in DH and DS were observed.
In particular, RanAcK71 shows a less positive DH but is also less entropically
favored. Overall this leads to only a small change in DG and a nity (800 nM) but
points towards a slight change in binding mechanism. The disruption of the salt-
bridge between K71Ran and D103RanGAP thus has only a small e↵ect on the Ran-
RanGAP interaction. By constrast, RanAcK99 shows both a less favorable DH
and DS and the a nity is lowered to 17µM. This suggests that indeed acetylation
at K99Ran disturbs the interaction of Ran with the aforementioned acidic patch of
RanGAP.
Since RanAcK99 showed no e↵ect on RanGAP-mediated GTP hydrolysis (Fig. 3.5c),
it was possible that the observed decrease in a nity of Ran for RanGAP upon
acetylation at K99Ran was RanBP1-dependent. The RanGAP-stimulated GTP
hydrolysis was thus tested in presence of RanBP1 for RanWT and RanAcK99.
However, no di↵erence was observed for RanAcK99 in the presence of RanBP1
(Fig. 3.5d), suggesting that the decreased binding a nity does not adversely af-
fect the RanGAP-mediated hydrolysis. However, it should be noted that the mea-
surements of RanGAP-stimulated GTP hydrolysis were performed under multiple
Results 63
ba
c d
WT
Ac
K3
7
Ac
K6
0
Ac
K7
1
Ac
K9
9
Ac
K1
59
∆G
∆H
-T∆S
Kd (µM):
N-Value:
0.5
0.5
0.7
0.5
2.1
0.3
0.8
0.5
17.0
0.5
1.7
0.3
Cell: RanBP1•RanGppNHp
Injectant: RanGAP
-30
-20
-10
0
10
20
kc
al/
m
ol
0 10 20 30 40 50
0.0
0.5
1.0
1.5
WT
AcK99
Time (min)
Pe
ak
 A
re
a 
Ra
tio
 
GT
P 
/ (
GT
P 
+ 
GD
P)
 
Figure 3.5: Interaction of RanGAP with RanGppNHp·RanBP1. (a)
ITC trace of RanGppNHp·RanBP1 (40/40 µM) titrated with RanGAP (200 µM)
at 20 C. (b) Same as in (a) but with tritrant and analyte exchanged. (c)
Signature plots, N-values and a nities observed for binding of RanGAP to
RanBP1 in complex with acetylated Ran variants under the conditions used
in (a). The ITC traces can be found in the Appendix A.2. (d) RanGAP-
stimulated GTP hydrolysis of Ran in the presence of RanBP1 for RanWT and
RanAcK99 as indicated.
turnover conditions. Thus, an e↵ect of K99Ran acetylation on RanGAP-stimulated
GTP hydrolysis might in fact be observed under single turnover conditions.
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3.1.4 Impact of Ran acetylation on the interaction with
RanBP1
Next, it was tested whether Ran acetylation would interfere with binding to
RanBP1, as an important regulator of export complex disassembly. RanBP1 binds
to both RanGDP and RanGTP but with markedly di↵erent a nities, which is due
to a much higher dissociation rate between RanGDP and RanBP1. This is im-
portant for the release of Ran from RanBP1 after RanGAP-mediated hydrolysis
(Kuhlmann et al., 1997). The C-terminal tail of Ran containing the DEDDDL mo-
tif forms electrostatic interactions with a basic patch on RanBP1 and with K37Ran
and K152Ran. The interactions of Ran with its own C-terminus are not resolved in
the structure of RanGAP·RanGppNHp·RanBP1 (PDB: 1K5D) but are present in
both the structure of the CRM1·RanBP1·RanGTP complex (PDB: 3M1I) and the
RanBD1·RanGppNHp complex (PDB: 1RRP). It has been proposed that RanBP1
sequesters the C-terminal tail of Ran to mediate its dissociation from nuclear trans-
port receptors (Koyama and Matsuura, 2010; Vetter et al., 1999).
Given this the involvement of K37Ran in the interaction of Ran and RanBP1, it
was interesting to test if it was a↵ected by acetylation of Ran. First, the binding
of RanBP1 towards RanGDP was characterized using ITC. To this end, 20 µM
RanBP1 was titrated with 200 µM RanGDP, which resulted in an a nity of 7.1µM
in an exothermic reaction (Fig. 3.6a). This value correlates well with the reported
a nity for this interaction of about 10 µM (Kuhlmann et al., 1997). Since a nity
of RanBP1 for RanGTP was reported to be in the low nanomolar range, the
protein concentrations where lowered to 5µM RanGppNHp and 50 µM RanBP1
in order to increase the sensitivity of the measurements (exchange of titrant and
analyte was chosen for better quality). Under these conditions, an a nity of 3 nM
was observed.
Most RanAcKs showed binding to RanBP1 in both the GDP- and the GppNHp-
loaded form with a nities similar to RanWT (Fig. 3.6c and d). Unexpectedly,
the most pronounced e↵ect was observed for RanAcK159, which showed a di↵er-
ent thermodynamic profile but unaltered a nity in the GDP-bound form and an
approximately 10-fold decrease in a nity in the GppNHp-bound form (33 µM).
However, binding to RanBP1 was not a↵ected by acetylation of K37Ran.
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Figure 3.6: Interaction of RanBP1 with acetylated Ran. (a) ITC trace
of RanBP1 (20 µM) titrated with RanGDP (200 µM) at 20 C. (b) RanGppNHp
(5 µM) titrated with RanGppNHp (50 µM) at 20 C. (c and d) Signature plots,
N-values and a nities observed for binding of RanBP1 to acetylated RanGDP
or RanGppNHp variants, respectively. Conditions were as in (a) and (b), re-
spectively. The ITC traces can be found in the Appendix A.3 and A.4.
3.1.5 Ran acetylation interferes with export complex for-
mation
According to the current model, RanGTP and cargo cooperatively bind to export
receptors to mediate the cargo export (Monecke et al., 2013). CRM1 is a major
export receptor for many di↵erent cargo proteins, which bind to CRM1 via an
NES. To model export complex formation in vitro, Spn1 was used as a cargo
protein, which itself is an import adapter for splicesomal snRNPs and thus has to
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be recycled into the cytoplasm by nuclear export (Huber et al., 1998). The reason
for this choice was that it has been studied extensively for its binding mechanism
to CRM1, including the solution of the crystal structure of Spn1 in complex with
CRM1 and RanGTP (Monecke et al., 2009).
To establish an ITC-based export complex formation assay, the di↵erent combina-
tions of interaction partners were first tested for binding. The measurements had
to be carried out at 10 C and a lower stirring speed (700 rpm) since CRM1 showed
a tendency to precipitate at higher temperatures and at the usual stirring speed
of 1000 rpm. First, binding of Spn1 to CRM1 was measured at 200 µM and 20 µM,
respectively. The resulting binding isotherm is similar to those of previously re-
ported ITC experiments and yields a comparable a nity of 1.2µM (Fig. 3.7 top
left; reported a nity: 1.4µM). Also in accordance with published data, the titra-
tion of CRM1 with RanGppNHp did not produce an isotherm that would indicate
a binding event (Dong et al., 2009) (Fig. 3.7 bottom left). Other groups have re-
ported that RanGTP binds to CRM1 with a KD in the micromolar range, which
is lowered to a low nanomolar value in the presence of Spn1 (Paraskeva et al.,
1999; Petosa et al., 2004). When determined by ITC, an improvement in binding
was indeed observed in presence of Spn1, yielding a KD of 2 µM for the interaction
of RanGppNHp with CRM1 (Fig. 3.7 top right). This a nity is however about
three orders of magnitude lower than previously described. A possible explanation
for this discrepancy might be that binding constants have previously been deter-
mined with an indirect GAP-protection assay, in which the RanGAP-stimulated
GTP hydrolysis is used as a readout for the amount of CRM1-bound RanGTP (a
state in which GTP hydrolysis cannot occur). As suggested by the cooperative
model of export complex formation, the interaction of Spn1 and CRM1 was also
improved in presence RanGppNHp, resulting in a KD of 280 nM instead of 1.2 µM
(Fig. 3.7 bottom right). Albeit the di↵erence regarding the binding a nity of Ran
to the CRM1·Spn1-complex, the ITC-based in vitro assay thus overall reflected
the proposed mechanism of export complex formation (Fig. 3.7 center) (Monecke
et al., 2013).
In the crystal structure of the CRM1·Spn1·RanGTP CRM1 complex, Ran is em-
bedded in the center of the ring-shaped CRM1. Spn1, in turn, is bound to outer
surface of of this ring, not directly contacting Ran. However, given the coopera-
tivity in binding to CRM1, there is a clear indirect influence of Ran on the CRM1-
Spn1 interaction and vice versa. CRM1 and Ran have a large binding interface
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Figure 3.7: ITC-based in vitro export complex formation assay.
Isotherms of ITCs with indicated proteins or protein complexes. All measure-
ments were carried out at 10 C. In each case, for the titrant, a concentration of
200 µM was used and 20 µM for the analyte. Complexes were preformed with
a two-fold molar excess of Ran or Spn1 as indicated. The model in the center
illustrates the di↵erent binding combinations with a nities measured by ITC
in this study.
involving two electrostatic interactions between K37Ran and D931/T932CRM1, and
between K71Ran and D436/E843CRM1 (Fig. 3.8a, PDB: 3GJX).
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Ran acetylation could either directly influence the Ran-CRM1 interaction or could
indirectly alter the ability of RanGTP to promote binding of Spn1 to CRM1. The
first scenario was tested by titration of the preformed Spn1·CRM1 complex with
GppNHp-loaded acetylated Ran variants using the same conditions as described
above for RanWT. The binding of RanGppNHp to Spn1·CRM1 was largely un-
a↵ected by acetylation. Only RanAcK71 showed a decreased DH and an about
5-fold decrease in a nity (Fig. 3.8b).
The second scenario was tested by preforming the RanGppNHp·CRM1 complex
and subsequent titration with Spn1, also as described above for RanWT. Again all
acetylated Ran variants were able to bind and, in case of RanAcK37, 99 and 159,
the a nity was increased about 4 to 7-fold (Fig. 3.8c). For RanAcK37 and 159,
this is due to a more favorable entropic contribution while for RanAcK99 both
the enthalpy and entropy contribute to the higher a nity. Given these increased
a nities, it is possible that acetylation of K37, 99 and 159 would promote export
complex formation.
3.1.6 in vivo acetylation of Ran by KAT overexpression
Acetylated Ran was so far only found by high-throughput MS, for which enrich-
ment of acetylated peptides with an anti-AcK antibody-resin is a crucial step.
Thus, it was interesting to test under which conditions Ran acetylation would be
upregulated. However, detection of acetylation turned out to be challenging. In
initial attempts, anti-AcK agarose beads from ImmuneChem were used to immuno-
precipitate Ran from whole cell lysates of HeLa and HEK293T cells and the eluate
was subsequently probed with an anti-Ran-AB. Although these beads have been
used for AcK-peptide enrichment in high-throughput MS screen, this approach was
unsuitable mainly for two reasons: First, the immunoprecipitation (IP) is ideally
carried out under native conditions to ensure the integrity of the antibody, which
however also allows for co-immunoprecipitation of Ran by an acetylated binding
partner. Second, Ran bound non-specifically to the agarose beads, making the
specific detection of acetylated Ran impossible with this method.
As an alternative, Ran was overexpressed by transfection as a His6-tagged con-
struct in HEK293T cells. This approach has the major advantage that Ran can
be isolated by Ni-NTA pulldown under denaturing conditions in bu↵er containing
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Figure 3.8: Impact of Ran acetylation on in vitro export complex
formation. (a) Ribbon plot of the ternary Spn1·RanGppNHp·CRM1 complex
with potentially acetylated lysines shown as red sticks. The inset shows details
of the salt-bridges involving K37Ran and K71Ran in the Ran-CRM1 interface
(PDB: 3GJX). (b and c) Signature plots, N-values and a nities observed for
binding of (b) RanGppNHp (200 µM) to the Spn1·CRM1 complex (40/20 µM)
or (c) of Spn1 (200 µM) to the RanGppNHp·CRM1 complex (40 µM/20 µM).
All measurements were carried out at 10 C. The ITC traces can be found in
the Appendix A.5 and A.6.
8M Urea. Under these conditions proteolysis and loss of post-translational modifi-
cations is minimized due to the rapid denaturation and hence inactivation of most
enzymes in the lysate. After pulldown of His6-Ran the eluate was probed with the
pan-AcK AB. This method however does not involve enrichment for acetylated
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proteins as with the anti-AcK agarose and is thus not suitable for the detection
of low-stoichiometry acetylation. Due to the overexpression, it is also not suitable
for the analysis of potentially acetylated proteins that are normally present at low
levels since the respective KATs may not be su ciently active for their quanti-
tative modification. An additional complicating factor in the analysis is the fact
that detection sensitivity with the anti-AcK-AB varies from site to site. In case of
recombinant Ran, the sites AcK37, 99 and 159 showed particularly weak signals
even when 250 ng of purified acetylated protein were used for immunoblotting.
As shown in Fig. 3.9a by detection with the anti-Ran-AB, the expression and
isolation of His6-Ran from the cell lysate worked e ciently. However, no AcK-
signal was detected when His6-Ran from HEK293T (not shown). Within the
limitations of this assay, it can thus be assumed that the stoichiometry of Ran
acetylation is low under the cellular condition tested. Also, coexpression of His6-
Ran with selected KATs (one for each KAT family) did not result in an acetylation
signal for Ran, although all KATs were overexpressed as intended (Fig. 3.9a).
To further investigate the acetylation state of Ran, the samples (isolated His6-Ran
with or without KAT coexpression) were subjected to tryptic digest and subse-
quently analyzed by tandem MS. Label-free quantification with the MaxQuant
software was used to account for di↵erences in protein amounts between samples.
The intensities of the acetylated peptides were then normalized by the collected
intensities of unmodified Ran peptides in each sample. To increase the statisti-
cal robustness of the analysis, the experiment was performed twice. With this
method, surprisingly, none of the lysines were found acetylated that have pre-
viously described for human samples. Instead, acetylation at K134, K142 and
K152 was detected, with AcK152 being only present upon a-Tubulin overexpres-
sion while both AcK134 and AcK152 were found in all but the a-Tubulin- and
Gcn5-samples. Peptide intensities of these latter sites were approximately 2-fold
increased upon coexpression with TIP60, CBP and p300 suggesting that these
KATs directly or indirectly a↵ect Ran acetylation (Fig. 3.9b).
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Figure 3.9: MS based detection of acetylated Ran in HEK293T cells.
(a) Representative immunoblot of input and eluate samples of a Ni-NTA pull-
down of His6-Ran. The eluate samples containing His6-Ran were used for tan-
dem MS-analysis. (b) Intensity plot and hierarchical clustering of acetylated
peptides detected by tandem MS. Results from two independent experiments
were combined. Grey fields are shown if the corresponding sample was not found
in the respective sample.
3.1.7 An in vitro KDAC screen identifies SIRT1-3 as Ran
deacetylases
Next, the regulation of Ran by deacetylases was investigated. Given that, over the
course of this work, acetylated Ran was purified in a homogeneous and site-specific
manner, opened the possibility to individually test each site for deacetylation by
human KDACs. To this end, all eleven ‘classical’ KDACs (Class I, II and IV)
and the Sirtuins 1, 3, 6 and 7 (Class III) were obtained from commercial sources
as recombinant proteins. The enzymes had been expressed in E. coli or in cell
lines (insect or mammalian) and tested for activity with fluorigenic acetylated
substrate peptides (Fluor-de-Lys assay). At this point, the only KDAC that was
not purchased was SIRT2, which was instead purified from E. coli in the laboratory.
It turned out that the activities of the purchased enzymes di↵ered substantially
from the manufacturers specifications. As evident from the data of our own Fluor-
de-Lys assay, the signals vary drastically between KDACs although in each case
the amount of enzyme was calibrated to theoretically yield the same fold increase
over background (Fig. 3.10a and b).
Based on the newly obtained activities, a screen was performed to identify deacety-
lases of the five investigated acetylation sites of Ran. For this screen, 100 pmol
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Figure 3.10: Activities of recombinant KDACs used for in vitro
deacetylase screen. (a) Fluor-de-Lys assay of recombinant Sirtuins (Class
III s). The intensities obtained by fluorescence readout (Ex: 350 nm/ Emis-
sion: 450 nm) were normalized to the background signal and are shown as fold
increase. Error bars indicate the variation among technical triplicate measure-
ments. (b) The same as in (a) is shown for the classical KDACs (Class I, II
and IV).
of recombinant acetylated Ran were mixed with enzyme and incubated at 30 C
for 2 h (su ciently long to allow for complete deacetylation if deacetylation of
the respective site was as e cient as deacetylation of the fluorigenic peptide sub-
strate). The reactions were run in triplcates and then spotted onto nitrocellulose
membranes, which were then subjected to co-immunodetection with antibodies
against AcK and His6. To allow for densitometric quantification and simultane-
ous detection of both the AcK and His6 signals, fluorescent secondary antibodies
in di↵erent colors were used and fluorescent readout was carried out on a digital
scanner. As shown in Fig. 3.11a, none of the Ran acetylation sites were deacety-
lated by classical KDACs by more than 40%. This is in contrast to the Sirtuin
deacetylases (Class III). Here, incubation with SIRT2 led to an almost complete
loss of AcK immunoreactivity for RanAcK71. Also, the signal of RanAcK37 was
substantially decreased when incubated with SIRT1, -2 and -3 (Fig. 3.11b).
To confirm that SIRT1-3 can deacetylate Ran in vitro, the experiment was re-
peated in a similar fashion but this time analyzed by Western blotting. Again,
Ran was robustly deacetylated at K37 by SIRT1-3 and at K71 by SIRT2 after two
hours. Deacetylation only occured in presence of the obligatory co-factor NAD+
and was inhibited by the pan-Sirtuin inhibitor Nicotinamide (NAM; Fig. 3.12a).
Following the reaction over 90 minutes furthermore revealed that deacetylation of
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Figure 3.11: In vitro deacetylase screen for recombinant Ran. (a)
Classical KDACs (Class I, II and IV) were tested for deacetylation of Ran
acetylated at the indicated sites (incubation for 2 h at 30 C). Detection was
performed with an anti-AcK-AB and signals were adjusted based on the anti-
His6 loading control. Signals were normalized to a control reaction without
enzyme. Error bars indicate the variation among technical triplicate measure-
ments. (b) As in (a) but for Sirtuin deacetylases (Class III).
RanAcK37 occurred fastest with SIRT2 and again showed the specific deacetyla-
tion of RanAcK71 by SIRT2, which however was slower than deacetylation at K37
(Fig. 3.12b). Interestingly, in a microarray-based peptide screen for deacetylation
by Sirtuins, neither the RanAcK37 nor -AcK71 peptide was deacetylated, suggest-
ing that immobilization of the peptides prevented deacetylation or that secondary
structure elements are required for substrate recognition by these Sirtuins (Rauh
et al., 2013).
Since small GNBPs such as Ran change their confirmation depending on the bound
nucleotide, it was possible to test the influence of structural changes on the deacety-
lation. Both K37 and K71 are located in the switch regions of Ran (switch I and
II, respectively), which change their confirmation most dramatically. When GDP-
and GppNHp-loaded forms of Ran were compared regarding their deacetylation by
SIRT2, RanAcK37 was not di↵erentially deacetylated whereas an increased rate
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Figure 3.12: Deacetylation of RanAcK37 and -AcK71 by SIRT1-3.
(a)Western blot of deacetylation experiment. Ran was incubated with Sirtuins
for 2 h. SIRT1 and -2 are detected with an anti-His6-AB. SIRT3 is detected
with an anti-GST-AB. Concentration of Ran was 12 µM, the concentrations of
Sirtuins were chosen according to the activities determined in this study (SIRT1:
0.7 µM, SIRT2: 0.5 µM, SIRT3: 0.9 µM). NAM: Nicotinamide (10mM). (b)
Time course experiment under the same conditions as in (a). Samples were taken
at indicated time points. The graph shows the densitometric quantification of
the anti-AcK-AB detection.
of deacetylation was observed for GppNHp-loaded RanAcK71 (Fig. 3.13a and b).
This is surprising given that the switch II adapts are more rigid confirmation when
Ran is GTP-bound and may thus indicate that SIRT2, in addition to a certain
sequence context, requires structural elements for substrate recognition, which are
not present in the more flexible switch II loop of RanGDP.
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Figure 3.13: Deacetylation of RanGDP and -GppNHp by SIRT2. (a
and b) Time-resolved deacetylation of Ran loaded with GDP or GppNHp as
indicated. Concentration of Ran was 12 µM. The concentration of SIRT2 was
0.14 µM for RanAcK37 (molar ratio 1:86) (a) and 0.53 µM for RanAcK71 (molar
ratio: 1:23) (b). Samples were taken at indicated time points. The graph shows
the densitometric quantification of the anti-AcK-AB detection. This experiment
was conducted by and is also shown in the PhD Thesis of S. de Boor (2015).
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3.2 Analysis of di-deacetylation by Sirtuins
The above results regarding the deacetylation of Ran were the starting point for
a series of experiments, which aimed at the elucidation of Sirtuin substrate recog-
nition. The specificity of Sirtuins is highly debated and any further insight in
its underlying mechanisms should promote the understanding of Sirtuin biology.
With the GCEC at hand, deacetylation could be studied on natively folded pro-
teins rather than short peptides, making the results shown in the following second
part of this work particularly valuable for the lysine-acetylation research commu-
nity.
3.2.1 SIRT2 deacetylates Ran at two adjacent lysines
The observation that RanAcK37 is deacetylated by SIRT1-3 and the fact that Ran
also contains a lysine at position 38 o↵ered the opportunity to test the sequence
specificity of deacetylation. Some studies provide evidence that SIRT1-3 predom-
inantly act on unstructured regions and have little sequence specificity (Blander
et al., 2005; Khan and Lewis, 2005) while others implicate that substrate recog-
nition is dependent on the amino acid sequence surrounding the AcK but in a
context-dependent fashion (Garske and Denu, 2006; Smith et al., 2011). If indeed
SIRT1-3 deacetylate lysines in unstructured regions irrespective the of surrounding
sequence, RanAcK38 should be an equally good substrate.
To put the di↵erent models of Sirtuin substrate recognition to the test, RanAcK38
and moreover the di-acetylated variant RanAcK37/38 were purified as described
above for the other acetylation sites. Both purifications were successful and AcK
immunoreactivity indicated the incorporation of AcK as desired. However, the di-
acetylated RanAcK37/38 was less pure and lower yields were obtained suggesting
that incorporation of AcK is translationally less e cient than that of natural amino
acids under the conditions used. A RanAcK37 specific antibody that was initially
raised against the peptide TGEFE(AcK)KYVAT to detect acetylation at this site
in cell lysates was useful to discriminate between di↵erent acetylation states of
Ran. It shows high reactivity against RanAcK37, none against RanAcK38 and
very weak reactivity against RanAcK37/38 (Fig. 3.14a).
When the three di↵erent acetylated Ran variants AcK37, AcK38 and AcK37/38
were tested with SIRT2 in a time course experiment, deacetylation of AcK37 was
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substantially faster than that of AcK38 indicating that the amino acid sequence
plays a role in substrate recognition. Surprisingly, deacetylation of AcK37/38
was faster than that of the mono-acetylated RanAcK38, showing a rate similar to
RanAcK37 (Fig. 3.14b). Measurement of the a nities towards SIRT2 via ITC sup-
ports this observation in that both RanAcK37 and -AcK37/38 show an isotherm
consistent with an exothermic binding reaction and an a nity of 24 and 9.7µM,
respectively. This in constrast to RanAcK38, which shows no such thermodynamic
profile and thus probably binds SIRT2 with much weaker a nity (for the ITCs,
SIRT2 without an His6-tag was used; concentrations: 45µM Ran and 450 µM
SIRT2; Fig. 3.14c).
3.2.2 Mass spectrometric analysis of Ran di-deacetylation
Given the slow rate of AcK38-deacetylation, it seemed likely that deacetylation
of RanAcK37/38 occurs sequentially with AcK38 being deacetylated first. To
test this hypothesis, RanAcK37, -AcK38 and AcK37/38 were incubated with a
two-fold molar excess of SIRT2 and increasing NAD+ concentrations up to a
molar NAD+:Ran ratio of 1:1. Due to the excess of SIRT2, deacetylation was
expected to occur as a single turnover reaction and to be limited by the avail-
ability of the co-factor NAD+. As a result, only partial deacetylation of Ran
was expected with submolar NAD+ ratios. The reactions were blotted and either
detected with the anti-AcK-AB or the aforementioned specific antibody against
RanAcK37 (anti-RanAcK37-AB) using ECL and a CCD-camera system. As antic-
ipated, the acetylation signals of RanAcK37 and -AcK38 decrease with increasing
NAD+-concentrations when detection was performed with the anti-AcK-AB while
the signal of RanAcK37/38 drops only to an intermediate level, indicative of an
incomplete di-deacetylation due to the NAD+-limitation (two molecules of NAD+
are needed per di-acetylated substrate).
When detected with the specific anti-RanAcK37-AB, the signal of RanAcK37
drops with increasing NAD+ amounts (as observed before with the anti-AcK-AB)
while, as expected, RanAcK38 shows no signal. Strikingly, the signals of the
RanAcK37/38 samples increase toward a NAD+:Ran ratio of 1.0, indicating the
formation of RanAcK37 during the deacetylation of RanAcK37/38 (Fig. 3.15a and
b). However, a substantial di↵erence is observed between the maximum signals of
RanAcK37/38 and RanAcK37 when detected with the anti-RanAcK37-AB. This
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Figure 3.14: SIRT2 can deacetylate Ran at two neighboring lysines.
(a) SDS-PAGE of 5 µg of indicated Ran variants stained with Coomassie bril-
liant blue (CMB) and Western-blot of 250 ng of Ran variants detected with
indicated antibodies. (b) Time course of Ran deacetylation by SIRT2. Concen-
tration of Ran was 12 µM. The concentration of SIRT2 was 0.14 µM (molar ratio
1:86). This experiment was conducted by and is also shown in the PhD Thesis
of S. de Boor (2015). (c) Isotherms of ITCs with 45 µM Ran and 450 µM SIRT2.
Measurements were carried out at 20 C in Standard bu↵er supplemented 10mM
Nicotinamide.
could be due to two di↵erent reasons: Deacetylation of RanAcK37/38 might have
occurred at both sites with similar preference resulting in one Ran fraction acetyl-
modified at K37 (which is detected) and another fraction acetyl-modified at K38
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(which is not detected). Alternatively, the reaction product may comprise a mix-
ture of RanAcK37/38, RanAcK37 and fully deacetylated Ran. The latter scenario
would be consistent with the fast deacetylation rate observed for RanAcK37/38
since no RanAcK38 would form during the reaction.
To understand in more detail the deacetylation reactions in this experiment, the
samples of RanAcK37/38 were subjected to tandem MS. Given the inability of
trypsin to cut C-terminally of acetylated lysines, which would result in an un-
desirably long peptide for the di-acetylated form, GluC was chosen for digestion
instead. The data was scanned for peptides containing K37/38, including those
that were acetyl-modified. Of these unmodified and acetylated peptides, only a
minor fraction was identified by MS/MS as opposed to a larger fraction that was
found by matching. While this is not a problem for the di-acetylated peptide
since it stands out through its higher mass, identification by matching does not
allow the distinction between the AcK37 and the AcK38 peptide due to their same
theoretical mass. Moreover, even mono-acetylated peptides that were fragmented
could not always be assigned to one particular site, which is an inherent problem of
fragment ionization of di-lysine containing peptides. However, all MS/MS spectra
that allowed assignment of the acetyl-moiety were consistent with its localization
at K37. It thus appears likely that AcK38 peptides were not present in the sam-
ples and that mono-acetylated peptides identified by matching or with ambiguous
MS/MS spectra correspond to the AcK37 state. This assumption is further cor-
roborated by the fact that also in tryptic digests AcK38 was not found or only at
background levels. Consistent with the Western blot data (RanAcK37/38 detected
with anti-RanAcK37-AB), the average intensity of the mono-acetylated RanAcK37
peptide increased with increasing NAD+ concentrations. This is in contrast to the
di-acetylated RanAcK37/38 peptide, the average intensity of which decreases with
increasing amounts of NAD+ (Fig. 3.15c). Interestingly, also the average intensity
of the unmodified is increasing towards higher NAD+ ratios, suggesting complete
deacetylation of a fraction of initially di-acetylated Ran. This finding is consis-
tent with the Western-blot data where RanAcK37/38, at an NAD+:Ran ratio of
1.0, did not reach the same level of intensity as RanAcK37 at an NAD+:Ran ra-
tio of 0.0. Taken together, the above data support the model that SIRT2 first
deacetylates RanAcK37/38 at K38 and subsequently at K37.
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Figure 3.15: Sequential deacetylation of RanAcK37/38. (a) Ran
(12 µM) was incubated with SIRT2 (24 µM) in presence of the indicated fold-
amount of NAD+. The reaction was incubated for 10min followed by Western
blotting and detection with antibodies against AcK, RanAcK37 or Ran. (b)
The graphs show the raw ECL signal intensity as measured with ImageJ for the
indicated antibody detections. (c) Average peptide intensities from MS/MS
data of RanAcK37/38 at di↵erent NAD+ amounts. Samples are from the same
experiment as in (a) and (b).
3.2.3 Mutational analysis of the Ran di-deacetylation site
Since acetylation of K37Ran stimulates SIRT2-mediated deacetylation of AcK38Ran,
it was next investigated whether this e↵ect could be mimicked by the introduction
of di↵erent amino acids at position 37. Three mutated variants of RanAcK38 were
purified, carrying an alanine, glutamine or arginine at position 37 (Fig. 3.16a).
Glutamine is often used to mimic an acetylated lysine given its similar charge
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characteristics. However, due to the shorter chain length, it cannot account for the
sterical e↵ects that might result from acetylation of lysine. The charge conserving
mutation to arginine is often used to generate a lysine-mimetic residue that cannot
be acetylated. It can however result in steric hindrance and thus e↵ectively mimic
the e↵ect of lysine-acetylation in this regard. The mutation to alanine (as the
amino acid with the smallest side chain) eliminates any special chemical features
at that position.
To test which chemical property of AcK at position 37 prevails in the acceleration
of AcK38-deacetylation, the three mutated variants were tested in a time course
experiment with SIRT2. As shown in Fig. 3.16b, all three mutations lead to a faster
deacetylation of RanAcK38. This suggests that, among those tested, a lysine
at position 37 is the least favored residue for deacetylation of the neighboring
AcK38. Given the accelerated deacetylation of AcK38 by both the K37Q and
the K37R mutation furthermore indicates that steric and charge properties of the
acetyl-moiety are important for the faster deacetylation of AcK38 observed upon
acetylation of K37.
3.2.4 Structural insights into di-deacetylation
To gain structural insights into the recognition of the two neighboring AcK residues,
it was attempted to crystallize RanAcK37 or RanAcK37/38 in complex with
SIRT2. However, despite significant e↵orts no crystals were obtained. It should be
note that to date only structures of Sirtuins in complex with substrate peptides
have been solved but none with a protein substrate. Instead of co-crystallizing
SIRT2 with Ran protein, it was thus tried to use Ran-derived 13-mer peptides.
Several analogs of acetyl-lysine have been described, some of which bind substan-
tially stronger to Sirtuins than natural acetyl-lysine and can e↵ectively not be
deacetylated (Smith and Denu, 2007). Based on these data, Ran-peptides con-
taining N-(e)-trifluoroacetyl-L-lysine (TFAcK, peptide sequence: LTGEFEKKY-
VATL) were synthesized with the modified residue at the position(s) corresponding
to Ran K37, K38 or K37/38.
To confirm that these peptides show binding behavior similar to the full-length Ran
protein, their interaction with SIRT2 was tested by ITC. As shown in Fig. 3.17a,
the peptides TFAcK37 and TFAcK37/38 bind to SIRT2 with similar a nities of
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Figure 3.16: Mutational analysis of RanAcK38 deacetylation. (a)
SDS-PAGE of 5 µg of indicated Ran variants stained with Coomassie brilliant
blue (CMB). (b) Time course of Ran deacetylation by SIRT2. Concentration of
Ran was 12 µM. The concentration of SIRT2 was 0.06 µM (molar ratio 1:200).
The graph shows the densitometric quantification.
1.3 and 1.0 µM, respectively while the a nity of TFAcK38 is approximately five-
fold lower. Moreover, the binding enthalpy of TFAcK37 and TFAcK37/38 is more
favorable than that of TFAcK38 (-11.7 and -11.9 vs. -5.7 kcal/mol). Thus, the
peptides reflect the deacetylation behavior of the acetylated Ran protein, which
in turn suggests that the amino acid sequence surrounding residues K37 and K38
dictates the order of deacetylation. This conclusion is corroborated by the fact that
a peptide with the same sequence containing a ‘natural’ acetyl-lysine at position
K37 was also deacetylated as determined by a dot blot assay and detection with
the anti-AcK37-AB (Fig. 3.17b). Attempts to show the same for an AcK37/38
peptide failed due to the low signal intensity upon detection with the anti-AcK-
AB (peptides spotted on nitrocellulose were apparently not properly immobilized).
However, based on the above data, it appeared reasonable to use these peptides
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for co-crystallization with SIRT2 in order to gain insight into the mechanism of
the di-deacetylation.
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Figure 3.17: Interaction of Ran-derived N-(e)-trifluoroacetyl-L-lysine
peptides with SIRT2. (a) ITC data of 30 µM SIRT2 titrated with 300 µM of
the indicated peptide. Measurements were carried out at 20 C. (b) Dot-blot
showing the deacetylation of a peptide with the same sequence but containing
a natural acetyl-lysine at the K37-position. Concentrations were 133 µM for the
peptide and 0.5 µM for SIRT2.
Three SIRT2 constructs with di↵erent lengths were purified for the co-crystal-
lization screens, two of which were previously successfully crystallized (Finnin
et al., 2001; Yamagata et al., 2014). The resulting proteins were highly pure and
thus suitable for crystallization (Fig. 3.18a). To set up the initial crystallization
screens, each of the three SIRT2 constructs (at 10mg/ml) was mixed with a 1.2-
fold molar excess of RanTFAcK37 or RanTFAcK37/38 13-mer peptide. Sitting-
drop plates were used with three wells to allow for simultaneous screen of all three
constructs.
For the RanTFAcK37-13-mer peptide together with SIRT250-356, three crystalliza-
tion conditions were found (0.1M HEPES pH7.5/2.0M NH4SO4, 0.2M K-Na-
tratrate pH5.6/0.1M Na3-citrate/2.0M NH4SO4, 2.4 M Na2-malonate pH7.0), all
giving rise to growth of hexagonal-bipyramid crystals (Fig. 3.18b). Apart from the
crystals, precipitate was present, indicating that crystallization conditions could
be further optimized. However, the crystals did not reappear when optimization
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screens were performed. Thus, despite their small size (⇠50 µm ⇥ 20 µm ⇥ 50 µm),
the initially obtained crystals were used for data collection (crystals from the 0.1M
HEPES pH7.5/2.0M NH4SO4 condition).
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Figure 3.18: Crystallisation of SIRT2 with a RanTFAcK37 13-mer.
(a) SDS-PAGE of 5 µg of indicated SIRT2 constructs stained with Coomassie
brilliant blue (CMB). (b) Micrographs of protein co-crystals of SIRT2 and the
TFAcK37 13-mer grown in 2.4 M Na-malonate pH7.0. Scale bar: 100 µm.
The atomic structure of the complex was solved by molecular replacement and
refined up to a final resolution of 3.0 A˚. For molecular replacement, the previ-
ously solved structure of SIRT2 with a TFAcK-containing cyclic peptide was used
as a search model (PDB: 4L3O; Yamagata et al., 2014). The crystals contained
two SIRT2(50-356)·RanTFAcK37-13-mer complexes per asymmetric unit and be-
longed to the spacegroup P6122. Data collection refinement statistics as well as
the validation of the structure are shown in Table 3.2.4 and in Appendix A.7.
The solved structure of SIRT2(50-356)·RanTFAcK37-13-mer is shown in Fig. 3.19a.
As expected, the TFAcK residue is deeply buried in the active site of SIRT2 while
the N- and C-terminal residues are located along the central binding groove formed
between the Zn2+-binding domain and the Rossmann-fold domain. Su cient elec-
tron density of the peptide was only observed for the residues E34 V40. Thus,
the N-terminal residues L30, T31 and L32 as well as the C-terminal residues A41
and T42 are not included in the structure. This may be a result of their flexibility
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Table 3.1: Data collection, refinement and structure validation of
the SIRT2(50-356)·RanTFAcK37-13-mer-peptide structure (molecu-
lar replacement).
SIRT2(50-356)·RanTFAcK37-13-mer
Data collection
Space group P6122
Cell dimensions
a, b, c (A˚) 114.95, 114.95, 206.48
a, b, g ( ) 90.0 90.0 120.0
Resolution (A˚)a 56.61   3.00 (3.18   3.00)
Observed reflections 187174 (31766)
Unique reflections 16888 (2655)
Rsym or Rmergeb(%) 18.0 (72.1)
Rmeasb(%) 19.7 (78.6)
I/sI 13.7 (3.9)
CC1/2
c 0.994 (0.840)
Completeness (%) 100.0 (100.0)
Redundancy 11.1 (12.0)
Refinement
Resolution (A˚) 56.61 (3.0)
No. of used reflections 15978
Rwork/Rfreeb 23.16/27.11
Number of non-hydrogen atoms
Total 4606
Protein 4417
SO2 4 /Zn
2+ 10/2
Water 177
B-factors (A˚2)
Protein 49.05
SO2 4 72.23
Zn2+ 93.43
Water 51.94
Average B-factors (A˚2)
main chain 48.75
side chain 49.35
all atoms 49.23
R.m.s. deviations
Bond lengths (A˚) 0.010
Bond angles ( ) 1.537
Ramachandran plotd(%)
Favored 95.4
Allowed 4.4
Outliers 0.2
a Values for the highest-resolution shell in parentheses.
b see Material and Methods 2.6.3.
c CC1/2: correlation coe cient from Diederichs and Karplus (2013).
d MolProbity (Chen et al., 2010).
in the SIRT2-bound state of the peptide and may furthermore indicate that these
residues have a low contribution to SIRT2-binding.
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Figure 3.19: Structure of SIRT2 with RanTFAcK37 13-mer pep-
tide. Overview of the SIRT2(50-356)·RanTFAcK37-13-mer-peptide structure
is shown in ribbon and surface representation with the domains indicated in
di↵erent colors (compare with Fig. 1.8). The peptide is shown as stick model.
The close up shows the peptide with residue numbering according to the Ran
protein sequence.
Interestingly and consistent with previous substrate-Sirtuin structures (Avalos
et al., 2002; Zhao et al., 2003), the RanTFAcK37-13-mer is bound to the sub-
strate binding groove of SIRT2 mainly via hydrogen bonds between main chain
atoms of SIRT2 and the peptide (Fig. 3.20). In addition, the aromatic side chains
of F35 and Y39 are possibly involved in stacking interactions with the residues
F244 and F235 of SIRT2, respectively, suggesting that they have a role in the
specific recognition of the peptide (and most likely also RanAcK37). In case of
RanAcK38, these additional side chain interactions may not be possible due to
the positional shift by one residue, which could lead to the slower deacetylation
of this site by SIRT2. To clarify how SIRT2 specifically deacetylates Ran first
at K38 in the di-acetylated AcK37/38 background, attempts were made to also
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crystallize SIRT2 in complex with the TFAcK37/38-peptide, which however were
not successful. It is thus not possible to draw conclusions about the binding of
SIRT2 to this peptide.
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Figure 3.20: Molecular interactions between SIRT2 and the Ran-
TFAcK37 13-mer peptide. Polar interactions between the peptide and
SIRT2 are depicted. The peptide (brown) is shown as stick model and SIRT2
(grey) as ribbon model except for the residues participating in polar interac-
tions.
3.2.5 SIRT1 and SIRT3 are able to di-deacetylate Ran
To check if the ability to deacetylate two neighboring AcKs is universal to Class I
Sirtuins, SIRT1 and SIRT3 were also tested with RanAcK37/38 as a substrate.
As shown above in Fig. 3.12, RanAcK37 is not only deacetylated by SIRT2 but
also SIRT1 and SIRT3 and it thus appeared reasonable that the di-acetylated
variant would likewise be deacetylated by these closely related enzymes. SIRT1
and SIRT3 were purified using a two-step purification strategy, involving a n-
ity chromatography followed by SEC (Fig. 3.21a). Again, the activity of Sirtuins
1-3 was determined by a Fluor-de-Lys assay but this time at multiple concentra-
tions and thus greater accuracy. It turned out that all three Sirtuins had similar
activities so that the same molar concentrations could be used for deacetylation
assays (Fig. 3.21b). When RanAcK37/38 and RanAcK38 were tested with SIRT1
and SIRT3, a robust deacetylation was observed for both, although slower than
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for RanAcK37. Furthermore, similar to the behavior of SIRT2, deacetylation of
RanAcK38 was slower than RanAcK37 suggesting that Sirtuins 1-3 share molec-
ular features of substrate recognition and the ability to di-deacetylate substrate
proteins.
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Figure 3.21: Di-deacetylation by SIRT1 and SIRT3. (a) SDS-PAGE
of 5 µg of indicated Sirtuin constructs stained with Coomassie brilliant blue
(CMB). (b) Fluor-de-Lys activity assay of Sirtuins. Error bars represent three
independent measurements. (c)Western-blot of deacetylation experiment. The
reaction was performed for 30min. 12 µM of Ran was incubated with 0.8 µM of
the indicated Sirtuin.
3.2.6 PEPCK1 is not deacetylated by SIRT2 in vitro
In a physiological context, the acetylation of a lysine residue with an unfavorable
sequence context for deacetylation (such as K38 of Ran) would be relatively sta-
ble, which could result in a lasting e↵ect on protein function and/or intracellular
signaling processes. The acetylation of a neighboring lysine could then lead to a
release from this situation by stimulating the deacetylation of both residues by
Sirtuins 1-3.
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Along these lines, the literature was screened for proteins, which have been shown
to be acetylated at two neighboring lysine residues and deacetylated by SIRT1, -2
or -3. One such case is phosphoenolpyruvate carboxykinase 1 (PEPCK1), which
plays a major role in gluconeogenesis and for which acetylation of residues K70,
K71 and K594 has been reported. Acetylation of PEPCK1 promotes its degra-
dation and is negatively regulated by SIRT2 (Jiang et al., 2011). Not only is
PEPCK1 acetylated at two neighboring lysine residues but these two lysines are
followed by a tyrosine (KKY) as is also case for RanAcK37. It appeared possible
that this sequence represents a short motif for di-deacetylation. Interestingly, in
an in vitro selection screen for cyclic peptidic inhibitors of SIRT2, 10 out of 15 iso-
lated high a nity clones were found to contain the sequence R(I/V)(TFAcK)RY.
The IC50’s of these cyclic peptides was in the low nanomolar range but also a
shorter linear peptide with the sequence RI(TFAcK)RY showed an IC50 of 31 nM
(Morimoto et al., 2012). Given that arginine is physicochemically similar to ly-
sine, these results seemed to support the assumption that KKY is a target motif
of SIRT2.
Full-length PEPCK1-WT, -AcK70, -AcK71, -AcK70/71 and, for comparison, also
-AcK594 were purified with the GCEC. The resulting protein was approximately
80% pure and, when probed with the anti-AcK-AB, the acetylated variants showed
a signal while PEPCK1-WT did not (Fig. 3.22a). As an additional measure of
protein quality, the enzymatic activity of the recombinant PEPCK1 was confirmed.
In this activity assay, the PEPCK1-catalyzed reaction of phosphoenolpyruvate to
oxalacetate is coupled with the quantitative reduction of oxalacetate to malate by
malate dehydrogenase. In the latter reaction step, NADH is oxidized to NAD+,
which can be traced by a drop in emission at 470 nm when excited at 350 nm (see
Material and Methods 2.3.14). The specificity of the assay was tested by sequen-
tial addition of reaction components. A significant drop in fluorescence was only
observed when PEPCK1 was added and the reaction was drastically accelerated
upon addition of Mn2+ (MnCl2), which is a PEPCK1 co-factor. The slow reaction
rate observed without Mn2+ suggests that only a fraction of PEPCK1 protein pu-
rified from E. coli is Mn2+-bound. All PEPCK1 variants displayed robust activity
in this assay showing that the PEPCK1 was purified from E. coli in an active
form. Moreover, PEPCK1-AcK71 showed an increased catalytic rate and reached
a higher final fluorescence level. However, this observation has to be taken with
caution since the purity between the di↵erent PEPCK1 varies and thus the true
amount of enzyme in the assay cannot be accurately determined (Fig. 3.22b).
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Surprisingly, none of the acetylated PEPCK1-variants were deacetylated by SIRT2
in vitro when tested with low amounts of enzyme in preliminary experiments (not
shown). To rule out that deacetylation just occurs at a much slower rate (com-
pared for instance to RanAcK37), PEPCK1 was incubated for 2 h at 23 C with
increasing amounts of SIRT2 up to an equimolar ratio. Again, under the experi-
mental conditions used, no deacetylation was observed (Fig. 3.22c). Since only a
fraction of the purified PEPCK1 was active due to the lack of the co-factor Mn2+,
the experiment was repeated in MnCl2-containing bu↵er. Moreover, the concen-
tration of PEPCK1 was lowered to avoid possible multimerization or aggregation
of PEPCK1, which could limit access of SIRT2 to the PEPCK1 acetylation sites.
However, no deacetylation was observed at a 1:1 enzyme:substrate-ratio over the
course of 2 h (Fig. 3.22d).
It was thus tested if mutation of the amino acid residues surrounding the di-
acetylated site K70/71 would facilitate deacetylation by SIRT2. Two mutant vari-
ants of PEPCK1 were cloned, each coding for three amino acid substitutions N- or
C-terminally of the assumed binding motif KKY by the according Ran sequence
(natural PEPCK1 sequence: RRLKKYDNC, natural Ran sequence: EFEKKY-
VAT, ‘EFE’-mutant: EFEKKYDNC, ‘VAT’-mutant: RRLKKYVAT). However, in
contrast to the EFE-mutant, the VAT-mutant could not be purified from E. coli de-
spite significant e↵orts. The EFE-mutant was tested for deacetylation by SIRT2 in
the di-acetylated PEPCK1-AcK70/71-background. Strikingly, as the time course
experiment in Fig. 3.22e demonstrates, the PEPCK1-EFE mutant was deacety-
lated e ciently with a similar rate compared to RanAcK37. Since the deacety-
lation signal completely disappears over the course of the experiment, it is likely
that both acetyl-moieties of PEPCK-70/71-EFE are removed by SIRT2. Taken
together, these results suggest that, at least in vitro, PEPCK1 is not a substrate of
SIRT2. However, mutation of three amino acids N-terminal to the assumed SIRT2
binding motif KKY is su cient to convert PEPCK1 into a SIRT2-substrate, fa-
cilitating deacetylation of both AcK70 and AcK71. Thus, these residues (and
possibly also the residues VAT, which are found C-terminally of the KKY motif
in Ran) appear to dictate the substrate binding of SIRT2.
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3.2.7 Deacetylation of p53-AcK381/382
Next, the question whether di-deacetylation is a general mechanism was further
investigated with the tumor suppressor p53. The acetylation of p53 is required
for its stabilization and transactivation, which in turn leads to apopotosis and/or
cell-cycle-arrest. Acetylation of p53 has been described for 13 di↵erent lysines,
among them also two lysine pairs (K372/373 and K381/382) in the C-terminal
regulatory domain (Brooks and Gu, 2011; Reed and Quelle, 2014). To date, p53
has been described to be deacetylated by KDAC1 and SIRT1, although some
evidence also points towards deacetylation by SIRT2 (Ho↵mann et al., 2014; Peck
et al., 2010). While KDAC1 deacetylates p53 at K320, K373 and K382 (Ito et al.,
2002), SIRT1 is largely active on K382 (Vaziri et al., 2001) and potentially also
K120 and K164 (Zhang et al., 2014b). Importantly, the KATs CBP and p300, inter
alia, acetylate p53 at both lysine pairs, K372/373 and K381/382 (Gu and Roeder,
1997). Whether the di-acetylation at K381/382 can also be removed by SIRT1
has however not been tested. In a physiological context, the order and magnitude
of deacetylation by SIRT1 could have direct consequences on the activation levels
of p53. For instance, a preferential deacetylation of AcK382 in presence of an
acetylated K381 would e↵ectively lead to a faster inactivation of p53. On the
other hand, it is also possible that acetylation of both K381 and K382 decreases
the rate of deacetylation by SIRT1 and would thus promote p53 activity.
To investigate these di↵erent possible scenarios, acetylated and wild type p53 was
purified using the GCEC. However, in this case the expression of His6-tagged
protein and purification by Ni-NTA chromatography was not successful. Hence,
p53 was cloned into a vector allowing for the expression of GST-tagged acetylated
protein. With this strategy GST-p53 could be expressed but the treatment with
TEV-protease to remove the GST-tag was very ine cient when performed on the
column. This was possibly due the tendency of GST to dimerize plus the known
tetramerization of p53, which may lead to an occluded TEV-cleavage site. Thus,
GST-p53 was instead eluted first from the column and then treated with TEV-
protease in solution. p53 was then separated from GST and uncleaved GST-p53
by SEC. The acetylated p53 variants AcK381, AcK382 and AcK381/382 as well
as AcK120 and AcK164 were purified, the latter two sites because they have also
been reported to be deacetylated by SIRT1. The result of this purification method
is shown in Fig. 3.23a. As opposed to p53WT, all acetylated p53 variants showed
a signal when detected with the anti-AcK-AB. Significant di↵erences in the signal
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are however observed between C-terminally acetylated p53 and p53AcK120 and
-AcK164. As described above, this phenomenon was also observed with acetylated
Ran and can likely be attributed to the specificity of the anti-AcK-AB.
In an initial experiment, all p53 variants were tested for deacetylation by SIRT1 at
a molar ratio of 1:20. Interestingly, except for AcK164, all sites were deacetylated
after two hours of incubation, overall confirming previous reports regarding the
activity of SIRT1 towards p53 but for the first time showing directly that AcK381,
AcK382 and the di-acetylated p53AcK381/382 are SIRT1 substrates (Fig. 3.23b).
Moreover, this result speaks against previous observations that SIRT1 deacetylates
p53 at K164, although it cannot be ruled out that in vivo additional factors me-
diate deacetylation of this site by SIRT1.
Next, the dynamics of deacetylation at K120, K381 and K382 were further ana-
lyzed in a time-course experiment with a p53:SIRT1-ratio of 1:20. For compari-
son, RanK37AcK was also included. Under the conditions used, all p53 sites were
completely deacetylated after 5 to 15min and thus slightly faster than RanAcK37
(Fig. 3.23c). Given the fast deacetylation, it was di cult to judge, which site of the
lysine pair K381/382 is the preferential target of SIRT1. In another time course
experiment the SIRT1 concentration was thus reduced to a ratio of 1:200. Interest-
ingly, it turned out that both the two individual sites AcK381 and AcK382 and the
di-acetylated AcK381/382 are deacetylated at almost identical rates (Fig. 3.24a).
This raised the question whether the accelerated deacetylation of RanAcK38 upon
acetylation of the neighboring K37 is the result of a unique substrate recognition
of SIRT2 or merely dependent on the amino acid sequence context. To test these
two possibilities, the time-course experiment was repeated but in this case with
SIRT2 (SIRT2:p53 ratio 1:200). As shown in Fig. 3.24b, SIRT2 is able to e -
ciently deacetylate p53-AcK381, -AcK382 and -AcK381/382. Although SIRT2
has previously been described as p53 deacetylase, this experiment demonstrates
this activity for the first time in a direct manner (Ding et al., 2013; Ho↵mann et al.,
2014; Jin et al., 2008; Peck et al., 2010). Strikingly, no strong di↵erences between
the three p53 variants were observed regarding the SIRT2-catalyzed deacetylation
rates. This result suggests that the sequence context of the di-acetylation site
determines if its di-deacetylation is favored over the mono-deacetylation of one of
the individual sites. Furthermore, this appears to be true for both SIRT1 and
SIRT2.
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3.2.8 Deacetylation of p53-AcK372/373
In order to further corroborate the assumption that the di↵erent deacetylation
rates of neighboring AcK residues are due to the sequence context, the other di-
acetylation site of p53 (K372/372) was also tested for deacetylation with SIRT1
and SIRT2. The result of the purifications of p53-AcK372, -AcK373 and -AcK372/-
373 is shown in Fig. 3.25a. Interestingly, these acetylated variants all show a
double band when CMB-stained after SDS-PAGE. Likewise, two bands are visi-
ble when the proteins are detected with the anti-p53-AB. In contrast, detection
with the anti-AcK-AB results in two band only for the supposedly di-acetylated
p53-AcK372/373. These findings are consistent with the lower band being a trans-
lational termination fragment, which is the result of unsuccessful incorporation of
AcK at the desired positions. Since this fragment is of similar size as the full-length
protein product and most likely able to tetramerize, it cannot easily be removed
during the purification. In case of p53-AcK372/373, the premature translational
termination can occur twice and thus result either in a shortened non-acetylated
or a shortened acetylated variant (containing the AcK372 residue). The latter
fragment was detected with the anti-AcK-AB, visible as a double band in Fig.
3.25a (panel IB: AcK). Interestingly, freshly prepared dilutions of the anti-AcK-
AB detected the termination fragment only weakly compared to the full-length
p53-AcK372/373 protein (Fig. 3.25c and d).
The fact that a significant amount of p53 protein synthesized with the GCEC is
not full-length product also has implications for the results shown above regarding
the other p53 di-acetylation site K381/382. It is likely that in this case a fraction of
the protein is not acetylated or, in case of p53-AcK381/382 purifications, only car-
ries one C-terminal AcK-residue. The molecular weight between the termination
fragment and full-length protein is however to small to be visualized via standard
SDS-PAGE. This would also explain why in deacetylation assays p53-AcK381/382
showed residual background AcK-immunoreactivity (see Fig. 3.23c and 3.24a,b).
The acetylation site K372/373 has so far not directly been shown to be deacety-
lated by SIRT1. However, interactions between p53-AcK373 and SIRT1 have been
described as well as a decrease in p53 acetylation at K373 upon SIRT1 inhibition
(Frazzi et al., 2013; Knights et al., 2006). In fact, p53-AcK372, -AcK373 and
-AcK372/373 where e ciently deacetylated by SIRT1 in vitro (Fig. 3.25b). Next
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the kinetics of reaction were again further characterized by a time course exper-
iment with SIRT1 at a substrate:enzyme ratio of 1:200. As shown in Fig. 3.25c,
SIRT1 discriminates between the three di↵erent variants. At this enzyme con-
centration, deacetylation of p53-AcK372 and p53-AcK372/373 is not detectable
or relatively slow, respectively, while p53-AcK373 is completely deacetylated after
90min. When the deacetylation was tested with SIRT2, no such discrimination
between the two mono- or the di-acetylated variant was observed (Fig. 3.25d).
Taken together, these results show that, in contrast to the di-acetylation of p53 at
K381/382, di-acetylation at K372/373 has an inhibitory influence on the deacety-
lation of the AcK373 site. However, this seems to apply only to SIRT1 and not to
SIRT2 for this set of sites.
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Figure 3.22: Analysis of PEPCK1 deacetylation. (a) SDS-PAGE of 5 µg
of indicated PEPCK1 constructs stained with Coomassie brilliant blue (CMB).
(b) Coupled enzymatic activity assay for PEPCK1. (c) Deacetylation assay
with increasing concentrations of SIRT2. Molar ratios of SIRT2:PEPCK1 are
indicated. The reaction was performed for 2 h at 23 C. The concentration of
PEPCK1 was 12 µM. (d) Experiment as in (c) but with addition of 1mMMnCl2
and lower concentration of PEPCK1 (0.6 µM). (e) Time course of deacetylation
with PEPCK1 EFE-mutant and Ran. 20 µM substrate protein was incubated
for the indicated time with 0.1 µM SIRT2.
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Figure 3.23: Deacetylation of p53 by SIRT1. (a) SDS-PAGE of 5 µg
of indicated p53 constructs stained with Coomassie brilliant blue (CMB). (b)
Deacetylation assay with SIRT1 at molar SIRT1:p53 ratio of 1:20 (p53: 12 µM;
SIRT1: 0.6 µM). The reaction was performed for 2 h at 23 C. (c) Time course
of deacetylation experiment with same concentrations as in (b). Samples were
taken at indicated time points. The graph shows the densitometric quantifica-
tion.
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Figure 3.24: Dynamics of p53 deacetylation at the di-acetylation
site K381/382. (a) Time course of deacetylation experiment with a molar
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Figure 3.25: Deacetylation of p53 at the di-acetylation site
K372/K373. (a) SDS-PAGE of 5 µg of indicated p53 constructs stained with
Coomassie brilliant blue (CMB). (b) Deacetylation assay with indicated molar
SIRT1:p53 ratios (p53: 12 µM). The reaction was performed for 2 h at 23 C.
The asterisk indicates the acetylated translational termination fragment. (c)
Time course of deacetylation experiment with 12 µM p53 and 0.06 µM SIRT1.
Samples were taken at indicated time points. The graph shows the densitomet-
ric quantification. (d) Same as in (c) but with SIRT2.
4 Discussion
In the present work, the impact of lysine-acetylation on protein function of the
small GNBP Ran has been studied. The focus lay on intrinsic and RanGAP-
mediated nucleotide exchange as well as export complex formation between Ran,
CRM1 and Spn1. In a separate study conducted by S. de Boor (PhD Thesis,
2015), the other major molecular functions of Ran, that is intrinsic and RCC1-
mediated nucleotide exchange as well as interaction with importin-beta and NTF2,
were studied with regard to their sensitivity to Ran acetylation. Based on the
proteome-wide acetylation screen by Choudary et al. (2009), five acetylation sites
of Ran (K37, K60, K71, K99, and K159) were chosen for investigation, for many
of which it appeared likely that they would alter the above functions of Ran. The
extensive biophysical characterization performed in both studies was based on
the possibility to produce site-specifically lysine-acetylated Ran protein with the
GCEC. Moreover, the GCEC allowed for the identification of enzymes possibly
involved in the regulation of Ran acetylation.
4.1 Incorporation of acetyl-lysine with the GCEC
The purification of acetylated Ran with the GCEC was successful for all five sites
as demonstrated by specific immunoreactivity of these variants against a pan-
anti-AcK-AB and by the expected mass-shift in ESI-MS spectra consistent with an
added acetyl-moiety (Fig. 3.2b). Ran was also purified with two co-translationally
incorporated AcK residues (AcK37 and AcK38). Although su cient material was
obtained for the purpose of this study, the yield and purity was substantially
lower for di-acetylated than for mono-acetylated Ran (Fig. 3.14a). Similarly, the
purification of acetylated PEPCK1 and p53 was more challenging than of the cor-
responding wildtype protein and, moreover, this e↵ect was even more pronounced
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for the di-acetylated variants. In fact, di↵erences in yield were also observed be-
tween purifications of di↵erent mono-acetylated Ran variants despite their similar
stability in subsequent biochemical/-physical assays. These observations lead to
the conclusion that, with the E. coli strain and growth conditions used in this
study, the co-translational incorporation of acetyl-lysine in response to an amber-
stop-codon is less e cient than that of natural amino acids. However, the extent
to which the protein yields are reduced seems to be influenced by the position and
the amino acid context of the desired acetyl-lysine residue within the polypeptide
chain. While generally lower yields with the GCEC can be intuitively understood
in light of possibly suboptimal expression levels of PylRS/pylT and the compe-
tition with the endogenous release factor 2 (RF2), the reason for the positional
e↵ects observed for AcK incorporation is less clear. It is known that the speed of
translation is influenced by the codon composition of the corresponding mRNA
stretch. In particular, sequences that contain many codons whose tRNAs are un-
derrepresented or poly-proline coding sequences are translated substantially slower
than average (Pavlov et al., 2009; Zhang et al., 2009). The positioning of codons
for low abundance tRNAs often demarcates domain boundaries and thus assists
in individual domain folding by slowing down translation. Moreover, non-highly
expressed genes are enriched for such low-frequency codons (Thanaraj and Argos,
1996) while faster translated sequences often code for specific protein secondary
structures such as a-helices (Makhoul and Trifonov, 2002). Of course, such reg-
ulatory mechanisms do not apply to heterologous gene expression. However, the
e ciency of AcK-incorporation at a certain position may well be a↵ected by the
usage-frequency of surrounding codons and, vice versa, translational pausing due
to the incorporation of AcK may be particularly detrimental to the folding of
certain structural elements in a recombinantly produced protein.
4.2 Ran acetylation in regulation of export com-
plex formation and release
The biophysical experiments performed in this study were focused on the role of
Ran acetylation in nuclear export complex formation and GTP-hydrolysis. One
aspect in which Ran is influenced by acetylation is its intrinsic GTP-hydrolysis
rate, which was increased ⇠1.5-fold for RanAcK71 (Fig. 3.3c). The RanGAP-
stimulated GTP-hydrolysis was however largely una↵ected by acetylation at each
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of the sites tested (Fig. 3.4b). Although a 34-fold decrease in binding a nity
of RanGAP towards RanAcK99·RanBP1 was observed (0.5 µM for WT vs.17 µM
for AcK99; see Fig. 3.5c), this was not reflected in a slower RanGAP-stimulated
GTP-hydrolysis of Ran in complex with RanBP1 (Fig. 3.5d). These results suggest
that the RanGAP-mediated inactivation of Ran in the cytoplasm is most likely
not a↵ected by Ran acetylation.
The intrinsic GTP-hydrolysis rate of Ran is very low if compared for instance to
Ras (Klebe et al., 1995). While for Ras a relatively fast GAP-independent in-
activation might be important to avoid sustained ‘on’-signaling, it would merely
lead to a dissipation of the RanGTP gradient and therefore interfere with nuclear
transport (Brucker et al., 2010). However, it remains an open question how signifi-
cant a ⇠1.5-fold increase in intrinsic GTP-hydrolysis upon K71-acetylation would
be in a physiological context. The work of S. de Boor (PhD Thesis, 2015) has
shown that RanAcK71 is not able to bind to NTF2, the nuclear import carrier for
RanGDP, due to the disruption of an essential salt bridge. Thus, acetylation at
this site could adversely a↵ect the Ran gradient in two respects: Less Ran would
be transported into the nucleus and the RanGTP:RanGDP ratio would be shifted
towards RanGDP. As a consequence, these two e↵ects combined might lead to an
impaired nucleocytoplasmic transport in the cell.
Another aspect of Ran function that is a↵ected by acetylation is the assembly
and, possibly, disassembly of nuclear export complexes. The assembly of nuclear
export complexes requires the cooperative binding of RanGTP and the respec-
tive substrate to an export receptor (Monecke et al., 2009, 2013; Petosa et al.,
2004). In the present study, this cooperative binding was modeled in vitro with
purified components, one being the export receptor CRM1 and the other being
one of its substrates, Spn1. As expected, Spn1 showed a higher a nity towards
CRM1·RanGppNHp than to CRM1 alone. Vice versa, the binding of RanGppNHp
to CRM1 could only be detected in ITC when CRM1 was bound Spn1 (Fig.
3.7). While acetylation of Ran did not directly a↵ect its binding to CRM1, it did
promote binding of Spn1 to CRM1·RanGppNHp in case of K37-, K99- and K159-
acetylation (Fig. 3.8b and c). Interestingly, acetylation of these sites also increased
the a nity of RanGppNHp for importin-b (PhD thesis S. de Boor, 2015). These
two e↵ects taken together support a model in which Ran acetylation, on the one
hand, enhances import substrate release in the nucleus and, on the other hand,
promotes the assembly of nuclear export complexes. Moreover, the disassembly of
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nuclear export complexes might be a↵ected by Ran acetylation given the reduced
a nity of RanAcK159 for RanBP1 (⇠10-fold reduction in a nity in the GppNHp-
bound form of Ran; see Fig. 3.6b). Specifically, as a result of acetylation at this
site, RanBP1 might less e ciently bind to RanGTP complexed with CRM1 and,
thus, export complexes would be more stable in the cytoplasm (Lounsbury and
Macara, 1997; Maurer et al., 2001; Yaseen and Blobel, 1999). However, this e↵ect
depends on whether the lower a nity of RanAcK159 for RanBP1 is a result of an
altered on- or the o↵-rate.
Additional e↵ects of Ran acetylation were shown in the PhD thesis of S. de
Boor (2015). RCC1-mediated nucleotide exchange is dramatically altered upon
acetylation of Ran at K71 and K99. Interestingly, while both K71- and K99-
acetylation of Ran impair RCC1-mediated nucleotide exchange, di↵erent molecular
mechanisms are involved: GDP-bound RanAcK99 exhibits a decreased a nity for
RCC1 and a drastically reduced RCC1-induced nucleotide dissociation rate, which
essentially represents a loss-of-function phenotype. By contrast, Ran acetylation
at K71 leads to a drastically increased a nity for RCC1 and, as for acetylation at
K99, a slower RCC1-induced nucleotide release. With these properties, RanAcK71
resembles the dominant negative Ran mutant T24N (Dasso et al., 1994).
The above results demonstrate the broad regulatory spectrum of lysine-acetylation
(for an overview of the most pronounced e↵ects of Ran acetylation see the model
in Fig. 4.1). Especially for proteins with many di↵erent interactions partners such
as Ran and other members of the Ras superfamily, the consequences of lysine-
acetylation for protein function are complex and di cult to predict. An interesting
aspect in this regard is the fact that the alterations in protein-protein interactions
or catalytic activity observed in case of Ran acetylation could not always be at-
tributed to an obvious structural cause. This suggests that acetylation can lead
to global structural rearrangements in a protein (or at least in Ran) beyond the
small-scale changes in the immediate surrounding of the AcK residue (compare
Fig. 1.7).
4.3 Regulation of Ran acetylation
An important question is under which conditions Ran becomes acetylated to such
a significant level that it has a major impact on cellular function and at which sites
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Figure 4.1: Regulation of Ran functions by lysine-acetylation.
Overview of the most pronounced e↵ects of Ran acetylation found in this study
and the PhD thesis of S. de Boor (2015) (D: GDP, T: GTP).
Ran acetylation occurs most frequently. Ran is one of the most abundant proteins
in the cell (Bischo↵ and Ponstingl, 1991b), which, on one the hand, highlights
its essential cellular role and, on the other hand, suggests that substantial KAT
activity towards Ran would be required to perturb or regulate its function. How-
ever, this assumption does not necessarily hold true in all situations, for example,
if acetylation leads to a dominant-negative e↵ect. As mentioned above, the acety-
lation of Ran at K71 represents such a case with regard to the interaction with
RCC1. The significance of this finding is underscored by the fact that RCC1 is
about 25 times less abundant than Ran (Bischo↵ and Ponstingl, 1991a), meaning
that even relatively low amounts of RanAcK71 could have a strong influence on
cell physiology.
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Over the course of the present study, the above question was addressed by sev-
eral means. Since initial attempts to isolate endogenous acetylated Ran from
cultured human cells that were treated with KDAC inhibitors failed, His6-tagged
Ran was co-expressed with selected KATs in HEK293T cells and subsequently
isolated under denaturing conditions. Immunodetection of these samples with an
anti-AcK-AB did not result in a signal, suggesting that Ran only a minor frac-
tion was acetylated or, alternatively, that Ran was acetylated predominantly at
sites that were not or only weakly detected by the anti-AcK-AB. In fact, upon
MS/MS analysis three acetylation sites were detected in Ran (K134, K142 and
K152), the intensities of the corresponding peptides were in some cases increased
in a KAT-dependent manner (Fig. 3.9b).
To date, twelve acetylation sites have been identified in Ran. The acetylation sites
studied here (K37, K60, K71, K99 and K159) were identified in several human
cell lines of di↵erent origin: MV-4-11 (myeloid leukemia cells), Jurkat (lymphoid
origin), A549 (epithelial origin), U20S (osteosarcoma cells) and HeLa S3 (cervical
cancer cells) (Beli et al., 2012; Choudhary et al., 2009; Mertins et al., 2013). How-
ever, the three sites found in this study were so far only detected in rat and/or
mouse tissue samples. It should be noted that tissue-specific global acetylation pat-
terns have been found in rat tissues (Zhao et al., 2010) and that lysine-acetylation
sites are often evolutionary conserved (Wang et al., 2010; Weinert et al., 2011).
The only human tissue samples that have been analyzed for lysine-acetylation in a
proteome-wide manner are skeletal muscle biopsies where no acetylated Ran was
detected (Lundby et al., 2012; Zhao et al., 2010). Collectively, these findings point
toward a tissue-specific occurrence of acetylated Ran, with di↵erent patterns of
acetylation sites being present in each tissue. Regarding this notion, it has also
to be taken into account that proteomic analyses are potentially biased towards
certain acetylation sites as a result of antibody-based AcK-specific enrichment of
peptides/proteins. As shown in this study and by others, even polyclonal anti-
AcK-ABs detect sites with di↵erent sensitivity depending on the sequence context
(Fig. 3.2a, Shaw et al., 2011), a fact that may significantly skew acetylome data
towards certain acetylation sites.
Ran is the Ras superfamily member for which the most acetylation sites have been
found, with Cdc42 being ranked second with seven known acetylation sites (see
Table 4.1). For Ras, only one acetylation site is known, which has a negative e↵ect
on nucleotide exchange catalyzed by its GEF SOS (Son of Sevenless, Yang et al.,
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2012). It is tempting to speculate that the high number of acetylation sites in Ran
is due to its predominantly nuclear localization, which may result in an increased
probability to encounter one of the many nuclear KATs. In the present study,
the Ran acetylation sites K134 and K142 were detected in 6 out of 8 samples and
K134-acetylation was upregulated upon coexpression of TIP60, CBP and p300
although it is not clear whether this is due to a direct or an indirect e↵ect. When
recombinant Ran was incubated with KATs in vitro, additional acetylation sites
were identified (K23, K28, K37, K60, K99 and K123), three of which are among
those discovered by others in human cells (PhD Thesis S. de Boor, 2015). This
underscores the propensity of Ran to serve as a substrate for KATs even though
the exact conditions that lead to Ran acetylation at particular sites in vivo have
yet to be found out. Several factors might promote KAT activity towards Ran in
vivo, such as an increase in acetyl-CoA levels (Donohoe et al., 2012; Wellen et al.,
2009), alterations in the localization of KATs (Keck and Pemberton, 2011) or the
presence of stimulatory cofactors (Li et al., 2003b). It will be interesting to see if,
under these di↵erent conditions, the acetylation of Ran fulfills specific regulatory
functions or if it rather reflects a disease state of the respective cell or tissue.
Table 4.1: Lysine-acetylation sites of Ras superfamily members.
Lysine-acetylation sites found by MSa
GNBP Human Mouse Rat
Ran K37,60,71,99,152,159 K60,71,159 K23,28,37,60,99,134,152,159
K-Ras K104 - -
N-Ras - - -
H-Ras - - -
Rap1A - - K151
Rap1B - - K151
RhoA - - K133,135
RhoB - - -
RhoC - - -
Cdc42 K135,144,153 - K128,133,135,144,150,153,166
Rac1 - K132, K133 K147,153
Rab1A K61 - K61,132,140
Rab1B K58 - -
Rab7A - - K32
Rab7B - - -
Rab7L - - -
Arl1 - - K152
Arf1 K36,142 K142 K36,142
a Acetylation sites from Phosphosite Plus are shown (Hornbeck et al., 2015).
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To understand the role of acetylation for the function of a protein, it is equally im-
portant to know how this modification is reversed by KDACs. The site-specifically
acetylated protein that can be produced with the GCEC allows for the identifi-
cation of KDAC activity towards any given acetylation site (provided the protein
can be recombinantly produced). Di↵erent experimental approaches can be envi-
sioned to this end. For instance, acetylated recombinant protein may be incubated
with whole cell lysates to globally test for the presence of KDAC activity and
then (if applicable) further narrowed down to a particular enzyme by systematic
knockdown/-out of KDAC genes. In the present study, KDACs of Ran were iden-
tified by an in vitro screen with all 18 human KDACs (Fig. 3.11), the activity
of which was verified beforehand in a fluorimetric deacetylation assay (Fig. 3.10).
The screen led to the identification of SIRT2 as a specific KDAC for RanAcK71
and of SIRT1-3 as KDACs for RanAcK37. The fact that SIRT3 is predominantly
found in mitochondria makes it an unlikely candidate for in vivo Ran deacety-
lation while the localization of SIRT1 and SIRT2 would allow these enzymes to
deacetylate Ran in the nucleus and the cytoplasm (Jin et al., 2007; Michishita
et al., 2005; North and Verdin, 2007).
Like many other small GNBPs such as Ras, Cdc42 and Rac, Ran is only slowly
turned over with a protein half-life of 2.6-3 days in mouse liver tissues and HeLa
cells and⇠9.2 days in mouse brain tissue (Cambridge et al., 2011; Price et al., 2010;
Sandoval et al., 2013; Shukla et al., 2014). Thus, acetylated Ran may accumulate
significantly depending on the rate at which its acetylation is happening. This
may apply in particular to post-mitotic cells (such as neurons) and to tissues with
high Ran expression, including some cancer types, in which Ran expression has
been found to be upregulated (Azuma et al., 2004; Vanegas et al., 2003). In light
of these considerations, it seems surprising that KDACs of Ran were only found for
two sites (K37 and K71) in the KDAC screen performed here. However, as for the
identification of KATs by means of in vitro experiments or KAT-overexpression, it
cannot be ruled out that other KDACs are involved in Ran deacetylation in vivo.
This is particularly the case for classical KDACs given their extensive regulation
by small molecules and interactions with other proteins (see below, Guenther et al.,
2000; Laherty et al., 1997; Watson et al., 2012).
In a broader sense, it is an interesting question whether a majority of the many
acetylation sites found in proteomic screens is targeted by the relatively few
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KDACs or if particularly the ones with a low stoichiometry are removed con-
currently with protein turnover. In this regard, it seems reasonable to hypothesize
that an ongoing co-evolution exists between KATs, KDACs and acetyl-acceptor
sites, at least for proteins in the cytosol and the nucleus. The outcome of this
co-evolution might be a large number of low-stoichiometry acetylation sites, many
with tolerable e↵ects for cell physiology and some which have to be tightly con-
trolled due to otherwise detrimental consequences. Finally, there are the often
high-stoichiometry acetylation events that are part of signaling cascades and other
dynamically regulated processes. An important step towards an understanding of
the acetylome is the recent development of MS tools for the absolute quantifica-
tion of acetylation sites (Baeza et al., 2014; Weinert et al., 2014). Nevertheless,
to discriminate between the above possibilities for so many identified acetylation
sites remains a formidable challenge for the scientific community and does not only
apply to acetylation but also to other post-translational modifications.
4.4 Implications for the substrate specificity of
classical KDACs
In the in vitro KDAC screen, none of the classical KDACs showed substantial
activity towards Ran, albeit the reportedly low sequence specificity of many of
these enzymes (Riester et al., 2007). However, it should be noted that their speci-
ficity was tested only on short peptidic substrates, which were varied in the po-
sitions  2/ 1,  1/+1 or +1/+2 with respect to the AcK moiety (Gurard-Levin
et al., 2010, 2009; Riester et al., 2007). In addition, these substrates were ei-
ther labeled with fluorphors, which alter the substrate recognition (Gurard-Levin
et al., 2009; Wolfson et al., 2014), or immobilized, which required for instance a
cysteine residue in a fixed position (Gurard-Levin et al., 2010, 2009). In other
studies, attempts were made to identify substrates of classical KDACs by using
proteomic approaches in combination with specific inhibitors. The resulting num-
ber of substrates was however relatively small and validation was again performed
with peptide substrates (Olson et al., 2014). Thus, relatively little is known about
how classical KDACs bind to full-length protein substrates. Nevertheless, some
conclusions may be drawn from comparison of the sequence context of the Ran
acetylation sites with the specificity profiles observed for the peptidic substrates.
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As shown in Table 4.2, except for RanAcK71 all sites are in principle suitable sub-
strates for classical KDACs if judged based on the positions  2/ 1 relative to the
acetyl-moiety. Similarly, the sequence context in positions +1/+2 matches the ob-
served substrate preferences of KDAC3 in case of RanAcK37 and KDAC8 in case
of RanAcK60 and -AcK71. However, yet another study, in which the positions
 1/+1 were analyzed, suggests that none of the five Ran acetylation sites studied
here is a likely substrate for the classical KDACs tested therein (KDAC2, KDAC3
and KDAC3 in complex with SMRT). On the one hand, this might explain their
lack of activity towards Ran in the present study. On the other hand, this finding
is surprising given that RanAcK37 and RanAcK60 fulfilled the respective sub-
strate criteria for the same KDAC (i.e. KDAC3 and KDAC8, respectively) upon
independent analysis of ‘upstream’ and ‘downstream’ residues. This discrepancy
may reflect the limitations of peptide-based deacetylation assays and strengthens
the case for using full-length proteins instead.
Table 4.2: Comparison of Ran acetylation sites with preferred substrate se-
quences of classical KDACs.
Match with enzyme preference
Site Sequence Secondary structure  2 and  1a  1 and +1b +1 and +2c
K37 FE-AcK-KY Loop KDAC3, -6 none KDAC3
K60 PI-AcK-FN b-strand KDAC8 none KDAC8
K71 QE-AcK-FG Loop none none KDAC8
K99 TY-AcK-NV a-helix KDAC6 none none
K159 FE-AcK-PF a-helix KDAC6 none none
a Riester et al. (2007)
b Gurard-Levin et al. (2009)
c Gurard-Levin et al. (2010)
Given the highly divergent functions of the di↵erent submembers of classical
KDACs, which have, inter alia, been observed in knockout studies (reviewed in
Haberland et al., 2009b), it is thought that their substrate specificity is dictated by
interaction with several co-factors (reviewed in Kelly and Cowley, 2013). In fact,
alterations in substrate recognition and activity of KDAC3 have been observed in
vitro when it was bound to its co-factors NCoR2 or SRMT (Guenther et al., 2001;
Gurard-Levin et al., 2009; Riester et al., 2007). Since in the screen performed
here, it was not low specificity that was observed but rather unexpectedly low
overall activity towards Ran (despite the apparent activity towards the fluorigenic
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standard peptides), it may be concluded that many co-factors of KDACs are in
fact required to enable them to bind protein substrates in the first place.
4.5 Implications for the substrate specificity of
Sirtuins
As for the classical KDACs, the substrate specificity of Sirtuins is a matter of
debate. Early studies on SIRT1 and yeast Hst2 suggest that Sirtuins have little
sequence preference but require the AcK moiety to be located in unstructured
regions. These conclusions were in part drawn based on structural data, which
show that side chains of amino acids flanking the AcK do not substantially con-
tribute to the binding of peptide substrates to Sirtuins (Avalos et al., 2002; Zhao
et al., 2003). The requirement for unstructured conformations has been shown by
comparing the Hst2-mediated deacetylation of chemically acetylated Cytochrome
c and RNAseA, either in native native form or after heat-denaturation. In both
cases, the heat-denatured protein turned out to be a much better substrate than
its natively folded counterpart. In the same study, several peptides were shown
to be deacetylated by Hst2, mostly regardless of their sequence (Khan and Lewis,
2005). Blander et al. (2005) used a degenerate library of acetyl-peptides and deter-
mined the relative abundance of each amino acid in the positions surrounding the
central AcK for those peptides that were deacetylated by SIRT1. Again, it seemed
that Sirtuins have no preferred target sequence. By contrast, when Garske and
Denu (2006) probed SIRT1 specificity with a combinatorial library and individ-
ually identified deacetylated peptides, significant enrichment of certain sequences
was found. This discrepancy is most likely due to the di↵erent methods used in
these two studies, the former only yielding an average of all preferred sequences
so that the apparent context-dependent substrate recognition of SIRT1 was over-
looked. Since then other studies have confirmed the context-dependency of SIRT1
binding and extended this finding to SIRT3 as well as other Sirtuins (Gurard-Levin
et al., 2010; Rauh et al., 2013; Smith et al., 2011).
Based on the results of the present work, it appears that, at least in vitro, SIRT1-
3 share some features of substrate recognition. A total of 15 acetylation sites
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has been analyzed for deacetylation by Sirtuins and in addition three sets of di-
acetylation sites. In Fig. 4.2, the sequence context of these sites shown in com-
parison with the specificity profile of SIRT3 obtained by Smith et al. (2011). Note
that the di↵erently sized letters do not represent relative residue frequencies for
each position (as in classical consensus sequence representations) but rather re-
flect the discriminative weight of residues at specific positions in the prediction
of SIRT3 substrate specificity. From this comparison, it is di cult to identify
clear sequence-based di↵erences that would explain the e cient deacetylation of
some sites and the non-suitability of others. This applies to both the comparison
among the sequences as well as the comparison to the specificity profile of SIRT3.
For instance, RanAcK159 is surrounded by favorable residues at the most critical
positions, namely a Tyr at  4, a Phe at  2, a Phe at +2 and a Leu at +3 and
yet turned out to be no substrate for SIRT3. The  1 Glu and +1 Pro may be
responsible for the lack of SIRT3 activity towards this site. However RanAcK37,
-AcK38 and AcK37/38, which are SIRT3 substrates, also have disfavored residues
at specificity determining positions.
Thus, a di↵erent way to understand the deacetylation of specific sites by Sirtuins
might be to compare the sites’ structural environments (see Fig. 4.3). Although
the known protein structures of sites tested here do not o↵er insights into their
actual positioning upon acetylation, some conclusions may nevertheless be drawn
from their visual inspection in the non-acetylated state. Of the sites that were
no substrates, RanK99 and PEPCK1-K594 are part of a-helices and RanK60 is
centrally positioned in a b-strand. In these cases, the N- and C-terminal amino
acid residues of the AcK residue and the AcK residue itself might be less accessible
for Sirtuin binding. Similarly, p53-K164 and RanK159 reside at the end of a b-
sheet or an a-helix, respectively, and thus the potentially recognizable residues
are at least partially engaged in a rigid structure. Moreover, the accessibility of
p53-K164 might be lowered also due to the closely spaced tetramerization domain
of p53 (not shown in Fig. 4.3). PEPCK1-K71 and K72 are found in a loop and at
least three residues N- and C-terminally also appear relatively accessible. Thus,
it is perhaps surprising that these sites of PEPCK1 turned out to be no substrate
for SIRT2. However, the fact that it was deacetylated upon mutation of three
N-terminal residues suggests that either the structure of the loop was previously
not su ciently accessible (but was with the mutations) or, alternatively, that the
natural N-terminal amino acid sequence was not suitable for SIRT2 binding.
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Figure 4.2: Sequence context of acetylation sites tested for deacety-
lation. All sites tested for deacetylation in this work are listed with their se-
quence context from position -4 until +4 and colored according to their sidechain
characteristics. The discriminative profile of SIRT3 represents the relative con-
tribution of residues/positions to SIRT3 specificity as di↵erently sized letters.
The total column height reflects how important the respective position is for
specificity (ND: not determined; Smith et al., 2011).
The C-terminus of p53 with the acetylation sites K372/373 and K381/382 is highly
disordered and thus likely behaves similar to peptides regarding the binding to the
active site of Sirtuins. For each of the mono- and the di-acetylated p53 variants,
deacetylation was observed, which suggests limited sequence specificity of SIRT1
and SIRT2 on disordered polypeptide stretches. The other sites that were deacety-
lated e ciently by Sirtuins, namely p53-K120, RanK37/38 and RanK71, all reside
in loop regions and appear to be highly accessible. An interesting observation in
this regard is the fact that SIRT2 deacetylated RanAcK71 faster in its GppNHp-
bound than in its GDP-bound form. This is surprising given that the switch-II
loop is more flexible in the GDP-bound form of Ran. However, K71Ran in RanGDP
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is pointing inwards away from the solvent, which is not the case in RanGppNHp
and hence perhaps allows more e cient binding by SIRT2 (Fig. 4.3).
From the structural analysis of the di↵erent acetylation sites tested here, it may
be concluded that one important element of substrate recognition by Sirtuins is
the accessibility and perhaps flexibility of both the AcK residue and its N- and
C-terminally adjacent amino acids. In addition, there is certainly a sequence com-
ponent to Sirtuin-substrate interaction. This was demonstrated with the deacety-
lation of RanAcK38, the rate of which is substantially lower than for the adja-
cent RanAcK37, and by the fact that mutation of PEPCK1 in three positions N-
terminally of the two AcK residues allowed its deacetylation by SIRT2. Moreover,
at least with SIRT1, the deacetylation of p53-AcK373 was somewhat preferred
over that of p53-AcK372 and -AcK372/373. Taken together, a combination of
structural and sequence requirements have to be fulfilled to allow for deacetyla-
tion by the Sirtuins tested here. Whether other factors play a role in substrate
recognition in vivo and whether these findings can be generalized to the other
Sirtuins is however still an open question.
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Figure 4.3: Structural context of sites tested for deacetylation. Ribbon
and surface plots of structures with acetylation sites highlighted in green. The
sidechains of position -4 until +4 are shown as sticks. The C-terminal sites
of p53 are not shown since they are intrinsically disordered. PDB IDs – p53:
2OCJ, PEPCK1: 1KHF, RanGDP: 1BYU, RanGppNHp: 1IBR.
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4.6 On the role of di-acetylation
In this work, the deacetylation of two adjacent lysines by Sirtuins was studied
only for three proteins (Ran, PEPCK1 and p53). It should be noted however
that to date the acetylation of two neighboring lysines has been found for 978
sites and 771 proteins in human (according to current entries on Phosphosite.org,
Hornbeck et al., 2015), although it is di cult to assess how many of these potential
di-acetylation sites have actually been identified as simultaneous modifications.
Nevertheless, this large number suggests an important role for di-deacetylation in
vivo. The acetylation of p53 has been shown to be of major importance for the
regulation of its anti-tumorigenic e↵ects and it is only poorly understood how the
many di↵erent sites are regulated by a multitude of KATs and KDACs (reviewed
in Reed and Quelle, 2014). It is thus an important finding that deacetylation of
p53 by SIRT1 and SIRT2 occurs even upon acetylation of two adjacent lysines. In
addition, a number of di-acetylation sites are also found in histones. With regard
to the ‘histone code’, which has been proposed to explain the interplay of di↵erent
histone modifications (Strahl and Allis, 2000), di-acetylation and/or its removal
might be an important mechanism for the regulation of gene expression. The fact
that histones possess many lysine residues in their N-terminal tails may also lead
to o↵-target acetylation events catalyzed by KATs, which could be counteracted
by Sirtuins even if two adjacent lysines are a↵ected.
4.7 Conclusions and Outlook
In this and the accompanying work by S. de Boor (PhD Thesis, 2015), five Ran
acetylation sites were studied regarding their e↵ects on Ran protein function. Ran
acetylation was found to influence the interaction of Ran with RCC1, NTF2,
RanBP1 and the nuclear transport receptors CRM1 and importin-b. These re-
sults not only demonstrate the broad regulatory spectrum of lysine-acetylation for
Ran function but more generally implicate that the molecular e↵ects of lysine-
acetylation are diverse and often not easy to predict. Since the GCEC enables the
site-specific incorporation of acetyl-lysine into recombinant protein and hence the
study of individual acetyl-modifications, it is a valuable tool for the understanding
of these molecular e↵ects.
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Another central aspect regarding the impact of lysine-acetylation on protein func-
tion is its stoichiometry. The results shown in the present and the accompanying
study suggest a low stoichiometry of Ran acetylation, at least under the condi-
tions and the cell lines tested. Nevertheless, Ran acetylation sites were identified in
HEK293T cells and these were upregulated in response to coexpression with KATs.
In addition, in vitro KAT assays showed that Ran is a potential substrate of KATs.
Interestingly, the acetylation sites identified in Ran isolated from HEK293T cells
were di↵erent from those previously found in human. Based on high-throughput
MS data of mouse and rat tissue samples, the patterns of Ran acetylation sites
appear to be highly tissue-specific, which may be a result of di↵erent metabolic
states and/or di↵erential expression of KATs. The above findings together with
the strong and, in some cases, dominant-negative consequences of Ran acetylation
on its function suggest that it has a significant impact on cell physiology. To es-
tablish the conditions under which Ran becomes acetylated to what level and at
which sites is an important but challenging future task, which will likely require
further high-throughput MS data and further advances in MS-based quantification
techniques.
The in vitro KDAC screen, which was performed to gain insights into the negative
regulation of Ran acetylation, revealed several, in part unexpected, aspects of
KDAC biology. Despite their reportedly low specificity for peptidic substrates,
none of the classical KDACs was found to deacetylate Ran. Whether this was
due to the absence of additional co-factors or does in fact reflect a high specificity
towards full-length protein substrates remains to be resolved. As opposed to the
classical KDACs, Sirtuins did show activity towards Ran, at least for two sites.
The further results regarding the deacetylation of these two sites as well as sites
in p53 and PEPCK1 support the conclusion that, in a full-length protein context,
Sirtuins preferentially deacetylate AcK residues that are located in loop structures
with high accessibility. Nevertheless, the analysis of four di-acetylation sites shows
an additional sequence dependency of substrate recognition. The fact that SIRT1-
3 are able to deacetylate two adjacent AcK residues underscores the context-
dependent sequence requirements of Sirtuins, which has previously been observed
on peptidic substrates. How exactly this is achieved is an interesting question
for future studies. A major step forward, regarding both the structural and the
sequence requirements, would be the solution of further structures of Sirtuins
bound to their substrates, in particular to a full-length protein and to a peptide
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of a di-deacetylation site. In light of the recent discovery of additional lysine-acyl-
modifications, it will be interesting to see how Sirtuins (and KDACs in general)
are influenced by the presence of such modifications in the vicinity of their target
AcK sites.
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b   
a   
 
pRSFGST-pylT-pAcKRS-3
6733 bp
pRSFDuet-1-pylT-pAcKRS-3
6366 bp
Figure A.1: Maps of vectors used for GCEC. (a) Vector for the purifi-
cation of acetylated proteins with GST-tag. (b) Vector for the purification of
acetylated proteins with His6-tag
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Figure A.2: ITC measurements of RanGppNHp·RanBP1 and Ran-
GAP. RanGppNHp·RanBP1 (40/40 µM) was titrated with RanGAP (200 µM)
at 20 C.
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Figure A.3: ITC measurements of RanGDP and RanBP1. RanBP1
(20 µM) was titrated with RanGDP (200 µM) at 20 C.
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Figure A.4: ITC measurements of RanGppNHp and RanBP1.
RanGppNHp (5 µM) was titrated with RanBP1 (50 µM) at 20 C.
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Figure A.5: ITC measurements of RanGppNHp and CRM1·Spn1.
CRM1·Spn1 (20/40 µM) was titrated with RanGppNHp (200 µM) at 10 C.
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Figure A.6: ITC measurements of RanGppNHp·CRM1 and Spn1.
RanGppNHp·CRM1 (20/40 µM) was titrated with Spn1 (200 µM) at 10 C.
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Figure A.7: Ramachandran plots by residue type. Ramachandran anal-
ysis was performed with MolProbity version 4.2 (Chen et al., 2010; Lovell et al.,
2003). 95.4% (516/541) of all residues were in favored (98%) regions. 99.8%
(540/541) of all residues were in allowed (>99.8%) regions. There was one
outlier (phi, psi): Chain B Ala 133 (-44.7, 104.2).
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AcK Acetyl-L-lysine
CMB Coomassie Brilliant Blue
CRM1 Chromosomal maintenance 1
CV Column volume
ESI Electrospray-ionization
GAP GTPase activating protein
GCEC Genetic code expansion concept
GDP / GTP Guanosine diphosphate / triphosphate
GppNHp Guanosine-5’-[(b,g)-imido]triphosphate
GEF Guanine nucleotide exchange factor
GNBP Guanine nucleotide binding protein
GST Glutathione-S-transferase
HDACs Histone deacetylase
(RP)-HPLC (Reversed-phase) high pressure liquid chromatography
IB Immunoblot
IP Immunoprecipitation
IPTG Isopropyl-b-D-thiogalactopyranosid
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KATs Lysine-acetyl-transferase
KDACs Lysine-deacetylase
LB Lysogeny broth
MCS Multiple cloning site
MS Mass spectrometry
MW Molecular weight
NAD Nicotinamide adenine dinucleotide
NAM Nicotinamide
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NES Nuclear export signal
NLS Nuclear localization signal
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NPC Nuclear pore complex
NTF2 Nuclear transport receptor 2
PBS Phosphate bu↵ered saline
PDB Protein database
PEPCK1 Phosphoenolpyruvate carboxykinase 1
RanBP Ran binding protein
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Spn1 Snurportin 1
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